XPRIZE HEALTHSPAN | HEVOLUTION | SOLVE FSHD

QUALIFIED TEAMS BOOK 2025

TOP 100 HEALTHSPAN & TOP 8 FSHD TEAMS

REIMAGINE AGING

MAY 2025

PRIZE OVERVIEW

Launched in 2023 with an audacious goal, XPRIZE Healthspan is a 7-year, $101 million global competition to revolutionize the way we approach human aging. The competition will incentivize teams to develop and test therapeutics to improve healthy aging and close the gap between life expectancy and health expectancy. Competing teams will develop and test therapeutics that restore muscle, cognitive, and immune function by a minimum of 10 years, with a goal of 20 years. In addition, the winning team of the $10M FSHD Bonus Prize must demonstrate a therapeutic treatment that restores muscle function in individuals with stable Facioscapulohumeral Muscular Dystrophy (FSHD).

INVESTMENT LANDSCAPE

Efforts to extend healthspan are gaining traction, with significant investments coming from governments, the private sector, academia, and the pharmaceutical industry. This trend is expected to continue, with the World Health Organization projecting 1,000 new scientific papers tagged with “healthy aging” or similar terms.[1]

In a related area, the longevity market is expanding rapidly - in part due to technological advancements as well as a growing focus on extending healthspan. In 2019, the longevity market was valued at $110 billion[2], with substantial growth expected in the coming years.

Similarly, FSHD, one of the most common muscular dystrophies affecting approximately 1 million patients worldwide, is a tractable indication with several promising therapeutic approaches in development. Within the FSHD research community, the FSHD Clinical Trial Network (CTRN) is an important alliance for progress. With 31 sites across 9 countries, this network focuses on closing gaps in trial readiness, FSHD expertise, access to patients, and knowledge in the regulatory process.[3]

[1] World Health Organization. (2021). Global health estimates: Life expectancy and leading causes of death and disability. World Health Organization. https://iris.who.int/bitstream/handle/10665/338677/9789240017900-eng.pdf?sequence=1

[2] Rosenbaum, E. (2019, May 8). Tech’s next big disruption could be delaying death. CNBC. https://www.cnbc.com/2019/05/08/techs-next-big-disruption-could-be-delaying-death.html

[3] University of Kansas Medical Center. (n.d.). Our sites. FSHD Clinical Trial Research Network. Retrieved March 28, 2025, from https://www.kumc.edu/fshd-clinical-trial-research-network/about/our-sites.html

XPRIZE HEALTHSPAN & FSHD BONUS PRIZE

The companies profiled here are Qualifying Teams in XPRIZE Healthspan and the FSHD Bonus Track, representing the cutting edge of therapeutic interventions for extending healthy human lifespan and treating FSHD. As of January 31, 2025, from 621 registered teams, 187 teams have declared readiness to begin clinical trials in 2025-2026 through comprehensive Qualifying Submission applications detailing their therapeutic solutions, clinical trial approaches, and team expertise. Each team has been evaluated against rigorous scientific and clinical criteria by our independent Healthspan and FSHD Judging Panels. These interdisciplinary teams represent significant cross-sections of the translational geroscience research, proactive health and wellness, longevity medicine, and longevity biotechnology sectors, working collaboratively to develop evidence-based interventions that extend healthy human lifespan. Many teams are pursuing dual-track approaches, with 85% of FSHD Bonus Track applicants also competing in the main Healthspan competition. This lookbook highlights the Top 40 Milestone 1 ($10M) awarded Healthspan teams, the Top 8 FSHD Bonus Prize finalist teams awarded ($2M) and an additional 60 qualified teams entered in one or both tracks.

Investors and prospective partners are encouraged to meet the teams in person at the upcoming XPRIZE Healthspan Awards Ceremony and Investor Summit. You may also contact the teams directly or reach out with general inquiries to healthspan@xprize.org

TABLE OF CONTENTS

ACKNOWLEDGEMENTS

XPRIZE Healthspan is made possible thanks to the generosity of our Co-Title Sponsors Hevolution and SOLVE FSHD, as well as individual benefactors, including Christian Angermayer, Carl B. Barney, the Blundy Family, Kas Bordier, Peter H. Diamandis, Charlie and Lorie Epstein, the Eleanor and Howard Morgan Family Foundation, Dana and Rob Hamwee, Daniel Krizek, Nancy and Howard Marks, Chris Ouwinga, Christian Peneff, SeneGence, Mark S. Siegel, Todd and Karen Wanek, Sergey Young, and an anonymous donor.

Learn more about our sponsors and partners.

XPRIZE HEALTHSPAN | HEVOLUTION | SOLVE FSHD

HEALTHSPAN

40 MILESTONE 1 AWARDEES

TOP 100 HEALTHSPAN & TOP 8 FSHD TEAMS

REIMAGINE AGING

MAY 2025

COMPANY OVERVIEW

TEAM / COMPANY NAME
A NEW DIMENSION

TRACK
Healthspan, FSHD Bonus Track

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
San Jose, CA, USA

YEAR FOUNDED
2024

NUMBER OF EMPLOYEES
0

FUNDRAISING DETAILS

COMMERCIAL STAGE
Pre-Commercial Pilot

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Convertible Debt, Strategic Partnership, Government Funding, Philanthropic Funding

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Government, Philanthropic

AMOUNT OF CAPITAL SOUGHT
~$1M

CURRENT INVESTMENT STAGE
Seed

Sundeep Dugar
sdugar@aayamtx.com

A NEW DIMENSION

COMPANY DESCRIPTION

We are a group of with over 200 years of combined experience in US/EU pharmaceutical and clinical development, including academic research. We have a experience in the area of bioenergetics and healthspan. Members of the team have been engaged in clinical studies in this area for over a decade and can comfortably and confidently advance this project to commercial outcome.

CORE INNOVATION

The team is advancing a clinic ready first of its kind approach to augment the mitochondrial function in patients. This approach mimics the natural pathway associated with exercise. Hence, has all the associated controls rendering it very safe. We have demonstrated clinical outcome in various indications and are confident that it will show a positive outcome in healthspan and FHSD. Since it is a natural product it is also very safe which is critical for patients with various comorbidities.

HEALTHSPAN

Our intervention primarily addresses the depletion and dysfunction of mitochondria in aging. The mechanism of action mimics the mechanism associated with exercise. There is no other intervention that we are aware of that has shown such a pleotropic effect and the safety profile needed for an intervention. Loss of bioenergetics is the fundamental contributor of declining health with age. We address that!

LEADERSHIP TEAM

The team has >100 years of combined translational expertise in US pharma industry. The team also has >100 years of combined clinical development expertise in US/EU. The team also has had leadership role in the area of healthspan. Importantly the team has been working in the area of mitochondrial role in health for over 15 years and has for the first time determined the pathway associated with the benefits of exercise, the mechanism involved!!

TOP 40

ABE YOANDO PHARMA CO., LTD.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Abe Yoando Pharma Co., Ltd.

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Adachi, Tokyo, Japan

YEAR FOUNDED
1731

NUMBER OF EMPLOYEES
25

FUNDRAISING DETAILS

COMMERCIAL STAGE
Growth Stage (beyond initial customers)

REVENUE RANGE
$4M

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Project Equity, Strategic Partnership

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Philanthropic, Private Equity, Venture Capital

AMOUNT OF CAPITAL SOUGHT
$20M

CURRENT INVESTMENT STAGE
n/a

Tomonari Abe
t-abe@abeyoando.co.jp
corp.abeyoando.co.jp/

COMPANY DESCRIPTION

Founded in 1731 and rooted in the role of overseeing herbal medicine within the Tokugawa Shogunate government, Abe Yoando Pharma merges centuries-old medical expertise with cutting-edge bioscience under 10th generation head Tomonari Abe. By submitting original research to Japan's Ministry of Health, it became the first company worldwide to secure NMN's classification as a food product. While collaborating with eight domestic universities, including the University of Tokyo, the company has so far expanded to 12 countries. Leveraging deep historical knowledge with modern day innovation, Abe Yoando Pharma is a leader in the next-generation longevity space.

CORE INNOVATION

Abe Yoando Pharma 's strength lies in proprietary technology combining raw materials with advanced findings such as NMN with bioactive compounds isolated from Kampo (traditional Japanese herbal medicine). In collaboration with Keio University's School of Medicine, we demonstrated improvements in muscular, cognitive, and immune function in 18 month old mice. This patent-pending modality emphasizes a balance of safety and efficacy, addressing multiple aging factors with only a few carefully selected ingredients - an approach that we feel sets us apart from our competitors. By leveraging existing manufacturing lines and distribution networks, the company can rapidly bring these solutions to market while maintaining rigorous standards in both product quality and efficacy.

HEALTHSPAN

Our NMN-based formulation suppresses biological aging and contributes to the extending of healthspan. Building on mouse studies indicating suppressed declines in strength, cognition, and immunity, we are now at the threshold of advancing to human trials. High-dose NMN testing has already confirmed safety and increased levels of Adiponectin, a so-called "longevity hormone," suggesting even more robust effects with our new formula. This approach targets all 12 aging hallmarks using minimal components, prioritizing user safety while addressing and eradicating any ethical concerns. It accommodates diverse dietary and religious practices, offering a scientifically grounded method for enhancing healthy aging through complementary usage alongside everyday lifestyle habits.

LEADERSHIP TEAM

Under 10th generation head Tomonari Abe, who combines his experience working at SoftBank with an entrepreneurial mindset with inherited medical knowledge and history - he personally validates Abe Yoando Pharma's products by maintaining a scientifically proven biological age 5.6 years below his actual age. Team leader Dr. Nozomi Uemura (Ph.D., University of Tokyo), proficient in pharmacology and Kampo, oversees aging research. Meanwhile, Dr. Motoshi Hayano, a Specially Appointed Lecturer at Keio University and a former researcher under Professor in the Department of Genetics at Harvard University, David Sinclair, also reinforces the company's innovative drive. With further members from a former HR and systems executive from a publicly listed retailer to a CPA experienced in M&A round out management, and 25 full-time staff, the team are conscious of upholding the principle of "Jin" (benevolence).

COMPANY OVERVIEW

TEAM / COMPANY NAME
AgelessRx

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Ann Arbor, MI, USA

YEAR FOUNDED
2019

NUMBER OF EMPLOYEES
80

FUNDRAISING DETAILS

COMMERCIAL STAGE
Prefer not to say

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Prefer not to say

TYPE OF CAPITAL SOUGHT
Prefer not to say

TYPE OF INVESTORS SOUGHT
Prefer not to say

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Prefer not to say

Stefanie Morgan
stefanie@agelessrx.com
agelessrx.com

AGELESSRX

COMPANY DESCRIPTION

AgelessRx is a first of its kind longevity platform that offers the highest level of accessibility to treatments that make you feel better as you age. We believe that aging should not be treated as a dreadful inevitability but instead as a puzzle that can be solved, a fight that can be fought—and is worth fighting—just as a disease with a cure. But until now, only the very few could access the best, most effective longevity treatments. We're here to change that. Because what good is all the progress made in longevity research and therapies if only a select few have the access? Not good enough, if you ask us.

CORE INNOVATION

We are making scientifically backed, physician supervised, prescription longevity medicines to the average consumer right from the comfort of their own homes. Our telemedicine-based solution is backed by clinical evidence through our own and other research work, and each therapeutic plan is uniquely tailored to an individual by our team of expert physicians, all at a price point that doesn't require you to be a billionaire to access.

HEALTHSPAN

We have combined core longevity therapeutics that address elements of glucose regulation, pain management, inflammation, and more, that are essential to optimal healthspan and lifespan. Left un-treated, these are key areas of age-related decline. Our interventions are affordable, broadly accessible, and carefully managed, with the aim of democratizing access to these life quality improving therapies.

LEADERSHIP TEAM

Our team is co-led by a functional medicine physician licensed in all 50 states and the District of Columbia, and a Stanford and Harvard trained PhD scientist with a deep translational research background. Together they bring expertise across the fundamental domains of aging both on the research and practical application fronts, and are united by their passion for helping humans live longer, healthier lives.

ANI BIOME

COMPANY OVERVIEW

TEAM / COMPANY NAME
Ani Biome

TRACK
Healthspan, FSHD Bonus Track

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
San Francisco, CA, USA

YEAR FOUNDED
2023

NUMBER OF EMPLOYEES
12

FUNDRAISING DETAILS

COMMERCIAL STAGE
Early Commercial Demonstration

REVENUE RANGE
$500K

CAPITAL RAISED TO DATE
$7M in dilutive capital and $7M through non-dilutive grants

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Convertible Debt, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Angel, Family Office, Venture Capital, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
$25M

CURRENT INVESTMENT STAGE
Seed

Bruno Balen
genius@anibiome.ai
ani.ai

COMPANY DESCRIPTION

ANI is an AI-first longevity company advancing precision therapeutics by integrating multi-agent intelligence, digital biomarkers, and multi-omics profiling to address aging's systemic dysfunctions. Our approach, AffectoNeuroImmunology (ANI), models aging as a dynamic, interconnected process across affective, neural, and immune networks. Rather than targeting isolated pathways, ANI Biome's system benchmarks deviations from ideal homeostasis using digital biomarkers, then applies AI-driven interventions to recalibrate biological function. Our lead intervention, AB, is a predictive small-molecule therapy that optimizes gut-immune-mitochondrial interactions through short-chain fatty acid (SCFA) modulation, targeting systemic resilience and biological age reversal.

CORE INNOVATION

ANI's multi-layered intelligence framework integrates computational modeling, real-time digital biomarker tracking, and multi-omics validation to create dynamically adaptive therapeutics. We employ bacterial transformer models and graph neural networks (GNNs) to map microbiome-metabolite-pathway interactions, enabling precise modulation of gut-driven systemic processes. Rather than a static intervention, AB is refined dynamically through digital biomarker feedback (multispectral imaging, cognitive-neuro markers, immune tracking) and multi-agent AI optimization. This allows real-time adaptation of interventions based on individual biological responses, making ANI one of the first platforms to integrate predictive, AI-driven optimization into systemic longevity medicine.

HEALTHSPAN

Aging is the progressive loss of adaptive capacity across affective, neural, and immune networks, driven by energy dysregulation, chronic inflammation, and cellular inefficiency. AB targets these dysfunctions through SCFA-mediated recalibration of gut-immune-mitochondrial interactions, directly influencing bioenergetic capacity, inflammatory resolution, and neuromodulatory balance. Unlike conventional therapeutics that assume static metabolic pathways, ANI continuously benchmarks deviations from optimal function via multi-omics-integrated digital biomarkers—tracking neuro-ophthalmological signatures, immune activity, and metabolic markers in real time. This allows precise, personalized intervention design, predicting synergistic molecular inputs that systemically optimize biological function rather than targeting symptoms in isolation.

LEADERSHIP TEAM

ANI integrates AI, multi-agent systems, and digital biomarkers for precision longevity. CEO Bruno Balen develops AI architecture and multi-agent modeling for therapeutic discovery. COO Nika Pintar leads clinical deployment and AI-integrated biomarker validation. Dr. Mirna Andelic (Head of Neuroscience) specializes in multi-omics and AI-driven biomarker discovery. The team includes Dr. Eric Verdin (immune-metabolic aging), Dr. Evelyne Bischof (AI-driven longevity medicine), Dr. Domagoj Cikes (muscle metabolism), Dr. Morana Jaganjac (oxidative stress), Dr. Alexander Buko (metabolomics), and other experts, ensuring AI-driven precision and systemic health optimization.

COMPANY OVERVIEW

TEAM / COMPANY NAME
AutoPhagyGO

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Suita, Osaka, Japan

YEAR FOUNDED
2019

NUMBER OF EMPLOYEES
7

FUNDRAISING DETAILS

COMMERCIAL STAGE
Early Commercial Demonstration

REVENUE RANGE
$130K

CAPITAL RAISED TO DATE
$3M

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
No

TYPE OF CAPITAL SOUGHT
Corporate Equity, Corporate Debt, Academic/University Grants, Venture Capital

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Government, Private Equity, Project Finance, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Series-A

Eriko Ochi
info@autophagygo.com
autophagygo.com

AUTOPHAGYGO

COMPANY DESCRIPTION

AutoPhagyGO Inc. is a biotechnology company dedicated to advancing autophagy research and its applications in healthcare and drug discovery. Leveraging cutting-edge technology and collaborations with leading researchers, the company develops innovative solutions to target autophagy-related diseases, including neurodegenerative disorders, cancer, and metabolic conditions. AutoPhagyGO aims to bridge the gap between fundamental autophagy science and practical therapeutic development, driving innovation through proprietary platforms and strategic partnerships. With a strong commitment to scientific excellence, the company strives to unlock the full potential of autophagy for improving human health and longevity.

CORE INNOVATION

To extend healthy life expectancy, our team proposes a practical combination of dietary and health interventions to enhance autophagy, a biological system recently recognized as essential for achieving longevity, but has yet to be practically utilized. Our proposal focuses on restoring autophagy activity—a key mechanism to combat aging but has so far been underutilized. This initiative emphasizes the health benefits of key food ingredients that activate autophagy.

HEALTHSPAN

Autophagy maintains health by recycling cellular components, and its decline accelerates aging in organisms like C. elegans and mice. Research by Prof. Tamotsu Yoshimori and colleagues shows that restoring autophagy can extend lifespan while preserving health. Autophagy induction shares mechanisms with senolytics, targeting senescent cells. Pharmacological interventions such as metformin and mTOR inhibitors enhance autophagy and help mitigate age-related declines in cognitive, immune, and motor functions. Given its effects in model organisms, autophagy activation is expected to contribute to healthy lifespan extension in humans.

LEADERSHIP TEAM

Our team represents a unique collaboration between industry and academia, leveraging cutting-edge research, technology development, and practical implementation in the field of autophagy research in Japan. The team, established through collaboration with multiple industrial partners, is primarily led by AutoPhagyGO, Inc., a startup originating from Osaka University. The company is at the forefront of developing autophagy-inducing technologies, building on the legacy of groundbreaking autophagy research by Prof. Tamotsu Yoshimori and his team at Osaka University, Japan. These core technological advancements are further supported by an academic advisory board comprised of leading experts.

COMPANY OVERVIEW

TEAM / COMPANY NAME
BioAge Labs

TRACK
Healthspan

ORGANIZATION TYPE
Public Company

HQ LOCATION
California, USA

YEAR FOUNDED
2015

NUMBER OF EMPLOYEES
50-100

FUNDRAISING DETAILS

COMMERCIAL STAGE
n/a

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
n/a

TYPE OF CAPITAL SOUGHT
n/a

TYPE OF INVESTORS SOUGHT
n/a

AMOUNT OF CAPITAL SOUGHT
n/a

CURRENT INVESTMENT STAGE
n/a

bioagelabs.com

BIOAGE LABS

COMPANY DESCRIPTION

BioAge is a clinical-stage biopharmaceutical company pioneering therapies that target the fundamental biology of human aging to treat metabolic diseases. Our approach is based on analysis of human longevity data to identify key molecular drivers of healthy aging. Our lead program is a potent molecule that targets neuroinflammation—a central mechanism in metabolic aging, and we are also developing novel exercise mimetics to address metabolic disorders. By focusing on pathways revealed through our discovery platform, we aim to develop therapeutics that extend healthspan and transform the treatment of age-related metabolic conditions.

CORE INNOVATION

At BioAge, we've developed a discovery platform powered by data from thousands of individuals tracked for up to 50 years. By analyzing age-associated molecular changes alongside long-term health outcomes, our platform reveals the biological pathways that predict longevity and preserved function. This human-first discovery strategy gives us insights into why some people maintain better metabolic health with age, allowing us to develop product candidates that target these protective mechanisms to promote healthspan. By focusing on targets validated in human aging trajectories, our product candidates are designed to address the root causes of metabolic aging rather than just treating symptoms of individual diseases.

HEALTHSPAN

Age-related inflammation increases the risk of virtually all chronic diseases. The NLRP3 protein is a central regulator of the "inflammaging" process, driving tissue damage and metabolic dysfunction. Blocking this key inflammatory pathway has shown benefits in animal models: NLRP3 knockout mice live longer and maintain better cognitive and muscle function with age. By inhibiting NLRP3, our lead compound BGE-102 could reduce systemic inflammation and improve multiple aspects of health simultaneously. The brain-penetrant properties of our compound are crucial, as neuroinflammation affects not only cognition but also whole-body metabolism. This approach targets a fundamental mechanism of aging, potentially adding healthy, functional years to people's lives.

LEADERSHIP TEAM

BioAge's leadership combines deep scientific expertise with proven drug development experience. Our founding team built the company on the conviction that the biology of human aging would reveal powerful new therapeutic targets for extending healthspan. The executive team includes pharmaceutical industry veterans who have successfully guided multiple drugs through FDA approval, with particular strength in developing therapies for metabolic diseases. United by our mission to translate insights from aging biology into transformative medicines, our diverse team blends scientific innovation with clinical and commercial expertise to develop therapies that can genuinely extend the healthy, functional years of human life.

COMPANY OVERVIEW

TEAM / COMPANY NAME
BioArmor

TRACK
Healthspan, FSHD Bonus Track

ORGANIZATION TYPE
Non-Profit Organization

HQ LOCATION
Kuala Lumpur, Malaysia

YEAR FOUNDED
2024

NUMBER OF EMPLOYEES
4

FUNDRAISING DETAILS

COMMERCIAL STAGE
R&D

REVENUE RANGE
$100,000

CAPITAL RAISED TO DATE
$600,000

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Government Funding, Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Angel, Family Office, Philanthropic, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
$500,000

CURRENT INVESTMENT STAGE
Grant

Danny Kim
dkim@questincubator.org
questincubator.org

BIOARMOR

COMPANY DESCRIPTION

Quest Incubator inspires a new generation of students from each country to enter into XPRIZE competitions for learning and innovative solutions. It promotes both education and incubate new businesses to bring solutions to market.

CORE INNOVATION

Utilizing advance research with clinical trial proof utilizing herbal ingredients such as Tiger Milk Mushroom (Lignosus rhinocerus TM02®), Cordyceps (Ophiocordyceps sinensis OCS02®), and Curcumin possess antioxidant and anti- inflammatory properties that can mitigate the effects of aging.

HEALTHSPAN

Our solution shows increased reduction in inflammation and antioxidant responses combined with rhythmic activities enhance neuroplasticity, and TRE optimizes metabolic regulation, creating a comprehensive strategy for addressing aging-related health concerns.

LEADERSHIP TEAM

Leadership team headed by Danny Kim who is a veteran of 6 successful XPRIZE teams and the combination of local PhD researchers from throughout SE Asia and Silicon Valley USA provides the best access to experts and innovative thinking from students to create an unique longevity solution.

TOP 40

BOSTON HEALTHSPAN TEAM

COMPANY OVERVIEW

TEAM / COMPANY NAME
The Brigham Boston XPrize Healthspan Team

TRACK
Healthspan

ORGANIZATION TYPE
Non-Profit Organization

HQ LOCATION
Boston, MA, USA

YEAR FOUNDED
1832

NUMBER OF EMPLOYEES
Over 20,000

FUNDRAISING DETAILS

COMMERCIAL STAGE
n/a

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
No

TYPE OF CAPITAL SOUGHT
Strategic Partnership, Government Funding, Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Government, Philanthropic, Venture Capital, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
n/a

Drs. Shalender Bhasin, JoAnn Manson
sbhasin@bwh.harvard.edu
www.brighamandwomens.org

COMPANY DESCRIPTION

Brigham and Women's Hospital (BWH), a Harvard Medical School teaching affiliate, is internationally recognized for patient care excellence, biomedical research leadership, and healthcare professional education. As the #2 NIH-funded independent research hospital in the US, BWH is renowned for landmark studies including the Nurses' Health Study and Women's Health Initiative, with $876 million in annual research funding.

The 793-bed private, not-for-profit hospital serves 46,000 inpatient admissions, 3.5 million ambulatory visits, and 59,000 Emergency Department visits annually. With over 20,000 employees—including 3,000 physicians, 1,000 investigators, and 2,800 nurses—BWH is a founding member of Mass General Brigham Healthcare System, New England's largest integrated healthcare network.

BWH's Biomedical Research Institute enhances its global scientific leadership through centralized core and administrative services. Its research is supported by Partners Research Management's 300 staff and customized software tools including PeopleSoft, WorkDay, and InfoEd.

CORE INNOVATION

The candidate intervention must meet some minimal criteria for justifying its inclusion in a long-term, randomized placebo-controlled trial of healthspan extension: 1) evidence from animal and human studies that the drug has potential efficacy in treating two or more age-related diseases; 2) sufficient long-term preclinical toxicology data and human data from phase 2 or later phase studies providing evidence of safety and tolerability at doses that will be used in human trials; 3) availability of the drug and matching placebo to conduct the trial.

HEALTHSPAN

GLP-1 single or dual agonists improve health outcomes multiple age-related diseases by multiple interlinked mechanisms. GLP-1 agonists directly act on pancreatic beta cells to increase insulin secretion, reduce hepatic glucose production by inhibiting glucagon secretion, improve muscle insulin sensitivity through increased microvascular recruitment, reduce appetite and delay gastric emptying, reduce inflammation, enhance insulin sensitivity in skeletal muscle, improve endothelial function, and improve cardiovascular risk factors. Weight loss induced by GLP-1 drugs has salutary downstream effect on blood pressure, lipids, inflammation, CVD risk, heart failure, and sleep apnea.GLP-1 agonists also increase neuronal stem cell proliferation and differentiation in the brain and may thereby improve cognition.

LEADERSHIP TEAM

Our interdisciplinary team brings outstanding expertise in pharmaceutical and physical activity RCTs (Bhasin, Manson, Lincoff, Lipsitz, Travison), aging biology (Sinclair, Lipsitz, Bhasin), physical function assessment (Reid, Storer, Bhasin), cognitive evaluation (Marshall, Manson), immunologic function (Manson, Sinclair), and biomarkers of aging (Sinclair, Manson, Lipsitz, Bhasin). Joint PIs Drs. Shalender Bhasin and JoAnn Manson will lead the trial. Dr. Bhasin, Professor at Harvard Medical School and Director of Boston Pepper Aging Research Center, has led numerous pharmaceutical and exercise intervention trials. Dr. Manson, Lee Bell Professor of Women's Health, has led landmark studies including the Women's Health Initiative, VITAL, and COSMOS.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Canadian Translational Geroscience Network

TRACK
Healthspan

ORGANIZATION TYPE
University Team

HQ LOCATION
Montreal, Quebec

YEAR FOUNDED
2023

NUMBER OF EMPLOYEES
n/a

FUNDRAISING DETAILS

COMMERCIAL STAGE
Mature (already have a large mature business)

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Strategic Partnership, Government Funding, Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Government, Project Finance, Venture Capital, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
$1,000

CURRENT INVESTMENT STAGE
Academic/University Grants

Ocean Gallichon
Ocean.Gallichon.ccomtl@ssss.gouv.qc.ca
geroscience.ca/

CANADIAN TRANSLATIONAL GEROSCIENCE NETWORK

COMPANY DESCRIPTION

The Canadian Translational Geroscience Network, led by Dr. Gustavo Duque, coordinates our multidisciplinary team of leading clinician investigators in geroscience, geriatrics, immunology, and endocrinology. With more than 150 clinical trials brought to completion, our investigators are international clinical trial methodology leaders and hold key positions in major international initiatives, including the NIH-funded Geroscience Summit and the Global Geroscience Translational Clinical Trials Taskforce.

CORE INNOVATION

We are testing two compounds with established safety profiles that address complementary aging pathways. Extensive preclinical and clinical evidence supports their robust mechanistic alignment with aging hallmarks. Both compounds significantly affect muscle and immune function in animal models and humans. Therefore, we expect that our proposed clinical trial will demonstrate an effect on the participants' cognition, function, and immune systems, thus improving health span.

HEALTHSPAN

Our tested compounds improve health span through their combined biological mechanisms, which have already been demonstrated in preclinical and clinical studies. One preserves muscle, bone, and mitochondrial function, preventing frailty, while the other reduces oxidative damage and inflammation, protecting against cardiovascular and neurodegenerative diseases. Together, they support physical and cognitive function, key components of an extended health span.

LEADERSHIP TEAM

Our diverse multidisciplinary team has published 2,155 peer-reviewed articles, seven books, and >200 book chapters. More than 300 appearances in the national and international mainstream media in the last 5 years demonstrate interest in our work. Our global standing is reflected by our many publications in leading journals (a large proportion published with international collaborators) and multiple invited presentations at international conferences in the last 10 years (>400). This leadership extends to our commercial partnership with TSI Group LTD, where Chief Scientific Officer Dr. Naji Abumrad and his collaborator, Dr. John Rathmacher, both of whom participated in the discovery of HMB and 2-HOBA, bring unique expertise from leading the original NIH-funded clinical trials that established their safety and therapeutic profiles. Our team's proven track record in conducting practice-changing clinical trials and our established international collaborations position us uniquely to advance these compounds from discovery to clinical implementation.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Circadian

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Organization

HQ LOCATION
San Diego, CA, USA

YEAR FOUNDED
1963

NUMBER OF EMPLOYEES
800+

FUNDRAISING DETAILS

COMMERCIAL STAGE
Prefer not to say

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Prefer not to say

TYPE OF CAPITAL SOUGHT
Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Academic/University Grants

Satchin Panda
Satchin@gmail.com

CIRCADIAN

COMPANY DESCRIPTION

We are part of Salk Institute - it is a non-profit.

CORE INNOVATION

n/a

HEALTHSPAN

n/a

LEADERSHIP TEAM

Leader in Circadian rhythm basic and translational research.

TOP 40

EXOMED

COMPANY OVERVIEW

TEAM / COMPANY NAME
Exomed

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Mudgee, New South Wales, Australia

YEAR FOUNDED
2024

NUMBER OF EMPLOYEES
3

FUNDRAISING DETAILS

COMMERCIAL STAGE
Pre-Commercial Pilot

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
$400K

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Strategic Partnership, Government Funding, Industry

TYPE OF INVESTORS SOUGHT
Angel, Government, Venture Capital, Industry

AMOUNT OF CAPITAL SOUGHT
$2M

CURRENT INVESTMENT STAGE
Government & Industry Sponsored

Andrew Keipert
andrew.keipert@exomed.com.au
exomed.com.au

COMPANY DESCRIPTION

Exomed is an Australian biotech start-up redefining aging by treating it as a biological endpoint rather than an inevitable decline. Our patented oral exosome-based therapeutic leverages regenerative xenogeneic extracellular vesicles (EVs)—inspired by parabiosis research—to restore muscle, immune, and cognitive function. We believe that for aging to be treatable, solutions must be effective, safe, and accessible. Our approach transforms food-grade bovine plasma into a scalable, non-invasive therapy, ensuring global reach. Supported by HMRI, AMPC, CSIRO, and University Research Institutes, we are advancing clinical validation to bring scientifically proven, regenerative medicine to the world—turning longevity science into real-world impact.

CORE INNOVATION

Exomed is pioneering a first-in-class, all-natural, oral exosome-based therapeutic that targets aging at its root by restoring muscle, immune, and cognitive function. Our solution harnesses regenerative xenogeneic extracellular vesicles—natural carriers of youthful signals—sourced from food-grade bovine plasma. This safe, scalable, and non-invasive approach bypasses stem cell complexities, leveraging decades of parabiosis research for systemic rejuvenation. By integrating sustainable bioprocessing, oral delivery, and a complementary medicine regulatory pathway, Exomed offers a cost-effective, globally accessible intervention. We bridge the gap between cutting-edge longevity science and real-world impact, advancing healthspan for diverse populations worldwide.

HEALTHSPAN

Exomed's oral therapy employs regenerative xenogeneic extracellular vesicles from young bovine plasma to modulate key aging pathways. These EVs carry miRNAs and proteins that reduce systemic inflammation, enhance tissue repair, and rejuvenate stem cell function—mechanisms validated by heterochronic parabiosis research. Consumed daily, EVs resist GI degradation, enter circulation, and deliver both local and systemic benefits. Repeated dosing fosters oral tolerance, lowering immunogenic risks. By transmitting "youthful" signals, they recalibrate cellular aging, shifting epigenetic patterns and prompting tissue renewal, improved muscle strength, cognitive resilience, and immune competence. This progressive reprogramming maximises ones functional capacity throughout life.

LEADERSHIP TEAM

Exomed's leadership team combines scientific vision, operational execution, and strategic partnerships to drive breakthroughs in aging therapeutics. Dr. Geoff Keipert, a biopharmaceutical innovator with 25+ years of experience, leads regenerative medicine advancements, developing scalable, sustainable healthspan solutions. Andrew Keipert ensures seamless business execution, aligning R&D with commercialisation. Our strategic partnerships with CSIRO, Baker Institute, AMPC, and HMRI provide world-class expertise in extracellular vesicles, clinical trials, and supply chain infrastructure. Supported by leading researchers like Dr. Laura Vella and Assoc. Prof. David Greening, we are executing a scalable pathway to commercialisation—transforming exosome-based therapeutics into accessible solutions for healthy aging.

GI INNOVATION

COMPANY OVERVIEW

TEAM / COMPANY NAME
GI Innovation

TRACK
Healthspan

ORGANIZATION TYPE
Publicly Traded Company

HQ LOCATION
Seoul, Gyeonggi-do, South Korea

YEAR FOUNDED
2017

NUMBER OF EMPLOYEES
90

FUNDRAISING DETAILS

COMMERCIAL STAGE
Growth Stage

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
$300M+

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Project Equity, Strategic Partnership, Government Funding, Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Government, Philanthropic, Private Equity, Project Finance, Venture Capital, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
$100M

CURRENT INVESTMENT STAGE
Publicly Traded

Lee Farrand
lee.farrand@gi-innovation.com
gi-innovation.com

COMPANY DESCRIPTION

GI Innovation is a South Korean biotechnology company founded on the strength of its GI-SMART platform technology that enables the rapid optimization of diverse biological fusion proteins with excellent characteristics for manufacturing. We have multiple programs in clinical development for cancer and allergic diseases.

CORE INNOVATION

GI-102 is a next-generation targeted cytokine immunotherapy. Clinical trials in the US and Korea have shown outstanding monotherapy efficacy in solid tumors, driven by a reinvigoration of the immune system, primarily Natural Killer (NK) cells. Due to their role in surveillance of senescent cells and removal of cellular debris implicated in ageing, we hypothesize that GI-102 can slow or prevent systemic degeneration.

HEALTHSPAN

A weakening of the immune system is a core characteristic of ageing, that leads to susceptibility to chronic and infectious diseases. We hope that by safely priming the immune system to the higher levels of performance common to younger adults, we can lengthen healthspan in the elderly population. .

LEADERSHIP TEAM

We have a leadership team comprised of veteran pharmaceutical development professionals with strong discovery, translation and clinical experience, backed by an impressive team of experts in mechanistic biology and drug manufacturing.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Goda Lab

TRACK
Healthspan

ORGANIZATION TYPE
University Team

HQ LOCATION
Bunkyo City, Tokyo, Japan

YEAR FOUNDED
2012

NUMBER OF EMPLOYEES
52

FUNDRAISING DETAILS

COMMERCIAL STAGE
R&D

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Project Equity, Convertible Debt, Project Debt, Corporate Debt, Strategic Partnership, Government Funding, Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Government, Philanthropic, Private Equity, Project Finance, Venture Capital, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
$10M

CURRENT INVESTMENT STAGE
Seed

Keisuke Goda
goda@chem.s.u-tokyo.ac.jp
goda.chem.s.u-tokyo.ac.jp/

GODA LAB

COMPANY DESCRIPTION

The team behind this application leads the “Cell Aging Control” Endowed Chair at The University of Tokyo, a program dedicated to evaluating the quality and efficacy of extracellular vesicle-based therapies for regenerative medicine, in collaboration with The University of Tokyo Hospital. With extensive expertise in chemistry, bioengineering, clinical trial organization, management, and execution, as well as a strong background in study coordination, data management, and statistical analysis, the team is well-equipped to deliver on this project.

CORE INNOVATION

The team’s technology leverages super homotypic targeting (SHT) to enhance the therapeutic potential of extracellular vesicles (sEVs) using lanthanide ions (Eu^{33}). This approach improves sEV targeting efficiency by 25-fold, ensuring precise delivery of therapeutic molecules to muscle, brain, and immune cells. Unlike conventional sEV therapies, SHT maximizes on-target effects while minimizing off-target risks, improving both efficacy and safety. Additionally, the scalable and cost-effective engineering of sEVs with Eu^{33} allows for large-scale production, making this regenerative therapy widely accessible. By integrating advanced targeting technology with stem cell-derived sEVs, the solution provides a highly effective and sustainable approach to treating age-related diseases.

HEALTHSPAN

SHT-sEV therapy targets key aging-related dysfunctions, including sarcopenia, cognitive decline, and immune dysfunction, by enhancing tissue regeneration and reducing inflammation. The therapy delivers growth factors and anti-inflammatory molecules directly to affected cells, improving muscle strength, cognitive function, and immune resilience. Its ability to cross biological barriers enables non-invasive delivery, reducing treatment burden. By restoring cellular function in aging tissues, SHT-sEVs help maintain mobility, cognitive clarity, and immune competence, thereby extending healthspan and improving the quality of life in aging populations.

LEADERSHIP TEAM

The leadership team comprises experts in regenerative medicine, extracellular vesicle engineering, and aging research. It includes pioneering scientists in stem cell biology, nanomedicine, and targeted drug delivery, with extensive experience in translating innovative therapies from bench to bedside. Team members have led groundbreaking research on extracellular vesicles, published in high-impact journals, and hold patents in therapeutic targeting technologies. Additionally, the team has experience in biotech entrepreneurship, clinical trial design, and regulatory approval processes, ensuring a clear pathway for commercialization. Their collective expertise positions them to drive the successful development and implementation of SHT-sEV therapy for aging-related diseases.

TOP 40

HEALTHY LONGEVITY CLINIC

COMPANY OVERVIEW

TEAM / COMPANY NAME
Healthy Longevity Clinic

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Boca Raton, FL, USA

YEAR FOUNDED
2021

NUMBER OF EMPLOYEES
25

FUNDRAISING DETAILS

COMMERCIAL STAGE
Growth Stage (beyond initial customers)

REVENUE RANGE
$3,000

CAPITAL RAISED TO DATE
$6,000

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Philanthropic, Private Equity, Venture Capital

AMOUNT OF CAPITAL SOUGHT
$4,000

CURRENT INVESTMENT STAGE
Seed

Bolek Kerous
bolek@healthylongevity.clinic
healthylongevity.clinic/

COMPANY DESCRIPTION

HealthyLongevity.clinic specializes in the radical extension of healthy, active human life and making it accessible as soon as possible. Their unique advantage is its close connection to LongevityTech.fund portfolio companies and leading aging research institutions worldwide.

They have clinics in Prague, Boca Raton, and the Bahamas subsidiary with 25+ professional staff and serving 500+ longevity clients.

CORE INNOVATION

The core is an application of Klotho mRNA therapy within a comprehensive therapeutic and phased longevity program using cutting edge personalised diagnostics and medical care.

HEALTHSPAN

Our approach is based on a series of phases, in which we first set up and correct predispositions for rejuvenation and then apply an advanced gene therapy approach combined with proper and lifestyle support.

Our advanced mRNA therapy is grounded in increasing the expression of aKlotho with known and tested very broad pleitropic regenerative effects and functional improvements. We started human case studies that have already successfully proven the safety and efficacy of several individuals. Our development is based on a collaboration between HealthyLongevity.clinic and Klothea Bio, both portfolio companies of LongevityT ech.fund. All mRNA-based aKlotho applications are patented.

LEADERSHIP TEAM

Chief Medical Officer - Dr. Ana Baroni, MD, PhD. - one of the best longevity physicians in the world.

Chief Scientific Office - Dr. Morten Scheibye-Knudsen, MD, PhD - leading aging scientist

Team Lead and Strategist - Petr Sramek - Managing Partner of LongevityTech fund and HL.clinic CEO

Klotho team scientific lead - Carmela Abraham, PhD - world leading Klotho scientist

Klotho scientific advisor - Dr. Makoto Kuro-o, MD, PhD - Klotho gene discoverer

IHU HEALTHAGE

COMPANY OVERVIEW

TEAM / COMPANY NAME
IHU HealthAge

TRACK
Healthspan

ORGANIZATION TYPE
University Team

HQ LOCATION
Toulouse, Occitanie, Haute Garonne

YEAR FOUNDED
2024

NUMBER OF EMPLOYEES
450

FUNDRAISING DETAILS

COMMERCIAL STAGE
Non pharmacological intervention

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Government Funding, Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Government, Philanthropic, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Academic/University Grants

Martilde Cavalier
cavalier.ma@chu-toulouse.fr
ihuhealthage.fr/en/

COMPANY DESCRIPTION

A University Hospital Institute (IHU) is a centre of scientific and medical excellence whose aim is to accelerate the invention of tomorrow's medicine and improve healthcare. The 4 main missions of an IHU are:

Research: by bringing fundamental research closer to clinical concerns
Care: by accelerating the transition between research and therapeutic applications
Formation: to strengthen the transfer of knowledge
Valorization: economic development and innovation

CORE INNOVATION

The IHU HealthAge focuses its programme on preventing the decline in function associated with ageing, longevity, healthy ageing and geroscience. It is based on the implementation of preventive actions centred on function and on the acquisition of new mechanistic knowledge of the biology of ageing, with the aim of improving the quality of life of the elderly and reducing healthcare costs and loss of productivity. This will open up opportunities for innovation in the service of an ageing but sustainable society! Using the innovative approach of geroscience, the IHU HealthAge is deploying an action plan based on three key stages:

Identifying loss of function and frailty
Implementing and preventing on a large scale
Understanding and intervening in the biological process of ageing

HEALTHSPAN

The ICOPE Intense project will evaluate the impact of a high-intensity ICOPE programme on biological markers of ageing in individuals at high risk of functional decline. This proof-of-concept study will also assess the potential synergistic effect of ketone body supplementation.

LEADERSHIP TEAM

The Executive board supports and is led by the Director of the IHU. It is made up of the strategic coordinator, the operational coordinator and the administrative and financial manager. The strategic coordinator's role is to propose new scientific and clinical strategic directions to promote innovation within the IHU and to ensure the coherence of the overall policies of the various HealthAge IHU boards, while the operational coordinator implements the policy in collaboration with the director. The executive board meets on a weekly basis, and once a month brings together researchers from the various laboratories involved in the operational monitoring of actions relating to the different pillars.

https://ihuhealthage.fr/en/executive-board/

INTERVENE IMMUNE

COMPANY OVERVIEW

TEAM / COMPANY NAME
Intervene Immune

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Los Angeles, CA, USA

YEAR FOUNDED
2015

NUMBER OF EMPLOYEES
6

FUNDRAISING DETAILS

COMMERCIAL STAGE
Early Commercial Demo

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
$3.5M

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Philanthropic, Private Equity, Venture Capital

AMOUNT OF CAPITAL SOUGHT
$10M

CURRENT INVESTMENT STAGE
Seed

Robert Brooke
brooke@interveneimmune.com
interveneimmune.com

COMPANY DESCRIPTION

Intervene Immune focuses on reversing what we consider the single-most important driver of human aging: immunosenescence. With only seed financing so far, we now have interim Phase 2 data confirming the effectiveness of our core treatment in rejuvenating the immune system, improving key aging biomarkers, and improving body composition, physical fitness, and frailty. Our lead clinical program has U.S. patent protection and includes development of a novel growth hormone “bio-better” product. We have potential to greatly expand the already multi-billion-dollar market for this product in the U.S. by extending its use to the prevention and reversal of immunological aging.

CORE INNOVATION

Our therapeutic is directed towards thymus and immune system regeneration using a personalized medicine approach that optimizes doses of human growth hormone, DHEA, and metformin, within a supportive nutritional background. We have developed methods that enables us to safely regenerate the human thymus in patients now even while developing next-gen improvements. We have also developed an analytics platform that enables us to manage treatment for hundreds of volunteers, positioning us well to scale the treatment to a much larger patient population.

HEALTHSPAN

Thymic atrophy leads to immune system collapse and contributes to the aging of multiple organs. Our treatment restores immune function by boosting recent thymic emigrants and naïve T cells while reducing inflammation and senescent T cells. It significantly slows epigenetic aging, and in some there are cases of hair darkening and significant improvement of kidney function. It has shown a strong safety profile, with lowering of diastolic blood pressure, resting heart rate, and prostate cancer risk factors. Recent data has also shown marked improvement of frailty and physical fitness measures, including increases of leg strength and VO2max by over 20%.

LEADERSHIP TEAM

The Intervene Immune team is led by its co-founders Dr. Gregory Fahy and Robert Brooke. Dr. Fahy is a Fellow of the American Aging Association, editor and author of The Future of Aging, an accomplished inventor with over 40 issued patents, and has led the conduct of the TRIIM and TRIIM-X trial as the Principal Investigator. Robert Brooke, our CEO and CTO, is a bioengineer, former biotech investment analyst, inventor on multiple issued drug development patents, and prior founder of a publicly-traded cancer immunotherapy company. Both have successfully conducted our clinical trials in concert with our company staff and collaborators.

JAPAN LONGEVITY CONSORTIUM

COMPANY OVERVIEW

TEAM / COMPANY NAME
Japan Longevity Consortium

TRACK
Healthspan

ORGANIZATION TYPE
University Team

HQ LOCATION
Tokyo, Japan

YEAR FOUNDED
2023

NUMBER OF EMPLOYEES
5

FUNDRAISING DETAILS

COMMERCIAL STAGE
R&D

REVENUE RANGE
$1M

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
No

TYPE OF CAPITAL SOUGHT
Corporate Equity, Philanthropic Funding

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Philanthropic, Venture Capital

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Seed

Shigeo Horie
shorie@juntendo.ac.jp

COMPANY DESCRIPTION

The Japan Longevity Consortium is an interdisciplinary team comprising medical researchers, clinicians, healthcare startup executives, gym operators, and culinary experts. With expertise spanning anti-aging medicine, genetic science, statistics, cell biology, endocrinology, neurology, kinesiology, geriatrics, nephrology, urology, digital therapeutics, and nutrition, the team integrates diverse perspectives to tackle healthspan extension. Team Leader Shigeo Horie, a board-certified expert in urology, nephrology, and endocrinology, brings extensive experience in designing international clinical trials, supported by a collaborative network of professionals from various fields.

CORE INNOVATION

Our team aims to improve lifespan, muscle strength, immune function, and cognitive ability through the Scientific Zen program, which integrates fasting with Japanese whole-food diet, modulation of autonomic nervous system activity, regular exercise, and strength-enhancing supplements. The Scientific Zen Program bridges Japanese heritage health practices with cutting-edge science to promote holistic well-being and longevity.

HEALTHSPAN

Our teamconducted a preliminary observational study to assess whether lifespan, evaluated using second-generation epigenetic clocks, could be extended in prostate cancer survivors aged 66-76 who had undergone radical treatment and achieved remission. Participants engaged in a 2-day program consisting of a Japanese whole-food diet with mild fasting (up to 600 kcal/day) and yoga. The study revealed that the program had a moderate and significant rejuvenation effect on GrimAgeV2-based epigenetic age acceleration by 0.71 years ($p=0.03$). Interestingly, the rejuvenation effect was more pronounced in individuals showing greater upregulation of nutrient-sensing genes (SIRT1 and ribosomal genes) in participants' blood cells, indicating that these genes are key factors in exerting the rejuvenation effect of the program. Furthermore, another preliminary observational study showed that transcutaneous electrical acupoint stimulation (TEAS) improved heart rate variability (HRV), enhanced autonomic nervous system regulation, and achieved a "rewind" of PhenoAge-based epigenetic age acceleration by more than 2 years.

Based on these findings and supporting evidence from prior studies, we propose a 8-week intervention trial with a pre-post design. The primary objective of this trial is to investigate whether the Scientific Zen program (a combined regimen of Japanese whole-food diet with intermittent mild fasting, TEAS, yoga, strength-building exercises, and nutritional supplementation) can extend lifespan evaluated using epigenetic age acceleration and restore muscle, cognitive, and immune functions in men and women aged 50 to 80 years.

LEADERSHIP TEAM

Our team comprises nine laboratories from Juntendo University, the University of Tokyo, Osaka University and Shimadzu Corporation, all committed to advancing longevity science. In addition, the team includes companies specializing in food preparation, exercise programs, and the manufacture of medical devices for autonomic nervous system modulation, along with yoga professionals.

Our team brings together specialists across multiple disciplines with clearly defined roles. If selected for the semi-finals, we plan to establish the Consortium as a non-profit organization and secure funding through government grants and private donations. Professors Yoshimori (Osaka University), Horie, Hattori, and Watada (Juntendo University) have already collaborated on autophagy research. We ensure efficient communication through regular online and in-person meetings and use a cloud-based project management tool for real-time data sharing.

KIMERA LABS

COMPANY OVERVIEW

TEAM / COMPANY NAME
Kimera Labs

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Miami, FL, USA

YEAR FOUNDED
2015

NUMBER OF EMPLOYEES
50

FUNDRAISING DETAILS

COMMERCIAL STAGE
Growth Stage (beyond initial customers)

REVENUE RANGE
$18M

CAPITAL RAISED TO DATE
$5M SBA Loan

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Project Equity, Convertible Debt, Project Debt, Strategic Partnership, Government Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Corporate/Strategic, Family Office, Government, Philanthropic, Private Equity, Project Finance, Venture Capital, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
$20M - 120M

CURRENT INVESTMENT STAGE
Seed

Duncan Ross PhD
duncan.ross@kimeralabs.com
kimeralabs.com

COMPANY DESCRIPTION

Founded in 2012 by Duncan Ross, PhD, Kimera® Labs is a clinical-stage biopharmaceutical company specializing in large-scale GMP production and isolation of perinatal mesenchymal stem cell (MSC)-derived exosomes for research and clinical use. Manufactured in 28,000 sq ft of FDA inspected laboratories and clean rooms, Kimera's MSC-derived exosomes allow for more accessible therapeutic interventions and have proven effective in acceleration of wound healing, reducing inflammation, alleviating various neurological diseases, and promoting an extension of health span in various rodent models.

CORE INNOVATION

Kimera Labs' core technology is a highly isolated 120nm exosome derived from an FDA IND-approved primary placental mesenchymal stem cell (MSC) line. This exosome product, XoGlo® Pro, when paired with low-intensity focused ultrasound (LIFUS) in structured protocols, can be targeted to specific areas of the brain to not only treat a number of neurological diseases, but to reverse symptoms of aging. Kimera Labs and The Regenesis Project published findings associated with this project in Nature Scientific Reports in October 2023.

HEALTHSPAN

In addition to treating inflammation, MSC exosomes have been shown to be effective for delaying the aging process and restoring muscle and cognitive function in a variety of clinical and preclinical studies. LIFUS has been shown to induce gene expression changes in the targeted area that can improve the health of the patient. This study targets the hypothalamus, a region in the brain well associated with the aging process. This delivery of LIFUS combined with MSC exosomes will reduce inflammation in the hypothalamic region and restore neural stem cell populations to delay and reverse some of the complications of aging.

LEADERSHIP TEAM

The team is a collaboration between Kimera Labs, led by Duncan Ross, PhD., Founder and CEO, and Sheldon Jordan, MD, leader of The Regenesis Project. Dr. Ross's exosome research has been and continues to be employed by many physicians and clinics in a variety of regenerative medicine protocols. Dr. Jordan is a double-board-certified neurologist and clinical researcher with subject matter expertise in several key areas of neuroimaging, interventional pain management, and regenerative medicine, and has served as the principal investigator on upwards of 50 clinical trials, ranging from pre-clinical to clinical Phase III interventional studies.

TOP 40

LIONHEART HEALTH, INC.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Lionheart Health, Inc.

TRACK
Healthspan, FSHD Bonus Track

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Newport Beach, CA, USA

YEAR FOUNDED
2022

NUMBER OF EMPLOYEES
8

FUNDRAISING DETAILS

COMMERCIAL STAGE
Early Commercial Demo

REVENUE RANGE
$1M

CAPITAL RAISED TO DATE
$1.2M

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Convertible Debt

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Private Equity, Venture Capital

AMOUNT OF CAPITAL SOUGHT
$23M

CURRENT INVESTMENT STAGE
Series A

Howard Leonhardt
howard@leonhardtventures.com
lionhearthealthstim.com

COMPANY DESCRIPTION

Orange County, CA based Lionheart Health, Inc. has a patented technology platform based on bioelectric controlled protein expressions to reverse aging 20 years inside and out. Their primary business model is to license thriving medspas, sports medicine clinics, vet clinics and longevity focused medical concierge clinics. Via these licenses they receive a 7% gross sales royalty on their service sales with the Lionheart patented software and equipment. Sites have opened in New York, Newport Beach, Santa Barbara, San Diego, Los Angeles, Scottsdale and Mexico. The company has goal to have 124 clinics generating royalty revenues within 60 months. The company has recruited an all-star team for their commercialization launch including co-CEO Scott Hoots whom sold over 235 regenerative medicine franchises during his 4 year tenure as CEO of his previous company QC Kinetix. They also recruited Chad Hacker former VP of Consumer and Digital Marketing for Abbvie Allergan Aesthetics. Tessa Sphar former onboarding specialist leader for Expotential Fitness of Irvine, CA, that opened up over 60 franchise locations during her tenure there, has also joined the team.

They have over 500 patent claims covering healthspan longevity and medical aesthetics. Clinical data on over 1000 patients. 5 FDA product clearances for skin and hair regeneration, joint regeneration, sexual health and rapid body toning. The company won the coveted Abbvie Allergan Innovation of the Year in Medical Aesthetics. They are an official 2nd level entrant in the $101 Million Xprize Healthspan Longevity Competition based on 20 years improvement in muscle health, brain health and immune health. Via it's trained certified licensed locations they offer the patented Lionheart Klotho Wellness Program.

CORE INNOVATION

Bioelectric controlled protein expressions for regeneration and healthspan.

HEALTHSPAN

Regenerates muscle, immune health and brain health with bioelectric controlled protein expressions and when needed bioelectric enhanced biologics including klotho expressing stem cells.

LEADERSHIP TEAM

Howard Leonhardt Founder Inventor Executive Chairman & co-CEO - Over 650,000 patients have been treated with Leonhardt inventions. 2024 revenues > $2 billion. Multiple exits since founding Leonhardt Ventures LLC 1982. Over 500 patent claims. Scott Hoots - Sold over 235 regenerative medicine franchises as CEO of QC Kinetix. Franchisor of year 2024. Chad Hacker - Former VP of Consumer and Digital Marketing Allergan Aesthetics helps lead them into a $60 billion acquisition by Abbvie. Tessa Sphar led opening of over 60 Exponential Fitness Franchises as onboarding training leader. Dr. Leslie Miller Chief Medical Officer - 250 publications, leader of over 115 clinical studies, Editor and Author of leading textbook on Regenerative Medicine. Dr. Doris Taylor - former Regenerative Medicine research leader at Duke U, U Minnesota and Texas Heart Institute. Dr. Dipti Itchhaporia - 2022 President American College of Cardiology. Dr. Allyson Berkey - 30 years clinical experience in regenerative medicine.

LOGIN (LONGEVITY INNOVATOR)

COMPANY OVERVIEW

TEAM / COMPANY NAME
LogIN (Longevity Innovator)

TRACK
Healthspan

ORGANIZATION TYPE
Publicly Traded Company

HQ LOCATION
2-1 Seiryo-cho, Aoba-ku,Sendai Miyagi, Japan

YEAR FOUNDED
2000

NUMBER OF EMPLOYEES
3

FUNDRAISING DETAILS

COMMERCIAL STAGE
R&D

REVENUE RANGE
$849,771

CAPITAL RAISED TO DATE
$53.5M

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Project Equity, Strategic Partnership, Government Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Government, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
Case by case

CURRENT INVESTMENT STAGE
Publicly Traded

Toshio Miyata
miyata@med.tohoku.ac.jp
renascience.co.jp/en

COMPANY DESCRIPTION

Our team is a mixed team of physician-scientists with different medical fields from multiple academic institutions and a start-up company listed in the Tokyo Stock Exchange. Most, if not all, members in this application are principal investigators who have conducted 9 clinical trials with the PAI-1 inhibitor TM5614 (the drug of this application). Experts in immunology, metabolism, stem cell biology, and aging biomarkers come together to verify its anti-aging benefits.

CORE INNOVATION

Preclinical and clinical studies, utilizing our PAI-1 inhibitors, have discovered unexpected findings that PAI-1 inhibitors 1) inhibit replicative senescence, 2) revert pathological features of Hutchinson^{3} Gilford progeria patient-derived fibroblasts, 3) improve pathological features in a mouse aging klotho model, and 4) revert pathological features in animal models of various agerelated diseases (vascular, respiratory, neurocognitive, metabolic, cancer, immune systems).

HEALTHSPAN

PAI-1 plays a significant role in regulating both innate and adaptive immunity against cancer and aging. We showed that PAI-1 promotes immune evasion in tumors by increasing PD-L1 expression through the JAK/STAT signaling pathway, thereby impairing immune clearance of cancer cells. Notably, our PAI-1 inhibitor exerts similar immune checkpoint inhibitory benefits with nivolumab and ipilimumab, and reversed these effects, leading to anti-tumor immune system and tumor regression. Recently, it was revealed that aged cells express PD-L1, and administration of nivolumab to spontaneously aging mice decreased the total number of aged cells and prevented various age-related phenotypes. Immune checkpoint molecules thus play an important role not only in cancer but also in aging, suggesting a promising strategy for anti-aging therapy. PAI-1 inhibitor thus provides clinical benefits by regulating both innate and adaptive immunity against cancer and aging.

LEADERSHIP TEAM

Number of patents filed: 3. Number of patents received: 3. Designated as a rare disease drug by the government.

TOP 40

LONO JAEYAK

COMPANY OVERVIEW

TEAM / COMPANY NAME
Lono Jaeyak

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Gunsan Jeonbuk-do, South Korea

YEAR FOUNDED
2024

NUMBER OF EMPLOYEES
3

FUNDRAISING DETAILS

COMMERCIAL STAGE
R&D

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
No

TYPE OF CAPITAL SOUGHT
Corporate Equity, Project Debt, Corporate Debt, Strategic Partnership, Government Funding, Academic/ University Grants

TYPE OF INVESTORS SOUGHT
n/a

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Pre-Seed

Eunjae Yang
rob2659@naver.com

COMPANY DESCRIPTION

Our team of senotherapeutics experts is dedicated to developing the optimal combination of senomorphic and senolytic agents to effectively normalize senescent cells. We have successfully created a technology demonstrating unparalleled efficacy in reversing the aging process within senescent cells. We believe this groundbreaking approach holds the potential to significantly extend both lifespan and healthspan by mitigating age-related phenotypes.

CORE INNOVATION

We possess the senotherapeutics cocktail with the best efficacy, which addresses various causes of aging.

HEALTHSPAN

The senotherapeutics cocktail we developed are inhibitors of aging-dependent hyperactive molecules or activators of aging-dependent hypoactive molecules, and it displays massive synergism of senotherapeutics.

LEADERSHIP TEAM

We have been successfully conducting developments of the senotherapeutics cocktail under my leadership. We have struggled to figure out its applications toward aging-related diseases, completed government-funding R&D projects, and composed research papers.

TOP 40

LONGEVERON INC

COMPANY OVERVIEW

TEAM / COMPANY NAME
Longeveron Inc

TRACK
Healthspan

ORGANIZATION TYPE
Publicly Traded Company

HQ LOCATION
Miami, FL, USA

YEAR FOUNDED
2014

NUMBER OF EMPLOYEES
29

FUNDRAISING DETAILS

COMMERCIAL STAGE
R&D

REVENUE RANGE
$2.4M

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Project Equity, Strategic Partnership, Government Funding, Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Government, Philanthropic, Private Equity, Project Finance, Venture Capital, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Publicly Traded

Brian G. Rash, PhD
brash@longeveron.com
longeveron.com

COMPANY DESCRIPTION

Longeveron is a clinical trial-stage biopharmaceutical company with a team of experienced scientists and clinicians actively engaged in the Healthspan task, focusing on aging-related frailty, immune dysfunction, and Alzheimer's disease. Our investigational product is Lomecel-BTM, a clinical-stage stem cell therapy, that has completed five clinical trials in the USA. The unique properties of Lomecel-BTM indicate potential abilities to repair and rejuvenate muscle, the immune system, and improve brain function in cognitive decline.

CORE INNOVATION

Cell based therapy with Lomecel-BTM, a mesenchymal stem cell (MSC), is a particularly attractive treatment candidate for multiple aging related conditions, as it encompasses pro-vascular, immunomodulatory, and tissue repair mechanisms of action. For cognitive decline in aging, including the delay or prevention of Alzheimer's disease, these functions could represent a neuroprotective dimension to treatment that addresses root causes of neuronal death. The pleiotropic mechanisms of action (MOA) of Lomecel-BTM are aligned with the treatment of multiple aging related disease states and hence improved healthspan, and could prove more effective than a single drug and single MOA.

HEALTHSPAN

Based on the data from our published clinical trials, we observe improvements in muscle, immune, and cognitive function compared with placebo. These stem cells secrete a variety of important factors, including proteins and exosomes, that act on target cells in many places in the body. The precise mechanisms of action are a matter of ongoing research.

LEADERSHIP TEAM

Our team has successfully executed clinical trials for Lomecel-BTM for the past 10 years, and consists of multiple seasoned clinical investigators, scientists with extensive cardiac, geroscience, neuroscience, stem cell, and brain research backgrounds, expert biostatisticians, and experienced regulatory support personnel required to manage the scope and logistical complexity of a Finals clinical trial for the X-Prize Healthspan competition. We have conducted trials internationally under FDA and PMDA approval, and are skilled at handling and distributing our therapeutic product world-wide in a manner complaint with regulatory laws.

LONGEVITY IMMUNOTHERAPY

COMPANY OVERVIEW

TEAM / COMPANY NAME
Longevity Immunotherapy

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Irvine, CA, USA

YEAR FOUNDED
2019

NUMBER OF EMPLOYEES
13

FUNDRAISING DETAILS

COMMERCIAL STAGE
R&D

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
$38M

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Strategic Partnership, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Corporate/Strategic, Family Office, Venture Capital, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Series A-1

Mark Cabato
mark@immunisbiomedical.com
immunisbiomedical.com

COMPANY DESCRIPTION

Immunis is a clinical-stage biotech developing stem cell-derived biologics to address age and immune-related diseases. Immune health and metabolic health decline with age, commonly manifesting as muscle atrophy (sarcopenia), obesity and reduced physical function. Our investigational IMM01-STEM therapeutic contains all-natural biomolecules published in aged mouse models to improve muscle mass and strength, enhance immune cell recruitment, increase lean mass, reduce fat mass and increase physical activity. Immunis completed a Phase 1/2a clinical trial testing IMM01-STEM's safety, tolerability and efficacy in sarcopenic individuals with knee osteoarthritis and is conducting a Phase 2 placebo-controlled study in adults with sarcopenic obesity.

CORE INNOVATION

Immunis developed and patented IMM01-STEM, a multi-active biologic containing hundreds of naturally secreted stem cell factors that can influence multiple cellular pathways simultaneously. In published preclinical mouse models, IMM01-STEM is immunomodulatory, improves physical function, enhances muscle growth, strength and regeneration, and improves metabolism and fat content. Our completed Phase 1/2a clinical trial of IMM01-STEM in older adults with muscle atrophy associated with knee osteoarthritis demonstrated safety and preliminary efficacy (NCT05211986). Our FDA-approved Phase 2a/b placebo-controlled, randomized and blinded clinical trial will evaluate IMM01-STEM dosing and efficacy to improve muscle strength and function in older individuals with sarcopenic obesity (NCT06600581).

HEALTHSPAN

Sarcopenia will affect 100% of people as they get older, and it is often observed in conjunction with obesity. Sarcopenic obesity is a major medical challenge as there are no pharmaceutical treatments. Weight loss drugs may cause unintended muscle loss, which is linked to increased disability, hospitalization, chronic inflammation and diminished quality of life. IMM01-STEM aims to reverse these negative effects by 1) promoting muscle growth, strength, tissue regeneration and capillary blood supply, 2) reducing intramuscular fat and toxic ceramide content, 3) decreasing body fat and improving overall physical function, a powerful combination well-suited to improve healthspan.

LEADERSHIP TEAM

Dr. Hans Keirstead, Team Leader of Longevity Immunotherapy, is the Chairman of Immunis and CEO of HIP. Dr. Keirstead has longstanding academic and business relationships with key team members Dr. Gabriel Nistor (Chief Medical Officer at Immunis) and Dr. Thomas Lane (Chief Science Officer at Immunis) that span over three decades. Together, Drs. Keirstead and Nistor have 1) founded several successful biotechnology companies that were sold to major pharmaceutical companies, 2) designed and executed 18 multi-center clinical trials and 3) been granted over 120 patents. These accomplishments demonstrate our leadership's mastery in transforming scientific innovation into real-world human therapies.

COMPANY OVERVIEW

TEAM / COMPANY NAME
MetHealthspan

TRACK
Healthspan

ORGANIZATION TYPE
University Team

HQ LOCATION
New York City, NY, USA

YEAR FOUNDED
1754 (Columbia University)

NUMBER OF EMPLOYEES
13,000

FUNDRAISING DETAILS

COMMERCIAL STAGE
Readily Scalable

REVENUE RANGE
$6.6B

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Government Funding, Academic/ University Grants

TYPE OF INVESTORS SOUGHT
Government, Philanthropic, Academic/ University Grants

AMOUNT OF CAPITAL SOUGHT
$10M

CURRENT INVESTMENT STAGE
Grant

Jose Luchsinger
jal94@cumc.columbia.edu
colombia.edu

METHEALTHSPAN

COMPANY DESCRIPTION

University based research center.

CORE INNOVATION

Experience with clinical trials in the aging space, multidisciplinary team.

HEALTHSPAN

Metformin has pleiotropic effects that affect multiple pathways that influence aging.

LEADERSHIP TEAM

PI Luchsinger is an expert in clinical trials and prevention on cognitive aging. Co-investigator Teresi is an expert in gerontology and clinical trials. Co-investigator Hanley is an expert in multisite clinical trials.

TOP 40

MINICIRCLE

COMPANY OVERVIEW

TEAM / COMPANY NAME
Minicircle

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Austin, TX, USA

YEAR FOUNDED
2019

NUMBER OF EMPLOYEES
15

FUNDRAISING DETAILS

COMMERCIAL STAGE
Growth Stage (beyond initial customers)

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Government Funding

TYPE OF INVESTORS SOUGHT
Corporate/Strategic, Family Office, Government, Philanthropic, Venture Capital

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Seed

Hannah Cweigenberg
coordinator@minicircle.clinic
minicircle.io/

COMPANY DESCRIPTION

Minicircle is the gene therapy technology for people to build the future they envision for themselves.

CORE INNOVATION

Our team at Minicircle developed the irrationally neglected plasmid gene therapy approach in stealth for over five years to create a safer, more accessible, 10x more affordable gene therapy platform to advance human longevity.

HEALTHSPAN

Our decentralized, modified Phase 1 clinical trial using our Follistatin plasmid gene therapy had zero adverse effects reported, and also efficacy including lean mass gain, body fat reduction, and lowered epigenetic age, all consistent with literature. Preliminary internal data for ^{3}-Klotho are also promising, consistent with literature reports of improved cognition. We propose to test the combination of FST and KL in older persons to optimally target aging-induced frailty, cognitive decline, and immunoinflammatory dysregulation as outlined by the XPRIZE Healthspan guidelines.

LEADERSHIP TEAM

The Minicircle Team Leader is CEO of Minicircle, Inc., Mac Davis. Our team Co-Lead is Director of Longevity Research, Ryan Rossner, Ph.D. Our Principle Investigator is Dr. Glenn C. Terry.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Mitochondrial Bioenergetics and Ketone Utilization

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
San Diego, CA, USA

YEAR FOUNDED
2023

NUMBER OF EMPLOYEES
2

FUNDRAISING DETAILS

COMMERCIAL STAGE
Pre-Commercial Pilot

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Project Equity, Convertible Debt, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Angel, Family Office, Government, Philanthropic, Private Equity, Venture Capital, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
$1.5M

CURRENT INVESTMENT STAGE
Pre-Seed

Vassili Kotlov
vassili@mitargos.com

MITOCHONDRIAL BIOENERGETICS AND KETONE UTILIZATION

COMPANY DESCRIPTION

The MIDR1V3 & Mitargos: Advancing Brain Health

MIDR1V3 and Mitargos unite wellness with purpose, revolutionizing brain bioenergetics. MIDR1V3 offers a clean, fat-based energy beverage to enhance focus, reduce fatigue, and support brain health—while funding neurodegenerative research. Mitargos' MG-001 therapy targets energy deficits in Alzheimer's, TBI, and aging, benefiting active military, veterans, and contact sports. Together, they bridge consumer wellness with scientific innovation, redefining brain health and aging solutions through purpose-driven impact.

CORE INNOVATION

Core Differentiating Aspect: Novel Mitochondrial Bioenergetic Blood Markers, Dose-Response Insights & Scalable Impact

This project pioneers the use of mitochondrial bioenergetic blood-based markers to demonstrate a never-before-shown dose-response relationship between exogenous ketones and enhanced mitochondrial function. By leveraging R13BDO, an exogenous ketone precursor, this study provides direct proof of its impact on ATP production and metabolic efficiency in energy-intensive organs like the brain, heart, and muscles. The initial OTC MIDR1V3 beverage and future sustained-release twice-daily pharmaceutical formulation offer a scalable intervention targeting aging, TBI, and dementia. This novel approach sets a new standard for assessing mitochondrial health while delivering accessible solutions for neurodegeneration and longevity.

HEALTHSPAN

Aging is marked by a decline in mitochondrial ATP production, leading to energy deficits in high-demand organs like the brain, heart, and muscles. This energy gap contributes to neurodegeneration, impaired muscle function, and reduced resilience to stress. Our intervention, using exogenous ketones via the MIDR1V3 beverage and a future pharmaceutical formulation, provides an alternative fuel source that bypasses glucose limitations, enhances mitochondrial efficiency, and reduces oxidative stress. By improving cellular energy metabolism, reducing inflammation, and supporting muscle preservation, our approach targets aging at its core—enhancing cognitive function, physical endurance, and overall longevity.

LEADERSHIP TEAM

Dr. Anthony Molina, Professor of Medicine at UC San Diego and Research Chief in Geriatrics, leads groundbreaking research in mitochondrial bioenergetics and aging. As Scientific Director of the Stein Institute for Research on Aging, he oversees major studies, including the Successful Aging Evaluation (SAGE). Dr. James Lowder, a hematologist/oncologist with 30+ years of clinical development experience, co-led the first human study on R13BDO safety and pharmacokinetics. Vassili Kotlov, CEO of Mitargos, brings 20+ years in biotech, pharma, and diagnostics commercialization. Together, they drive innovation in mitochondrial-targeted therapies for aging, neurodegeneration, and metabolic health.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Mito-tags

TRACK
Healthspan

ORGANIZATION TYPE
University Team

HQ LOCATION
Palo Alto, CA, USA

YEAR FOUNDED
2025

NUMBER OF EMPLOYEES
n/a

FUNDRAISING DETAILS

COMMERCIAL STAGE
Prefer not to say

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Strategic Partnership, Government Funding, Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Government, Philanthropic, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Academic/University Grants

Colwyn A Headley
Cheadley@Stanford.edu

MITO-TAGS

COMPANY DESCRIPTION

Our team specializes in mitochondrial bioengineering & mitochondrial transplantation for the immune-neuro-cardiovascular axis.

CORE INNOVATION

Mito-tags are a first-in-class platform enabling antibody-guided mitochondrial transplantation. By conjugating healthy mitochondria to cell-specific antibodies (e.g., anti-CD31, anti-CD11a), Mito-tags achieve precise, receptor-mediated delivery to vascular and immune cells. This restores cellular bioenergetics, reduces oxidative stress, and reverses senescence and exhaustion phenotypes. Unlike encapsulated or scaffold-based approaches, Mito-tags promote rapid, direct uptake by target cells—unlocking organelle-level rejuvenation without invasive manipulation.

HEALTHSPAN

Mito-tags improve healthspan by restoring mitochondrial function in aging and chronically stressed cells, especially within the immune and vascular systems. By delivering healthy mitochondria directly to senescent or exhausted cells, Mito-tags rejuvenate bioenergetics, reduce oxidative stress, and enhance cellular resilience. This leads to improved immune surveillance, vascular function, and tissue regeneration, thereby delaying the onset of age-related diseases and preserving physiological function over time.

LEADERSHIP TEAM

Our interdisciplinary team brings together leading experts in mitochondrial biology, immunology, neuroscience, vascular aging, and clinical trial design. The effort is led by Dr. Colwyn Headley, inventor of Mito-tags and a recognized leader in aging-associated mitochondrial dysfunction. He is joined by Dr. Philip Tsao, a nationally renowned expert in cardiovascular medicine and vascular biology, and Dr. Irene Llorente, a specialist in neuroscience and regenerative therapeutics. With decades of combined research excellence, the team offers the translational insight, operational capacity, and scientific rigor to successfully execute this transformative therapeutic program.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Mitochondrial All-Stars

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Needham, MA, USA

YEAR FOUNDED
2006

NUMBER OF EMPLOYEES
60

FUNDRAISING DETAILS

COMMERCIAL STAGE
n/a

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Project Equity, Strategic Partnership

TYPE OF INVESTORS SOUGHT
Corporate/Strategic, Family Office, Venture Capital

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Corporate

David A. Brown, PhD
david.brown@stealthbt.com
stealthbt.com/our-company

MITOCHONDRIAL ALL-STARS

COMPANY DESCRIPTION

Stealth BioTherapeutics is a small privately held company developing innovative therapies for mitochondrial disorders. Our dedicated team has progressed mitochondria-targeted therapies far along in the clinic, having completed several Phase 2/3 trials in rare and age-related diseases. Stealth's mission is to lead the development of mitochondrial medicine to improve the lives of patients with diseases involving mitochondrial dysfunction, an area of high unmet clinical need. Stealth is located in the Boston area and has approximately sixty employees.

CORE INNOVATION

This application proposes to improve healthspan with elamipretide, a clinical-stage mitochondria-targeting peptide perfectly positioned to treat age-related declines in energy production. Elamipretide has an established record for safety (tested in over 1700 humans to date) and scientific investigation (over 150 peer-reviewed publications by groups spanning the globe). This includes published data showing efficacy of elamipretide improving muscle energetics in aged individuals. Our solution includes this innovative therapy, a battle-tested team bringing mitochondrial therapies into the clinic, and a clinical center of excellence poised to recruit aged individuals.

HEALTHSPAN

Mitochondria are the powerhouses of cells, and mitochondrial dysfunction is a substantial contributor to the loss of healthspan. In particular, there is unequivocal evidence that age-related declines in the cellular energy grid drive the loss of muscle function, trigger inflammatory cascades, and contribute to losses in cognition. Elamipretide has been shown to improve age-related declines in cellular energy production in humans and animal models of aging. Elamipretide targets the inner mitochondrial membrane to restore mitochondrial structure and function, and has been shown to improve muscle, cognitive, and inflammatory markers associated with aging.

LEADERSHIP TEAM

Dr. David A. Brown is team leader and is Senior Vice President at Stealth BioTherapeutics. He has twenty five years of experience researching cellular energy production, including studying elamipretide for over fifteen years. Dr. Brown is an experienced scientist, leader, and enthusiastic 'mitochondriac'. Dr. Jim Carr is Chief Clinical Development Officer at Stealth BioTherapeutics and oversees all clinical and regulatory activities. Dr. Carr has progressed elamipretide development through numerous late-stage trials and regulatory milestones, including an ongoing Phase 3 study in age-related macular degeneration. Dr. Carr has decades of experience in industry. Dr. David J. Marcinek is Professor at the University of Washington and is co-director of the Healthy Aging and Longevity Institute and the Nathan Shock Center at UW. He has two decades of experience studying the biology of aging both in humans and in laboratory studies, with a focus on mitochondria-targeted interventions.

COMPANY OVERVIEW

TEAM / COMPANY NAME
NUS Academy for Healthy Longevity

TRACK
Healthspan

ORGANIZATION TYPE
University Team

HQ LOCATION
Singapore

YEAR FOUNDED
2023

NUMBER OF EMPLOYEES
20

FUNDRAISING DETAILS

COMMERCIAL STAGE
Academic Institution

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
No

TYPE OF CAPITAL SOUGHT
Philanthropic Funding, Academic/ University Grants

TYPE OF INVESTORS SOUGHT
Corporate/Strategic, Family Office, Government, Philanthropic, Project Finance, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Academic/University Grants

Andrea Britta Maier
a.maier@nus.edu.sg
longevityacademy.sg

NUS ACADEMY FOR HEALTHY LONGEVITY

COMPANY DESCRIPTION

The NUS Academy for Healthy Longevity, based in Singapore, is dedicated to advancing research and clinical applications in precision geromedicine. Led by Professor Andrea Maier, our multidisciplinary team comprises experts in gerontology, digital health, clinical psychology, and health management innovation. Our laboratory and clinical facilities support cutting-edge research in geromedicine, employing advanced technologies for biological, clinical, and digital phenotyping and biomarker analysis. Through collaborative partnerships, we aim to revolutionize healthy aging and extend healthspan by developing innovative, personalized interventions.

CORE INNOVATION

Our core innovation lies in our multimodal precision geromedicine intervention, a highly personalized approach that moves beyond the “one-size-fits-all” model. This intervention integrates lifestyle modifications, dietary supplements, and repurposed drugs to optimize muscle, cognitive, and immune function. Using comprehensive baseline diagnostics, we tailor interventions to individual biological, clinical, and digital markers of aging. Our research leverages cutting-edge biomarker analysis, genomics, and AI-driven data interpretation to continuously refine therapeutic strategies, ensuring maximal efficacy. By individualizing preventative care, our approach paves the way for a new paradigm in longevity medicine.

HEALTHSPAN

This is an 8-week single-arm study with 20 middle-aged to older adults (age 50–80 years) which aims to evaluate the effectiveness and feasibility of a multimodal precision geromedicine intervention which consists of two parts: a basic intervention, provided to all participants, and a personalized intervention. Our primary outcomes are related to muscle (e.g., VO2peak), cognition (NIH Toolbox Fluid Composite score), and immune function (CD4+:CD8+ ratio). Additionally, we will evaluate a multitude of secondary outcomes related to the biology of aging (e.g., biological age) as well as those related to feasibility (e.g., adherence to the interventions, participation and dropout rate).

LEADERSHIP TEAM

Our leadership team is spearheaded by Professor Andrea B. Maier, MD, PhD, an internationally recognized expert in geroscience and precision geromedicine. She is the Director of the NUS Academy for Healthy Longevity, with extensive experience in internal medicine, aging research, and translational medicine. Supporting her is Professor Cuilin Zhang, a clinical epidemiologist specializing in disease prevention, and Associate Professor Paul MacAry, an expert in immunology and biotech innovation. The team includes a diverse group of research fellows, clinicians, and data scientists, all committed to pioneering advancements in longevity science through interdisciplinary expertise, clinical research, and global collaborations.

COMPANY OVERVIEW

TEAM / COMPANY NAME
NYC-Vita

TRACK
Healthspan

ORGANIZATION TYPE
University Team

HQ LOCATION
New York, NY, USA

YEAR FOUNDED
1968

NUMBER OF EMPLOYEES
n/a

FUNDRAISING DETAILS

COMMERCIAL STAGE
Pre-Commercial Pilot

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Strategic Partnership, Government Funding, Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Government, Philanthropic, Private Equity, Project Finance, Venture Capital, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Academic/University Grants

Dr. Miriam Merad
miriam.merad@mssm.edu
icahn.mssm.edu

NYC-VITA

COMPANY DESCRIPTION

NYC-Vita unites more than 30 experts from Mount Sinai's Aging Program with a group of advisors to drive innovations in healthy aging. Our multidisciplinary team integrates expertise in inflammation, muscle biology, and cognitive health with advanced skills in proteomics, genomics, epigenetics, and ex vivo imaging. With a strong basic and clinical research foundation, we are poised to transform scientific insights into therapies that extend human healthspan and counteract physiological decline.

CORE INNOVATION

Our Semi-Finals Trial will test a novel combination of two well-known antiaging strategies—exercise and spermidine supplementation—with lamivudine, a drug we have shown can inhibit aging driven myelopoiesis, and rapamycin, an established anti-aging drug that suppresses inflammatory macrophages. Together, these interventions—all currently in clinical trials with no reported safety concerns—all target aging macrophages to rebalance these cells and enhance immune function, improve muscle and cognitive health, and extend healthspan.

HEALTHSPAN

We are conducting a Phase 1b trial testing safety and feasibility of combining exercise withtherapeutics to mitigate inflammation and aging via their effects on tissue health and the protective activities of tissue-resident macrophages. Spermidine restores tissue resident macrophages, enhances autophagy and mitochondrial health, and extends longevity. Rapamycin targets mTOR, improves cellular and metabolic homeostasis, and restores vaccine responses, while lamivudine, a reverse transcriptase inhibitor, reduces inflammaging. Key measures include adherence and safety (CTCAE criteria) at the 60-dayprimary endpoint, and senescence and immune markers (e.g. NLR), with comprehensive immune and proteomics analysis over an extended 180-day intervention period.

LEADERSHIP TEAM

NYC-Vita unites multidisciplinary experts from the Icahn School of Medicine at Mount Sinai. In partnership with pioneers in the discovery and validation of blood biomarkers and advanced imaging, we aim to monitor human healthspan at the molecular, cellular, and tissue level. Team lead Dr. Miriam Merad, a pioneer in macrophage biology, inflammaging, and deep immune profiling, collaborates closely with Dr. Fanny Elahi, an expert in cognitive decline markers. Dr. Zahi Fayad, a specialist in imaging and longevity, leads the muscle team. Dr. Thomas Marron, Director of the Early Phase Trial Unit, pioneers the design of innovative, adaptive clinical trials integrating immune profiling.

TOP 40

PROMETHEUS CELL TEAM

COMPANY OVERVIEW

TEAM / COMPANY NAME
Prometheus Cell Team

TRACK
Healthspan

ORGANIZATION TYPE
University Team

HQ LOCATION
Shanghai, China

YEAR FOUNDED
2013

NUMBER OF EMPLOYEES
15

FUNDRAISING DETAILS

COMMERCIAL STAGE
n/a

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Strategic Partnership, Government Funding, Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
n/a

AMOUNT OF CAPITAL SOUGHT
$1M

CURRENT INVESTMENT STAGE
n/a

Orion Fan
medpjoryan427419@gmail.com

COMPANY DESCRIPTION

Our team specializes in age-related diseases, cell and gene therapy, and personalized regenerative medicine. Leveraging resources from Shanghai Tongji Hospital as well as the Chinese National Base for Stem Cell Research, we developed a breakthrough Autologous Rejuvenated Cell (ARC) technology, which reprograms dermal fibroblasts into rejuvenated mesenchymal stem cell-like Prometheus cells. Our goal is to use Prometheus cells to treat age-related medical conditions and even reverse aging.

CORE INNOVATION

Our team proposes a groundbreaking therapy utilizing autologous rejuvenated mesenchymal stem cell-like (Prometheus) cells to extend healthspan and lifespan. These cells, derived from epigenetic reprogrammed dermal fibroblasts via bioactive molecules, exhibit robust immune-modulatory, anti-inflammatory, and trophic functions by secreting factors such as BDNF and PDGF. Preclinical and compassionate-treatment studies in aging and ALS models highlight their safety, efficacy in reducing inflammation, preserving motor neuron function, and enhancing immune health. Building on these findings, the team will optimize dosing strategies during semi-finals testing to maximize therapeutic benefits against aging and related conditions.

HEALTHSPAN

Building on preliminary data showing an about 1.2-fold increase in telomere length with no safety concerns, the semi-finals study will evaluate Prometheus cell therapy in 16 participants aged 50–80. This trial employs a robust self-controlled design, measuring DNA methylation changes (primary endpoint), telomere length, naive CD8 T cells, muscle function, and cognitive performance (secondary endpoints). The study spans a 1-month screening phase, 4-month treatment period, and 5-month follow-up, using cutting-edge laboratory and statistical methods to refine therapeutic metrics and mechanisms for healthspan extension.

LEADERSHIP TEAM

Led by Dr. Yi Eve Sun, a renowned expert in stem cell biology and regenerative medicine, the multidisciplinary team combines academic excellence, clinical expertise, and entrepreneurial vision. Dr. Sun's extensive experience in neural repair and aging is complemented by the clinical leadership of Dr. Aibing Liang and Dr. Wenlin Ma, who bring expertise in geriatrics and clinical trials. Dr. Wenmin Zhu's commercialization experience ensures efficient transition from research to market-ready products.

TOP 40

COMPANY OVERVIEW

TEAM / COMPANY NAME
Rejuvenation through Low Frequency Ultrasound

TRACK
Healthspan

ORGANIZATION TYPE
University Team

HQ LOCATION
San Antonio, TX, USA

YEAR FOUNDED
2024

NUMBER OF EMPLOYEES
0

FUNDRAISING DETAILS

COMMERCIAL STAGE
Pre-Commercial Pilot

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
No

TYPE OF CAPITAL SOUGHT
Academic/University Grants

TYPE OF INVESTORS SOUGHT
Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Academic/University Grants

Blake B. Rasmussen, PhD
rasmussenb@uthscsa.edu

REJUVENATION THROUGH LOW FREQUENCY ULTRASOUND

COMPANY DESCRIPTION

University lab.

CORE INNOVATION

Novel approach, use of low frequency ultrasound in humans to alter components of aging.

HEALTHSPAN

Rejuvenation of senescent cells.

LEADERSHIP TEAM

Blake Rasmussen, PhD. Professor & Chair, UT Health San Antonio School of Medicine, Department of Cellular & Integrative Physiology; Elena Volpi, MD, PhD, Director of the UT Health San Antonio Barshop Institute for Longevity & Aging Studies.

RPRGAON-PROGERIA/PRG S&TECH

COMPANY OVERVIEW

TEAM / COMPANY NAME
RPRGAON-Progeria/PRG S&Tech

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Busan, South Korea

YEAR FOUNDED
2017

NUMBER OF EMPLOYEES
50

FUNDRAISING DETAILS

COMMERCIAL STAGE
R&D

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
$40M

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Strategic Partnership, Government Funding

TYPE OF INVESTORS SOUGHT
n/a

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Series B

melissa1250@prgst.com
bk728@prgst.com
prgst.com

COMPANY DESCRIPTION

PRG S&Tech, a South Korea-based biotech company specializing in rare disease research and drug development, has been dedicated to studying Hutchinson-Gilford Progeria Syndrome (HGPS), a rare disorder characterized by accelerated aging approximately 10 times faster than normal. Through years of investigation into the pathogenesis of HGPS, we identified Progerin, a mutant form of lamin A protein, as a critical driver of the disease. We developed Progerinin, a small molecule that selectively induces the degradation of Progerin. It is in Phase 2a trial from January 2025 in Boston Children's Hospital. First clinical efficacy data is expected to come by September 2025.

CORE INNOVATION

Our company identifies the causes of rare genetic diseases and develops treatments based on these findings through PPI(Protein-Protein Interaction Inhibitor) screening methods and optimization technologies for Hit chemicals.

HEALTHSPAN

Emerging evidence from HGPS research suggests that Progerin accumulation also plays a role in natural aging processes, particularly in tissues such as arteries, muscles, and adipose. Building on this, our team conducted a 4-week study of a topical skin serum containing 1% Progerinin in healthy individuals, which showed a statistically significant 23.6% improvement in dermal density. These findings support the broader potential of Progerinin in mitigating age-related degeneration. As part of our commitment to advancing healthy aging, we aim to explore the therapeutic benefits of oral Progerinin in clinical trials targeting general populations.

LEADERSHIP TEAM

Since Progerinin has already entered Phase 2 clinical trials, its manufacturing processes for large-scale production have been securely established. This significantly increases the potential for achieving economies of scale compared to compounds in the preclinical stage. A supply chain for the synthesis, storage, and distribution of Progerinin has already been established, providing a solid foundation for large-scale production and global distribution. Data derived from Phase 2 clinical trials can serve as critical evidence of Progerinin's potential for commercial manufacturing scalability. This adds a level of credibility that surpasses preclinical compounds.

SANJEEVINI

COMPANY OVERVIEW

TEAM / COMPANY NAME
Sanjeevini

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Mumbai, Maharashtra, India

YEAR FOUNDED
2014

NUMBER OF EMPLOYEES
100

FUNDRAISING DETAILS

COMMERCIAL STAGE
Growth Stage (beyond initial customers)

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
~$40M

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Convertible Debt, Strategic Partnership, Academic/ University Grants

TYPE OF INVESTORS SOUGHT
Corporate/Strategic, Family Office, Private Equity, Venture Capital

AMOUNT OF CAPITAL SOUGHT
$25M

CURRENT INVESTMENT STAGE
Series C

Vishal Gondal
vishal@goqii.com
goqii.com

COMPANY DESCRIPTION

GOQii is a leading preventive health-tech company that integrates advanced wearables, personalized coaching, and gamification to drive lasting lifestyle transformations. Combining AI-driven analytics with behavioral science, GOQii empowers individuals to proactively manage their health, prevent chronic diseases, and extend their healthspan. Inspired by gaming principles, its rewards-driven ecosystem keeps users engaged, making wellness an interactive and motivating experience. By blending technology, real-time coaching, and data-driven insights, GOQii transforms health management into an enjoyable and sustainable journey, helping millions take control of their well-being and lead healthier, longer lives.

CORE INNOVATION

The Sanjeevini SuperLife Project uniquely integrates cfDNA and omics-based diagnostics with a gamified, AI-driven health engagement platform to enhance healthspan. Unlike traditional longevity approaches, it combines biological age assessment, personalized interventions including nutrition, exercise, and cognitive training, and real-time progress tracking using interactive avatars and rewards. Our solution drives measurable improvements in immunity, muscle mass, cognition, and organ aging, ensuring long-term impact through behavioral science, digital health innovations, and scalable implementation. This holistic, tech-enabled approach makes longevity actionable, engaging, and accessible, setting it apart from conventional healthspan interventions.

LEADERSHIP TEAM

GOQii's leadership team brings together experts from diverse backgrounds, including health-tech, AI, genomics, and behavioral science. With leaders from institutions like IIT Bombay, Ashoka University, HN Reliance Hospital, and Acrannolife Genomics, the team blends expertise in digital health, precision medicine, and gamification. Their experience spans AI-driven diagnostics, clinical research, and large-scale preventive healthcare programs. By integrating advanced analytics, wearable technology, and personalized coaching, they are pioneering a scalable, engaging, and data-driven approach to longevity and healthspan extension. This multidisciplinary team is committed to transforming global health through cutting-edge research, technology, and behavioral science.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Team GlyNAC

TRACK
Healthspan

ORGANIZATION TYPE
University Team

HQ LOCATION
Houston, TX, USA

YEAR FOUNDED
n/a

NUMBER OF EMPLOYEES
n/a

FUNDRAISING DETAILS

COMMERCIAL STAGE
Prefer not to say

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Prefer not to say

TYPE OF CAPITAL SOUGHT
Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Philanthropic, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Prefer not to say

RV Sekhar MD
rsekhar@bcm.edu

TEAM GLYNAC

COMPANY DESCRIPTION

Baylor College of Medicine is a medical school involved in healthcare, research and education.

CORE INNOVATION

GlyNAC is proved to reverse multiple defects in aging, primarily mitochondrial dysfunction.

HEALTHSPAN

GlyNAC has thus far been shown in a completed RCT to improve/reverse 7 aging hallmarks.

LEADERSHIP TEAM

Dr. Sekhar is team lead, and has over 27 years in aging research and he discovered GlyNAC.

COMPANY OVERVIEW

TEAM / COMPANY NAME
The Healthy Mind and Body

TRACK
Healthspan

ORGANIZATION TYPE
University Team

HQ LOCATION
Saint Louis, MO, USA

YEAR FOUNDED
2013

NUMBER OF EMPLOYEES
25

FUNDRAISING DETAILS

COMMERCIAL STAGE
Well Established Academic Institution

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
No

TYPE OF CAPITAL SOUGHT
n/a

TYPE OF INVESTORS SOUGHT
n/a

AMOUNT OF CAPITAL SOUGHT
n/a

CURRENT INVESTMENT STAGE
n/a

Eric Lenze, MD
lenzee@wustl.edu
healthymind.wustl.edu

THE HEALTHY MIND AND BODY

COMPANY DESCRIPTION

The Healthy Mind Lab aims to improve health outcomes by studying treatments that promote healthy minds and healthy bodies across your lifespan.

CORE INNOVATION

The Healthy Mind Lab at Washington University School of Medicine in St. Louis focuses on cutting-edge research to understand and improve mental and physical health through innovative, science-backed solutions. Our team's differentiating aspect lies in our multidisciplinary approach, combining neuroscience, psychology, and technology to create personalized interventions. By leveraging advanced analytics, we identify novel biomarkers and design targeted therapies to enhance cognitive function, reduce stress, and promote mental well-being. This approach allows us to deliver more effective, tailored solutions that address the root causes of health challenges, ultimately improving long-term outcomes for individuals.

HEALTHSPAN

Our therapeutic intervention improves healthspan by targeting the three critical domains of physical, cognitive, and immune health in older adults. Through a personalized, multicomponent approach, we promote healthy behaviors, optimize medical therapies, and enhance cognitive function. We combine evidence-based lifestyle management, geroprotective medications, and advanced cognitive training to mitigate the effects of aging. By incorporating adaptive exercise, dietary interventions, and treatments like senolytics and anti-aging supplements, we aim to improve strength, memory, and overall health, potentially offsetting aging by 20 years. Our intervention is scalable, accessible, and tailored to individual needs, ensuring broad impact across diverse populations.

LEADERSHIP TEAM

Dr. Eric Lenze, Wallace & Lucille Renard Professor of Psychiatry and Chair of the Department of Psychiatry at Washington University School of Medicine, leads the Healthy Mind Lab, focusing on aging, mental health, and clinical trials across the lifespan.

Dr. Breno Diniz, Associate Professor of Psychiatry at the UConn Center on Aging is a researcher specializing in the development of biomarkers for age-related neurodegenerative disorders.

Together, they bring extensive expertise in aging, mental health, and clinical research to our leadership team.

COMPANY OVERVIEW

TEAM / COMPANY NAME
TIME TRAVELER AND CURREIO

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Taito, Tokyo, Japan

YEAR FOUNDED
n/a

NUMBER OF EMPLOYEES
5

FUNDRAISING DETAILS

COMMERCIAL STAGE
R&D

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Prefer not to say

TYPE OF CAPITAL SOUGHT
Prefer not to say

TYPE OF INVESTORS SOUGHT
Angel

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Pre-Seed

Tomoatsu Hayashi
hayashi@ttraveler.jp
ttraveler.jp/

TIME TRAVELER

COMPANY DESCRIPTION

TIME TRAVELER Inc. (TT Inc.) is a startup established to translate the research achievements of Professor Tetsu Akiyama into societal benefits. At TT Inc. are focused on developing inhibitors targeting Neurotrimin (NTM), a membrane-associated and secreted protein implicated in aging, with the aim of extending lifespan and achieving healthy longevity. Curreio Inc. (Curreio) specializes in drug discovery based on structural analysis using cryo-electron microscopy. The company also leverages AI-driven in silico screening technology to design small-molecule compounds using structural analysis data.

CORE INNOVATION

In collaboration with TIME TRAVELER Inc., Curreio is advancing drug discovery efforts targeting NTM, a membrane/secreted protein that promotes aging. NTM is a novel molecule that we identified as a promoter of aging. Remarkably, we have confirmed that the NTM-neutralizing antibody exhibits potent anti-aging effects, including the suppression of age-related muscle weakness and improvement in insulin resistance. With a humanized NTM-neutralizing antibody already developed, we are ready to initiate clinical trials to advance its therapeutic potential. As NTM inhibitors are expected to suppress aging and potentially extend both healthspan and lifespan, this aligns well with the objectives of this competition, motivating our submission.

HEALTHSPAN

We will administer the NTM-neutralizing antibody to a small group of participants (approximately 20 participants in the treatment group and 20 participants in the placebo group) who have pre-sarcopenia or sarcopenia and meet specific criteria. Improvements in motor function before and after administration will be evaluated. The primary endpoint is muscle strength measurement using the 6-Minute Walk Test, with secondary assessments including grip strength, muscle mass, and BMI etc.

LEADERSHIP TEAM

TIME TRAVELER:
Winner of the 2024 Astellas Pharma x LINK-J Co-Sponsored Pitch Contest for Research and Technology Seeds Leading to Innovative Cancer Treatments.
https://www.link-j.org/event/post-7557.html

COMPANY OVERVIEW

TEAM / COMPANY NAME
Timeline

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Lausanne, VD, Switzerland

YEAR FOUNDED
2007

NUMBER OF EMPLOYEES
50

FUNDRAISING DETAILS

COMMERCIAL STAGE
Growth Stage (beyond initial customers)

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Prefer not to say

TYPE OF CAPITAL SOUGHT
Government Funding, Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Corporate/Strategic, Academic/ University Grants, Prefer not to say

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Series D

Chris Rinsch
press@timeline.com
timeline.com

TIMELINE

COMPANY DESCRIPTION

Timeline (parent company Amazentis), a pioneering longevity biotech founded at the Swiss Federal Institute of Technology (EPFL), is dedicated to redefining healthspan through its clinically proven, proprietary bioactive technology, Mitopure® (Urolithin A). With over 15 years of research, multiple clinical studies, and 50+ patents, Timeline's cutting-edge nutrition and skincare solutions support cellular health, muscle function, immune aging, cognitive function, and skin vitality. The company has published its research in top peer-reviewed journals, including Nature Medicine and Nature Metabolism. Backed by Nestlé Health Science and L'Oréal, Timeline aims to extend healthspan by making the science of aging accessible to all.

CORE INNOVATION

Urolithin A (UA) is a safe, natural and well documented mitophagy activator. Timeline has developed this over 15+ yrs. of research into a supplement backed with broad intellectual property for healthspan and longevity benefits that are backed by exciting pre-clinical and clinical science. This allows UA to have emerged as one of the most exciting nutritional discoveries in the last 15 years. Today there are thousands of consumers already integrating UA into their daily rituals- we believe the potential to scale is massive and that the confirmatory positive clinical data in a large multi-centric study for longer duration will really make UA as the "longevity molecule to beat".

HEALTHSPAN

Our team Timeline has helped put Urolithin A (UA) on the map as one of the leading Gero protective agents over the last 15+ years with sustained pre-clinical and clinical research. UA is a gut microbiome derived postbiotic compound that was identified as a potent mitophagy activator(Ryu et al. 2016; Nature Medicine). Since this seminal publication the field of research around UA has exploded (with every year ~100 new research publications). Our team has not only characterized the mechanism of action and the protective effects of UA on mitochondrial health and its impact on various organ systems, but in the last 10+ years we have conducted many RCTs across a range of human populations documenting it's impact on improving muscle, skin and immune health during the aging process. We continue to partner with leading experts on clinical studies and sponsor many new trials on UA exploring its' impact on metabolic and brain health. We believe, that UA has the potential in longer, large scale trials to show an impact on muscle, immune and brain aging thereby positioning it in pole position and perfectly aligned with the objectives of the XPrize Healthspan competition.

LEADERSHIP TEAM

The Timeline team brings together 50+ years of combined experience in clinical trials, mitochondrial biology, and geroscience research. The team is guided by a vastly experience board that includes top scientists, entrepreneurs and leading industry leaders in the biotech and consumer health space. The team is also advised by a world-class panel of top experts.

VITA

COMPANY OVERVIEW

TEAM / COMPANY NAME
VITA (Hospital del Mar Research Institute/Center for Genomic Regulation/ IrsiCaixa)

TRACK
Healthspan

ORGANIZATION TYPE
Non-Profit Organization

HQ LOCATION
Barcelona, Catalonia, Spain

YEAR FOUNDED
1992

NUMBER OF EMPLOYEES
400

FUNDRAISING DETAILS

COMMERCIAL STAGE
R&D

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
No

TYPE OF CAPITAL SOUGHT
Strategic Partnership, Government Funding, Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Corporate/Strategic, Family Office, Government, Philanthropic, Academic/ University Grants

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Academic/University Grants

Rafael de la Torre
rtorre2@researchmar.net
imim.cat/en_index.html

COMPANY DESCRIPTION

Fundació Hospital del Mar Research Institute (HMRI) is a leading biomedical research institution in Barcelona, specializing in translational medicine, aging, and neurodegenerative diseases. In collaboration with the Center for Genomic Regulation (CRG) and IrsiCaixa, our team develops innovative therapeutic strategies to extend healthspan by targeting key aging mechanisms. With extensive expertise in clinical trials, biomarker discovery, and pharmacological research, we aim to translate scientific breakthroughs into scalable, accessible health solutions for aging populations worldwide.

CORE INNOVATION

Our innovation lies in a first-of-its-kind combination therapy integrating lamivudine (a retrotransposon inhibitor), epigallocatechin gallate (EGCG), and a lifestyle intervention to simultaneously target multiple hallmarks of aging. Unlike conventional approaches that focus on isolated mechanisms, our strategy reduces inflammaging, enhances mitochondrial resilience, and restores cellular homeostasis, tackling aging at its root. Backed by leading experts in aging, pharmacology, and translational medicine, and supported by cutting-edge biomarker discovery and rigorous clinical validation, our solution is scalable, cost-effective, and ready for real-world impact in healthspan extension.

HEALTHSPAN

Our intervention integrates lamivudine, EGCG, and a multimodal lifestyle approach to enhance cognitive, immune, and muscle function. Clinical studies show that EGCG combined with lifestyle interventions improves cognitive health, while lamivudine has demonstrated anti-inflammatory and neuroprotective effects in preclinical and pilot clinical trials. Our approach targets inflammaging, mitochondrial health, and genomic stability, key factors in aging-related decline. By leveraging these mechanisms, we aim to extend healthspan by improving physiological resilience and delaying age-related deterioration, offering a scalable and cost-effective strategy for aging populations.

LEADERSHIP TEAM

Our leadership team comprises distinguished experts in aging, neurodegeneration, pharmacology, and translational medicine:

Dr. Rafael de la Torre (IMIM, Team Lead): Internationally recognized clinical pharmacologist and Director of the Integrative Pharmacology and Systems Neuroscience Research Group at IMIM, with extensive experience in clinical trials and multimodal interventions for cognitive aging.

Dr. Mara Dierssen (CRG, Co-Lead): Neurobiologist renowned for her research on Down syndrome. Internationally recognized expert contributing significantly to understanding cognitive deficits and developing therapeutic strategies.

Dr. Bonaventura Clotet (IrsiCaixa): Internationally recognized expert in infectious diseases and director of IrsiCaixa, with extensive experience in retroviral research.

This multidisciplinary leadership ensures robust expertise in preclinical-to-clinical translation, biomarker development, and healthspan interventions, positioning us at the forefront of innovative aging research.

YOXLO

COMPANY OVERVIEW

TEAM / COMPANY NAME
YOXLO

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Oegstgeest, Zuid Holland, The Netherlands

YEAR FOUNDED
2023

NUMBER OF EMPLOYEES
3

FUNDRAISING DETAILS

COMMERCIAL STAGE
R&D

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Project Equity, Convertible Debt, Strategic Partnership, Government Funding, Philanthropic Funding

TYPE OF INVESTORS SOUGHT
Angel, Family Office, Government, Philanthropic, Private Equity, Project Finance, Venture Capital

AMOUNT OF CAPITAL SOUGHT
$1M

CURRENT INVESTMENT STAGE
Family and Friends

Stef Verlinden
healthspan@yoxlo.com
yoxlo.com

COMPANY DESCRIPTION

YOXLO is a healthspan-extending biotech company developing Youngenine, an innovative nutritional supplement designed to optimize muscle strength, cognition, and immune function. Youngenine features a patented blend of bioactive ingredients that directly target aging processes. As a semifinalist in the XPRIZE Healthspan competition, YOXLO is gaining global visibility and strategic funding opportunities. With a soft launch planned for 2026, a science-backed formula, and HACCP-certified production, YOXLO is pioneering the longevity market. Youngenine is set to become the first supplement with clinically validated potential to slow aging in these three crucial areas.

CORE INNOVATION

YOXLO's breakthrough lies in Youngenine's proprietary bioactive formulation, designed to directly target key aging pathways and improve muscle strength, cognition, and immune function. Youngenine's patented blend optimizes efficacy and user compliance. The formulation has been refined through preclinical data and real-world user feedback, ensuring a science-backed solution. With HACCP-certified production and a strong research foundation, YOXLO is setting a new standard in healthspan extension. As a semifinalist in the XPRIZE Healthspan competition, the company is uniquely positioned for validation and large-scale market impact.

HEALTHSPAN

Youngenine targets key aging pathways to help maintain muscle strength, cognition, and immune function—three critical factors in age-related decline. Its patented bioactive formulation supports cellular resilience by optimizing antioxidant capacity, reducing inflammation, and enhancing metabolic function. Preclinical and real-world data suggest Youngenine has the potential to not only slow age-related decline but also improve key markers of healthspan.

LEADERSHIP TEAM

YOXLO's leadership team brings together expertise in science, marketing, operations, and law to drive healthspan innovation. CEO/CSO Dr. Stef Verlinden (MD, biotech & aging expert) leads the scientific strategy, supported by René den Admirant (CCO, commercial strategy & scaling), Louis Kock (COO, operations & logistics), and Julliet Smit (Legal Counsel, IP & compliance). The team is backed by a renowned Scientific Advisory Board specializing in cognitive aging, muscle frailty, and clinical trials. With a track record in product innovation, regulatory compliance, and commercialization, YOXLO is uniquely positioned to develop science-backed solutions for extending healthspan.

XPRIZE HEALTHSPAN | HEVOLUTION | SOLVE FSHD

FSHD

8 FINALIST TEAMS

TOP 100 HEALTHSPAN & TOP 8 FSHD TEAMS

REIMAGINE AGING

MAY 2025

ALTAY THERAPEUTICS INC.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Altay Therapeutics Inc.

TRACK
FSHD Bonus Track

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
San Carlos, CA, USA

YEAR FOUNDED
2019

NUMBER OF EMPLOYEES
5

FUNDRAISING DETAILS

COMMERCIAL STAGE
Pre-Commercial Pilot

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
$8.8M

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Project Equity, Strategic Partnership, Government Funding, Philanthropic Funding

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Philanthropic, Private Equity, Venture Capital

AMOUNT OF CAPITAL SOUGHT
$40M

CURRENT INVESTMENT STAGE
Series A

Ali Ozes
ali@altaytherapeutics.com
altaytherapeutics.com

COMPANY DESCRIPTION

Altay Therapeutics pioneers breakthrough treatments by targeting transcription factors previously considered undruggable. Our innovative drug discovery approach identifies viable drug binding sites and creates highly specific small molecule inhibitors with optimal pharmaceutical properties. Our innovative platform has enabled us to create industry-leading treatments for neuromuscular disorders and cancer, with our lead therapeutic candidate scheduled to begin clinical trials in 2026.

CORE INNOVATION

Altay Therapeutics has developed DX5057, a first-in-class oral small molecule inhibitor of the DUX4 transcription factor. DX5057 is currently under development to be a disease modifying therapy for Facioscapulohumeral Muscular Dystrophy (FSHD). Unlike ASOs and siRNAs, small moelcules have key advantages that include, more reliable pharmaceutical properties, more efficient exposure into target tissue and oral delivery. Our program is uniquely positioned to address this significant unmet medical need, supported by robust preclinical data, an experienced management team, and strategic partnerships with leading clinical centers globally.

HEALTHSPAN

Our lead compound, DX5057, represents a novel therapeutic approach that protects muscle tissue through two complementary mechanisms: breaking down harmful DUX4 protein and stimulating muscle regeneration pathways. In preclinical studies, sustained treatment with DX5057 fully restored muscle function in DUX4-affected tissue. The compound's ability to degrade DUX4 resulted in lasting therapeutic effects, suggesting potential for long-term disease stabilization.

LEADERSHIP TEAM

Altay Therapeutics is led by Dr. Ali Rayet Ozes (CEO) and Dr. Osman Nidai Ozes (CSO), who developed the company's novel approach for identifying druggable binding sites. Mike Grey, an accomplished pharmaceutical veteran with over 40 years of experience, serves as Executive Chair. The scientific team includes experts across key drug development experts that include: Dr. Lee Latimer (medicinal chemistry), Dr. Klaus Jensen (DMPK), Dr. Angela Lynch (toxicology), Dr. Bingidimi Mobele (process chemistry), and Dr. Alejandro Dorenbaum (clinical development). This experienced team combines strong understanding of small molecule development, having collectively contributed to multiple FDA-approved therapeutics and clinical-stage drug candidates.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Ani Biome

TRACK
Healthspan, FSHD Bonus Track

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
San Francisco, CA, USA

YEAR FOUNDED
2023

NUMBER OF EMPLOYEES
12

FUNDRAISING DETAILS

COMMERCIAL STAGE
Early Commercial Demonstration

REVENUE RANGE
$500K

CAPITAL RAISED TO DATE
$7M in dilutive capital and
$7M through non-dilutive grants

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Convertible Debt, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Angel, Family Office, Venture Capital, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
$25M

CURRENT INVESTMENT STAGE
Seed

Bruno Balen
genius@anibiome.ai
ani.ai

ANI BIOME

COMPANY DESCRIPTION

ANI is an AI-first longevity company advancing precision therapeutics by integrating multi-agent intelligence, digital biomarkers, and multi-omics profiling to address aging's systemic dysfunctions. Our approach, AffectoNeuroImmunology (ANI), models aging as a dynamic, interconnected process across affective, neural, and immune networks. Rather than targeting isolated pathways, ANI Biome's system benchmarks deviations from ideal homeostasis using digital biomarkers, then applies AI-driven interventions to recalibrate biological function. Our lead intervention, AB, is a predictive small-molecule therapy that optimizes gut-immune-mitochondrial interactions through short-chain fatty acid (SCFA) modulation, targeting systemic resilience and biological age reversal.

CORE INNOVATION

ANI's multi-layered intelligence framework integrates computational modeling, real-time digital biomarker tracking, and multi-omics validation to create dynamically adaptive therapeutics. We employ bacterial transformer models and graph neural networks (GNNs) to map microbiome-metabolite-pathway interactions, enabling precise modulation of gut-driven systemic processes. Rather than a static intervention, AB is refined dynamically through digital biomarker feedback (multispectral imaging, cognitive-neuro markers, immune tracking) and multi-agent AI optimization. This allows real-time adaptation of interventions based on individual biological responses, making ANI one of the first platforms to integrate predictive, AI-driven optimization into systemic longevity medicine.

HEALTHSPAN

Aging is the progressive loss of adaptive capacity across affective, neural, and immune networks, driven by energy dysregulation, chronic inflammation, and cellular inefficiency. AB targets these dysfunctions through SCFA-mediated recalibration of gut-immune-mitochondrial interactions, directly influencing bioenergetic capacity, inflammatory resolution, and neuromodulatory balance. Unlike conventional therapeutics that assume static metabolic pathways, ANI continuously benchmarks deviations from optimal function via multi-omics-integrated digital biomarkers—tracking neuro-ophthalmological signatures, immune activity, and metabolic markers in real time. This allows precise, personalized intervention design, predicting synergistic molecular inputs that systemically optimize biological function rather than targeting symptoms in isolation.

LEADERSHIP TEAM

ANI integrates AI, multi-agent systems, and digital biomarkers for precision longevity. CEO Bruno Balen develops AI architecture and multi-agent modeling for therapeutic discovery. COO Nika Pintar leads clinical deployment and AI-integrated biomarker validation. Dr. Mirna Andelic (Head of Neuroscience) specializes in multi-omics and AI-driven biomarker discovery. The team includes Dr. Eric Verdin (immune-metabolic aging), Dr. Evelyne Bischof (AI-driven longevity medicine), Dr. Domagoj Cikes (muscle metabolism), Dr. Morana Jaganjac (oxidative stress), Dr. Alexander Buko (metabolomics), and other experts, ensuring AI-driven precision and systemic health optimization.

ARMATUS BIO

COMPANY OVERVIEW

TEAM / COMPANY NAME
Armatus Bio

TRACK
FSHD Bonus Track

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Columbus, OH, USA

YEAR FOUNDED
2020

NUMBER OF EMPLOYEES
5

FUNDRAISING DETAILS

COMMERCIAL STAGE
R&D

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
$13.5M

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Strategic Partnership, Philanthropic Funding

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Philanthropic, Private Equity, Venture Capital

AMOUNT OF CAPITAL SOUGHT
$65M

CURRENT INVESTMENT STAGE
Seed

Rachel Salzman
rsalzman@armatusbio.com
armatusbio.com

COMPANY DESCRIPTION

Armatus Bio is a preclinical-stage biotechnology company developing vectorized RNAi medicines for autosomal dominant neuromuscular disorders. ARM-201 is a first-in-class drug designed to result in steady-state silencing of toxic DUX4, the genetic cause of facioscapulohumeral muscular dystrophy (FSHD). ARM-201 has completed a robust series of preclinical studies, and the company has begun regulatory engagement with FDA to prepare for human dosing. Based in Columbus, Ohio, Armatus Bio is collaborating with world-renowned gene therapy experts at Nationwide Children's Hospital.

CORE INNOVATION

ARM-201 is a novel, vectorized, engineered microRNA gene therapy that addresses the underlying genetic cause of FSHD. It was designed to target the pathological mechanisms of the disease by effectively reducing or eliminating DUX4 expression in muscle, thereby providing an effective disease-modifying treatment. Comprehensive preclinical experiments including in vitro pharmacology, in vivo pharmacology, biodistribution, and toxicology have demonstrated that ARM-201 effectively rescues the disease phenotype in both cellular and animal models. These transformative outcomes were illustrated via molecular, functional and pathological improvements. ARM-201 is thus uniquely suited to target the pathophysiology of FSHD.

HEALTHSPAN

Armatus' goal is to halt progression and preserve functionality for those affected by this debilitating, progressive neuromuscular disorder. Our comprehensive pre-clinical development program features multiple datasets that highlight a safe and effective treatment profile. Promising findings include DUX4 gene silencing, reduced DUX4 protein expression, and sustained therapeutic miRNA payload expression, thereby leading to long-term protection from muscle damage while preserving neuromuscular function. ARM-201 has a strong safety profile, including the absence of off-target effects at multiple dose levels. As such, we believe this therapeutic product holds strong promise to deliver transformative and durable outcomes for FSHD-affected individuals.

LEADERSHIP TEAM

Armatus is led by CEO Rachel Salzman, DVM, a seasoned biotech executive and expert in drug development in rare diseases; CFO Peter Kleinhenz, an accomplished life sciences financial executive; CTO Brian Price, PhD, a veteran in CMC product development; and acting CMO Steve Zelenkofske, DO, a clinical development expert. Scientific co-founder Scott Harper, PhD, is a molecular biologist and an international thought leader in gene therapy innovation for neuromuscular disease; his lab focuses on FSHD at Nationwide Children's Hospital (NCH). Advisors include Kevin Flanigan, MD, a neuromuscular disease clinical expert, and Carl Morris, PhD, an accomplished drug developer and muscle physiologist.

ASAGI LABS

COMPANY OVERVIEW

TEAM / COMPANY NAME
ASAGI Labs

TRACK
Healthspan, FSHD Bonus Track

ORGANIZATION TYPE
Non-Profit Organization

HQ LOCATION
Karuizawa-machi, Nagano, Japan

YEAR FOUNDED
2024

NUMBER OF EMPLOYEES
3

FUNDRAISING DETAILS

COMMERCIAL STAGE
R&D

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
No

TYPE OF CAPITAL SOUGHT
Strategic Partnership, Government Funding, Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Government, Philanthropic, Project Finance, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
$2M

CURRENT INVESTMENT STAGE
Academic/University Grants

Motoshi Hayano
mhayano@asagilabs.or.jp
asagilabs.or.jp/en

COMPANY DESCRIPTION

ASAGI Labs Foundation is a non-profit organization dedicated to promoting basic research on aging. It operates through collaborative projects with companies and philanthropy-based donations. ASAGI Labs Foundation has established a network of academic researchers focused on aging research and collaborates with the for-profit entity ASAGI Labs Inc. to commercialize intellectual property generated from its research. The primary roles of ASAGI Labs Foundation are to advance innovative aging research and support young talent, with a particular focus on the epigenome, inflammation, and the diversity of aging across species.

CORE INNOVATION

In Japan, high-quality medical data and extensive information on lifestyle factors, such as diet, related to the world's longest healthy life expectancy, have been accumulated. Additionally, innovative research on regenerative medicine using iPS cells, cellular senescence, and the epigenome is being conducted within Japanese academia. ASAGI Labs collaborates with such academic institutions to develop therapies for rejuvenation using compounds and treatments for immunosenescence through bioengineering. By integrating these efforts with medical data, ASAGI Labs holds multiple core technologies. Moving forward, the organization aims to continue generating diverse intellectual properties and fostering collaborations with ASAGI Labs Inc., pharmaceutical companies, and venture capital firms.

HEALTHSPAN

ASAGI Labs has conducted compound screening for controlling the epigenome and promoting cellular rejuvenation, leading to the identification of Ambroxol, an expectorant. Ambroxol is an approved drug that has been in use for over 30 years, making it highly affordable and proven safe. Its target protein is GBA1, a glucosylceramidase that regulates the functions of lysosomes, mitochondria, and autophagy. Through its effects on mesenchymal stem cells (MSCs), Ambroxol has the ability to improve cognitive function, muscle strength, and immunity.

LEADERSHIP TEAM

The ASAGI Labs team is led by Dr. Motoshi Hayano, Ph.D., an expert in the epigenome and aging. The team comprises members with experience in business development within pharmaceutical companies, consulting, and clinical trials, as well as clinicians specializing in neurology, orthopedics, respiratory medicine, and allergy/immunology. Dr. Hayano and the clinical specialists are affiliated with government-designated Clinical Research Core Hospitals, which are equipped to conduct clinical trials, including patient recruitment and trial implementation for elderly individuals and patients with FSHD. In Japan, clinical trials conducted within academia can be performed cost-effectively, with high patient adherence, enabling the ASAGI Labs team to build high-quality evidence.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Beat-FSHD

TRACK
FSHD Bonus Track

ORGANIZATION TYPE
Non-Profit Organization

HQ LOCATION
Los Angeles, CA, USA

YEAR FOUNDED
2024

NUMBER OF EMPLOYEES
n/a

FUNDRAISING DETAILS

COMMERCIAL STAGE
n/a

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Prefer not to say

TYPE OF CAPITAL SOUGHT
Prefer not to say

TYPE OF INVESTORS SOUGHT
Prefer not to say

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
n/a

Russell Rogers
Rogers.Russell@gmail.com

BEAT-FSHD

COMPANY DESCRIPTION

Beat-FSHD consists of a team of scientists and clinicians working together to develop safer and more effective therapeutic solutions for muscular dystrophies, including facioscapulohumeral muscular dystrophy. Our research portfolio spans the entire translational arc starting with drug discovery and preclinical development to clinical translation. At Beat-FSHD, we strive to deliver medical breakthroughs through our innovative pipeline.

CORE INNOVATION

Beat-FSHD team members have developed a game-changing noncoding RNA drug, called TY1, that reverses key disease manifestations in muscular dystrophy. Our lead compound, TY1, is a small chemically-modified oligonucleotide (patent pending), readily synthesized by solid phase chemistry. TY1 acts by an unprecedented mechanism (upregulation of the DNA exonuclease, TREX1), explaining its potent ability to target inflammation and fibrosis. In a proprietary micellar formulation (patent pending), TY1 is orally bioavailable, which is a significant advantage for therapeutics of a chronic illness such as FSHD.

HEALTHSPAN

Muscular dystrophies, such as FSHD, are associated with chronic inflammation that worsens disease outcomes. Immune cells, particularly macrophages, become dysregulated leading to the development of fibrofatty tissue replacement of living muscle. By targeting the immune system, TY1 supports repair and homeostasis of dystrophic muscle to improve strength and endurance.

LEADERSHIP TEAM

Russell Rogers, PhD is a muscle biologist focusing on cell therapy and regenerative medicine for human disease, including muscular dystrophies. He has been awarded grants from the Muscular Dystrophy Association and National Institutes of Health to develop and better understand how novel biologics work. Eduardo Marbán, MD, PhD is a clinical cardiologist with a deep commitment to using scientific insights to develop new and better treatments for a variety of deadly diseases. His 36-plus years of experience in patient care and research have led to key discoveries in gene and cell therapy, including the pioneering discovery of cardiosphere-derived cells, now known as deramiocel. Working together, Drs. Rogers and Marbán developed the preclinical framework that motivated the clinical testing of deramiocel to treat Duchenne muscular dystrophy.

EPICRISPR BIOTECHNOLOGIES, INC.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Epicrispr Biotechnologies, Inc.

TRACK
Healthspan, FSHD Bonus Track

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
San Francisco, CA, USA

YEAR FOUNDED
2018

NUMBER OF EMPLOYEES
37

FUNDRAISING DETAILS

COMMERCIAL STAGE
R&D

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Strategic Partnership, Government Funding, Philanthropic Funding

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Government, Philanthropic, Private Equity, Venture Capital

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Series B

Benson Cheng
benson.cheng@epic-bio.com
epicrispr.com

COMPANY DESCRIPTION

Epicrispr Biotechnologies is a leading epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company's proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells, enabling in vivo or ex vivo delivery via a single viral vector. Their lead program, EPI-321, aims to address the underlying molecular mechanisms of FSHD. It is delivered to muscle tissue within a single AAV vector (AAVrh74) which has been clinically validated for muscle delivery. Preclinical studies on EPI-321 have demonstrated its ability to robustly suppress pathological expression of the DUX4 gene and reduce muscle cell death. Clinical data is expected in 2025. In addition to a robust internal pipeline, the company partnered with Kite Pharmaceuticals to develop armored CAR-Ts.

CORE INNOVATION

We leverage the proprietary GEMS epigenetic editing platform for the development of EPI-321. This system uses ultracompact and safe CRISPR-and epigenetically-based technologies to epigenetically methylate the D4Z4 locus, which ultimately suppresses toxic DUX4 expression in muscle cells. EPI-321 is an AAVrh74-vectorized product, which is an AAV serotype that has been clinically validated to have favorable biodistribution to muscle cells and has been shown to be safe in human patients. Importantly, AAVrh74 is currently being used for in a commercially-available gene therapy product for Duchenne Muscle Dystrophy (DMD), further derisking the EPI-321 for use in FSHD patients.

HEALTHSPAN

EPI-321 is an promising investigational product that treats FSHD at the route cause. As a gene therapy that leverages epigenetic modulation, we anticipate that EPI-321 can provide durable response to patients with FSHD. At minimum, we anticipate that EPI-321 can slow the progression of FSHD, but preclinical data gives us confidence that EPI-321 could potentially halt disease progression.

LEADERSHIP TEAM

We have an exceptional team of biotech and pharma veterans in bringing multiple cell and gene therapies into the clinic, including commercially available. Epicrispr is also led by our CEO, Amber Salzman, who's family has also been impacted by FSHD and who has deep connection with the FSHD community.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Modalis Therapeutics Corporation

TRACK
FSHD Bonus Track

ORGANIZATION TYPE
Publicly Traded Company

HQ LOCATION
Tokyo, Japan

YEAR FOUNDED
2016

NUMBER OF EMPLOYEES
30

FUNDRAISING DETAILS

COMMERCIAL STAGE
R&D

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Prefer not to say

TYPE OF CAPITAL SOUGHT
Corporate Equity, Strategic Partnership

TYPE OF INVESTORS SOUGHT
Corporate/Strategic, Government, Philanthropic

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Publicly Traded

Yosuke Nakashima
yosuke@modalistx.com
modalistx.com

MODALIS THERAPEUTICS CORPORATION

COMPANY DESCRIPTION

Modalis Therapeutics, founded in 2016 and listed on the Tokyo Stock Exchange, is a forerunner in the field of epigenetic medicine. Modalis' proprietary CRISPR-GNDM® technology is capable of specifically modulating the expression of disease-relevant genes without introducing double-strand DNA breaks, which has been validated in disease animal models and non-human primates studies. Specializing in genetic disorders affecting the neuromuscular and CNS regions, Modalis's flagship program, MDL101, aims to treat LAMA2-CMD, a severe congenital form of muscular dystrophy to which no effective therapy exists.

CORE INNOVATION

The Core Innovation of this proposal is to apply Modalis Therapeutics' proprietary GNDM epigenome editing technology to the treatment of FSHD. This unique technology is a variation of CRISPR technology that uses a patented engineered Cas protein fused to an epigenetic repressor. When directed to a specific genetic locus using appropriate sgRNAs, this results in efficient and durable inhibition of gene expression at the target loci. When combined with an appropriate muscle-selective AAV delivery system and muscle-specific regulatory elements, our technology can be specifically targeted to silence DUX4 expression in the muscle of FSHD-affected individuals.

HEALTHSPAN

Our therapeutic intervention is designed to halt disease progression of FSHD. Pathology in FSHD is caused by the continual stochastic activation of DUX4 in the skeletal muscle of affected individuals. DUX4 expression is normally suppressed in adult muscle, and its inappropriate activation causes a host of cytopathologies, including muscle fiber death, and leads to muscle wasting. By applying our proprietary GNDM epigenome editing technology, we can target the DUX4 gene for robust and stable silencing, thereby correcting the root cause of FSHD, which should prevent further disease progression.

LEADERSHIP TEAM

Dr. DeSimone, has over a decade of experience in FSHD research and has published several research and review papers on the topic. He also has a strong background in studying transcription factor complexes, which underlie both GNDM technology and DUX4 expression. Yosuke Nakashima, MBA will provide leadership from a business development standpoint. Dr. Yamagata and Dr. Qin will provide leadership and expertise in GNDM technology and neuromuscular disease. Professor Emerson is also an expert on FSHD and has served as the Director of the Wellstone Center, and his laboratory developed the xenograft model that we will use in our project.

SNPM / CHU DE NICE

COMPANY OVERVIEW

TEAM / COMPANY NAME
SNPM / CHU de Nice

TRACK
FSHD Bonus Track

ORGANIZATION TYPE
Public Entity

HQ LOCATION
Nice, France

YEAR FOUNDED
1973

NUMBER OF EMPLOYEES
n/a

FUNDRAISING DETAILS

COMMERCIAL STAGE
Prefer not to say

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Academic/University Grants

TYPE OF INVESTORS SOUGHT
Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
n/a

CURRENT INVESTMENT STAGE
n/a

Jonathan PINI
pini.j@chu-nice.fr

COMPANY DESCRIPTION

UniversiThe SNPM Research Consortium is a multidisciplinary team dedicated to advancing therapeutics for neuromuscular diseases, with a focus on Facioscapulohumeral Muscular Dystrophy (FSHD1). Our expertise spans molecular biology, immunology, clinical trials, and biomarker-driven precision medicine. We are pioneering IL-6 inhibition as a novel treatment strategy to slow disease progression and improve patient outcomes. Through cutting-edge research, strategic collaborations, and innovative clinical trial designs, we aim to develop the first disease-modifying therapy for FSHD1, with broader implications for aging-related inflammation and muscle preservation. Our mission is to translate scientific breakthroughs into real-world clinical solutions.

CORE INNOVATION

Our core innovation lies in targeting IL-6-mediated inflammation as a disease-modifying strategy for FSHD1. Unlike existing approaches that focus on symptomatic management, we propose IL-6 inhibition as a direct intervention to slow disease progression, reduce fibro-fatty infiltration, and preserve muscle function.

HEALTHSPAN

Our therapeutic intervention targets IL-6-driven inflammation, a key contributor to muscle degeneration in FSHD1 and age-related decline. By blocking IL-6 signaling with satralizumab, we aim to reduce fibro-fatty infiltration, slow disease progression, and preserve muscle strength and function. This approach not only improves mobility and quality of life for FSHD1 patients but also addresses chronic inflammation linked to aging (“inflammaging”), with potential benefits for sarcopenia, frailty, and systemic inflammatory diseases. By integrating precision biomarkers and advanced imaging, we are pioneering a targeted therapy that enhances both neuromuscular health and overall functional longevity.

LEADERSHIP TEAM

Led by Professor Sabrina Sacconi, a leading neurologist specializing in FSHD1 and rare neuromuscular disorders, the team has spearheaded groundbreaking research on IL-6-driven inflammation and its role in disease progression. Our team includes experienced clinicians, molecular biologists, and regulatory experts, with a proven track record in biomarker-driven precision medicine and translational research. With extensive experience in multi-center clinical trials, regulatory approvals, and therapeutic innovation, our leadership is uniquely positioned to bring disease-modifying treatments to FSHD1 patients and beyond.

XPRIZE HEALTHSPAN | HEVOLUTION | SOLVE FSHD

HEALTHSPAN & FSHD

60 QUALIFIED TEAMS

TOP 100 HEALTHSPAN & TOP 8 FSHD TEAMS

REIMAGINE AGING

MAY 2025

COMPANY OVERVIEW

TEAM / COMPANY NAME
Accutar

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Cranbury, NJ, USA

YEAR FOUNDED
2015

NUMBER OF EMPLOYEES
100

FUNDRAISING DETAILS

COMMERCIAL STAGE
n/a

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity

TYPE OF INVESTORS SOUGHT
n/a

AMOUNT OF CAPITAL SOUGHT
$50M

CURRENT INVESTMENT STAGE
n/a

Jiaqi Ren
jiaqiren@accutarbio.com

ACCUTAR

COMPANY DESCRIPTION

Accutar Biotech is a leading AI-based drug discovery company. Since inception, Accutar has independently pushed four oncology drugs into human testing. Most recently, Accutar's breast cancer drug AC699 received Fast-track designation from FDA based on its excellent efficacy and safety profile of Phase 1 clinical data. Accutar also provide AI drug discovery solution to industry partners.

CORE INNOVATION

Accutar trained a universal force field for different applications including protein folding, ligand docking and drug ADME prediction etc. Based on public patent data, Accutar trained a proprietary chemistry based language model capable of designing patentable chemical compounds. Combination of Accutar forcefield and PatentGPT, Accutar is uniquely positioned to tackcle first-in-class targets which are otherwise extremely challenging tasks. The drug for Xprize competition is the first-in-class drug product of Accutar AI platform.

HEALTHSPAN

GID4 is a subunit of the GID-protein complex, an E3 ubiquitin-ligase complex that regulates the metabolic switch from gluconeogenesis to glycolysis. GID4 knockout has been reported to increase lifespan in c. elegance. Using Accutar's AI platform, we have invented first-in-class highly potent(low Nano molar potency) human GID4 inhibitor, we plan to test the drug's effects in preserving lean mass by reducing muscle protein degradation and enhancing autophagy with a goal to improve healthspan.

LEADERSHIP TEAM

Dr. Jie Fan, founder and CEO of Accutar, was trained in biostatistics at the UC, Berkeley, and earned doctorate degree in biology from Cornell/MSKCC. Driven by a vision to revolutionize drug discovery through machine learning and AI, ACCUTAR sought to integrate computational design with experimental validation to accelerate drug discovery.

Alexander Varshavsky, PhD, Professor at Caltech, served as advisor of the company. He has won numerous awards including the Breakthrough prize and Lasker award for his work in discovering the ubiquitination system and protein degradation.

Dr. Varshavsky helped Accutar selected the target for the company with longevity application potential.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Ageless - Genome Restoration Collective (AGRC)

TRACK
Healthspan, FSHD Bonus Track

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Singapore

YEAR FOUNDED
2023

NUMBER OF EMPLOYEES
10

FUNDRAISING DETAILS

COMMERCIAL STAGE
Early Commercial Demonstration

REVENUE RANGE
Prefer not to say

CAPITAL RAISED TO DATE
$2.7M

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Project Equity, Strategic Partnership, Government Funding, Philanthropic Funding

TYPE OF INVESTORS SOUGHT
Corporate/Strategic, Government, Philanthropic, Private Equity, Project Finance, Venture Capital, Academic/ University Grants

AMOUNT OF CAPITAL SOUGHT
$20M

CURRENT INVESTMENT STAGE
Seed

Yoshihito Otani
otani@livius.ltd
livius.ltd

AGELESS - GENOME RESTORATION COLLECTIVE (AGRC)

COMPANY DESCRIPTION

Our company is a pioneering bio-venture in functional and genetic analysis of miRNAs. We focus on miRNA-based therapeutics and developed a novel method to induce miRNA expression with FDA-approved small molecules, speeding commercialization. This method repairs mutated DNA, demethylates DNA, reactivates genes, and rejuvenates cells by targeting core aging hallmarks (DNA damage, epigenetic drift, senescence). Since nucleic acids drive breakthroughs, we aim to lead in nucleic acid medicine, gene therapy, and epigenetic treatment. We plan to submit at least two IND applications (AGA and dry eye) using existing investigational products; promising Investigator Initiated Trial results in AGA prove our concept.

CORE INNOVATION

Our core innovation is rooted in our expertise in the functional analysis and application of a specific miRNA. By using FDA-approved low-molecular-weight compounds (LMWCs) to induce endogenous target miRNA expression—rather than administering costly nucleic acids—we overcome the instability and high production costs associated with traditional gene therapies. This epigenetic approach enables DNA repair, demethylation, reprogramming, and cellular rejuvenation through a safe, low-dose oral regimen. Moreover, our method's ability to restore mutated gene sequences and enhance cellular function offers a transformative, scalable, and commercially viable therapy for aging and age-related diseases.

HEALTHSPAN

Our therapeutic intervention improves healthspan by addressing aging at the cellular level. Aging results from cellular decline due to DNA damage and dysregulation. Our approach activates a target miRNA that repairs DNA damage and reprograms cells, effectively rejuvenating them through epigenetic modulation. This restoration of muscle, immune, and cognitive functions delays age-related decline and promotes youthful vitality. Utilizing safe, low-dose FDA-approved LMWCs, our treatment extends robust healthspan and offers promising benefits for FSHD.

LEADERSHIP TEAM

Our leadership team unites global experts in epigenetics, clinical research, and anti-aging medicine. Chief Scientific Officer, Dr. Norimasa Miura, is a renowned physician and oncologist specializing in DNA repair and cellular reprogramming, holding key patents and awards like the Takeda Science Foundation Visionary Award. Chief Medical Officer, Dr. Howe Li, brings 28 years of clinical development and regulatory success, having guided numerous drug approvals worldwide. Clinical pioneer, Dr. Naoki Tsuji, oversees anti-aging applications at Tsuji Clinic. CEO, Masaki Miyamoto, and COO, Yoshihito Otani, ensure robust commercialization and global partnerships, forming a cohesive team to drive innovation forward.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Agemica

TRACK
Healthspan, FSHD Bonus Track

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Palo Alto, CA, USA

YEAR FOUNDED
2023

NUMBER OF EMPLOYEES
3

FUNDRAISING DETAILS

COMMERCIAL STAGE
Early Commercial Demonstration

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
$550K

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity

TYPE OF INVESTORS SOUGHT
Angel, Family Office, Venture Capital

AMOUNT OF CAPITAL SOUGHT
$5M

CURRENT INVESTMENT STAGE
Seed

Prof. Ronjon Nag
ronjon.nag@agemica.com
agemica.com

AGEMICA

COMPANY DESCRIPTION

Agemica's mission is to increase health span to 150 years via AI. We create vaccine and therapies for aging and diseases of aging.

CORE INNOVATION

We find therapies that have efficacy across broad range of diseases in each category of cancer, cardiovascular and neurodegenerative disease via targets that are shared between aging and the disease of aging. Our vaccines on the other hand provide long lasting protection against disease of aging.

HEALTHSPAN

We are creating vaccine and therapies via AI for disease of aging including cancer, cardiovascular and neurodegenerative disease and rare disease such as FSHD. We will run clinical trials for each category and do aging study on healthy volunteers as well. This ensures we get antiaging therapies approved via FDA standard ways as we approach aging via finding therapies and vaccines with broadest possible number of indications. Our cancer therapies at the moment are proven effective in 12 cancers in pre-clinical models. Our vaccines will create a long lasting protection for disease of aging with one shot every 2-5 years.

LEADERSHIP TEAM

We are pioneers in AI and repurpsing drug combinations.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Alpha Rejuvenation

TRACK
Healthspan, FSHD Bonus Track

ORGANIZATION TYPE
Currently operating as a Sole Proprietorship

HQ LOCATION
Kurashiki, Okayama Japan

YEAR FOUNDED
2024

NUMBER OF EMPLOYEES
1

FUNDRAISING DETAILS

COMMERCIAL STAGE
Pre-Commercial Pilot

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
No

TYPE OF CAPITAL SOUGHT
Prefer not to say

TYPE OF INVESTORS SOUGHT
Prefer not to say

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Pre-seed

Masuo Aoyama
masuo_a@hokokuken.com

ALPHA REJUVENATION

COMPANY DESCRIPTION

Our legal entity is registered in Japan as a sole proprietorship under the business name Alpha Rejuvenation, established for the purpose of participating in XPRIZE Healthspan. While legally structured as a sole proprietorship, our operations are driven by a collaborative effort between the sole proprietor (serving as the team leader) and a strategic partner who is a medical doctor. The team leader brings expertise in global environmental science, atomic physics, human biology, immunology, and aging research. Together, we are committed to extending healthspan and improving FSHD through proof-of-concept experiments that contribute to society.

CORE INNOVATION

Our team has identified the fundamental cause of aging and developed a technology to suppress its progression by directly addressing this root cause. While conventional approaches focus on alleviating the symptoms of aging, our method specifically targets the fundamental causative substance responsible for aging. Furthermore, by integrating multiple rejuvenation strategies, we enhance the potential for significant rejuvenation, aiming to achieve results that were previously difficult to attain. This unique combination of aging suppression and rejuvenation is what sets our technology apart from existing solutions.

HEALTHSPAN

Due to our ongoing patent application, we provide only a brief overview at this stage.

Healthspan: Having identified the fundamental cause of aging, we aim to suppress aging by eliminating it. Furthermore, we seek to rejuvenate the body through approaches that target stem cells, cellular function, and systemic effects, thereby improving healthspan.

FSHD: We aim to significantly eliminate the root cause of FSHD, improve muscle atrophy, and achieve a substantial therapeutic effect for FSHD.

LEADERSHIP TEAM

Our leadership team combines expertise across a broad range of fields, including global environmental science, atomic physics, human biology, immunology, and aging research. This multidisciplinary knowledge is essential for understanding and addressing the root causes of aging. The team is led by a researcher with expertise in these areas and a medical doctor with extensive clinical experience. Together, we leverage our strengths in both scientific research and clinical practice to develop innovative therapeutic solutions for aging and related diseases.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Aptah Bio

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
San Carlos, CA, USA

YEAR FOUNDED
2019

NUMBER OF EMPLOYEES
3

FUNDRAISING DETAILS

COMMERCIAL STAGE
R&D

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Project Equity, Strategic Partnership, Government Funding

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Government, Philanthropic, Private Equity, Venture Capital

AMOUNT OF CAPITAL SOUGHT
$15M

CURRENT INVESTMENT STAGE
Seed

Rafael Bottos
rbottos@aptah-bio.com
aptah-bio.com

APTAH BIO

COMPANY DESCRIPTION

Aptah Bio is a biotech startup that developed the RNA Widespread Correction (WiCo) platform by understanding the mechanisms underlying sporadic age-related diseases. This RNA rejuvenation technology enables the design of synthetic molecules that modulate small nuclear ribonucleoproteins (snRNPs). The lead molecule, APT20TTMG, specifically targets and corrects dysfunctions in the U1 snRNP complex, which is critical for proper splicing and inhibition of premature polyadenylation. The dysfunction of this complex has been implicated in multiple age-related diseases.

CORE INNOVATION

As the first drug designed to ensure the proper functioning of the U1 snRNP complex, APT20TTMG plays a central role in restoring RNA integrity. Previous preclinical data highlight its innovative and multi-targeted approach by restoring mRNA splicing homeostasis and avoiding premature polyadenylation. Currently, there is no technology similar to the RNA WiCo platform and APT20TTMG, which hold the potential to address the root cause of various age-related diseases without silencing or inhibiting specific genes.

HEALTHSPAN

By restoring proper splicing and RNA expression balance, our lead compound, APT20TTMG, reduces toxic protein production associated with conditions such as cancer and neurodegenerative diseases. This RNA rejuvenation technology addresses the root cause of cellular decline, improving tissue homeostasis and gene regulation. By correcting mis-splicing and prevent premature polyadenylation events, APT20TTMG enhances cellular function, delays disease progression, and extends healthspan, offering a transformative solution for age-related diseases.

LEADERSHIP TEAM

Aptah Bio is composed of leading scientists and experienced executives. The scientific team brings extensive expertise across several areas, including aging, genetics, neuroscience, pharmacology, and ophthalmology, while the executive team contributes decades of leadership experience in the pharmaceutical, biotech, and financial sectors. Together, the team creates a well-rounded approach to innovation and business development.

ASAGI LABS

COMPANY OVERVIEW

TEAM / COMPANY NAME
ASAGI Labs

TRACK
Healthspan, FSHD Bonus Track

ORGANIZATION TYPE
Non-Profit Organization

HQ LOCATION
Karuizawa-machi, Nagano, Japan

YEAR FOUNDED
2024

NUMBER OF EMPLOYEES
3

FUNDRAISING DETAILS

COMMERCIAL STAGE
R&D

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
No

TYPE OF CAPITAL SOUGHT
Strategic Partnership, Government Funding, Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Government, Philanthropic, Project Finance, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
$2M

CURRENT INVESTMENT STAGE
Academic/University Grants

Motoshi Hayano
mhayano@asagilabs.or.jp
asagilabs.or.jp/en

COMPANY DESCRIPTION

ASAGI Labs Foundation is a non-profit organization dedicated to promoting basic research on aging. It operates through collaborative projects with companies and philanthropy-based donations. ASAGI Labs Foundation has established a network of academic researchers focused on aging research and collaborates with the for-profit entity ASAGI Labs Inc. to commercialize intellectual property generated from its research. The primary roles of ASAGI Labs Foundation are to advance innovative aging research and support young talent, with a particular focus on the epigenome, inflammation, and the diversity of aging across species.

CORE INNOVATION

In Japan, high-quality medical data and extensive information on lifestyle factors, such as diet, related to the world's longest healthy life expectancy, have been accumulated. Additionally, innovative research on regenerative medicine using iPS cells, cellular senescence, and the epigenome is being conducted within Japanese academia. ASAGI Labs collaborates with such academic institutions to develop therapies for rejuvenation using compounds and treatments for immunosenescence through bioengineering. By integrating these efforts with medical data, ASAGI Labs holds multiple core technologies. Moving forward, the organization aims to continue generating diverse intellectual properties and fostering collaborations with ASAGI Labs Inc., pharmaceutical companies, and venture capital firms.

HEALTHSPAN

ASAGI Labs has conducted compound screening for controlling the epigenome and promoting cellular rejuvenation, leading to the identification of Ambroxol, an expectorant. Ambroxol is an approved drug that has been in use for over 30 years, making it highly affordable and proven safe. Its target protein is GBA1, a glucosylceramidase that regulates the functions of lysosomes, mitochondria, and autophagy. Through its effects on mesenchymal stem cells (MSCs), Ambroxol has the ability to improve cognitive function, muscle strength, and immunity.

LEADERSHIP TEAM

The ASAGI Labs team is led by Dr. Motoshi Hayano, Ph.D., an expert in the epigenome and aging. The team comprises members with experience in business development within pharmaceutical companies, consulting, and clinical trials, as well as clinicians specializing in neurology, orthopedics, respiratory medicine, and allergy/immunology. Dr. Hayano and the clinical specialists are affiliated with government-designated Clinical Research Core Hospitals, which are equipped to conduct clinical trials, including patient recruitment and trial implementation for elderly individuals and patients with FSHD. In Japan, clinical trials conducted within academia can be performed cost-effectively, with high patient adherence, enabling the ASAGI Labs team to build high-quality evidence.

COMPANY OVERVIEW

TEAM / COMPANY NAME
ASU Team Healthspan

TRACK
Healthspan, FSHD Bonus Track

ORGANIZATION TYPE
University Team

HQ LOCATION
Phoenix, AZ, USA

YEAR FOUNDED
1885

NUMBER OF EMPLOYEES
21,750

FUNDRAISING DETAILS

COMMERCIAL STAGE
Growth Stage (beyond initial customers)

REVENUE RANGE
$2.3B

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Strategic Partnership, Government Funding, Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Government, Philanthropic, Private Equity, Project Finance, Venture Capital, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
$10M

CURRENT INVESTMENT STAGE
Multiple companies on our team with multiple investor stages/needs

Judith Klein-Seetharaman
jkleinse@asu.edu
youthrenewal.com

ASU TEAM HEALTHSPAN

COMPANY DESCRIPTION

Our team comprises multi-institution partners from academia, biotechnology, and healthcare industries: Theriome, Youth Renewal Sciences, Nala, Connected mHealth, Memory Lane Games. Our transdisciplinary expertise in aging, multi-omics, analytical testing, computational modeling, clinical trials, nutrition interventions, physiology, community engagement, and patient care. ASU is leading this team based on its expertise in the diverse disciplines represented by our team, the extensive resources at ASU, such as its Clinical Research Services Core, Institutional Review Board (IRB), medical oversight, unusually powerful high performance supercomputing, vast and sophisticated laboratory equipment and services, and scientific expertise in the fields of aging and metabolic health.

CORE INNOVATION

Our core innovation treats aging as an entropy-driven process, where youth corresponds to lower entropy (better organ integrity). We use thermodynamic control (energy intervention) to reduce biological age and kinetic control (metabolite feedback) to accelerate regeneration. By reprogramming aged cells trapped in high-entropy states, we restore their regenerative potential. This approach targets key aging hallmarks—genomic instability, mitochondrial dysfunction, and proteostasis loss—to rejuvenate physiological systems. Digital twinning optimizes interventions, enhancing precision in restoring cellular order and reversing aging.

HEALTHSPAN

Our therapeutic intervention is a proactive personalized medicine intervention designed to retain health longer and, to the extent possible, to restore muscle, cognitive, and immune functions through adaptive homeostasis. Our intervention design combines multiple anti-aging strategies into a multi-component, personalized approach based on participant-specific quantitative multi-omics data using digital twinning, i.e. the virtual representation of the health status of an individual that can be dynamically updated with new data (here currently a metabolic test) from its physical counterpart. The twin allows us to guide and optimize intervention type, quantity, and maximize the extent to reverse biological age.

LEADERSHIP TEAM

Our leadership team includes Judith Klein-Seetharaman (ASU) as team lead, leveraging global connections and experience in large-scale scientific collaborations. Clinton Hughes (Youth Renewal Sciences) and Paniz Jasbi (Theriome) are providing the cross-institutional strategy and key components of the intervention: anti-aging clinics and Aristotle test, respectively. Scientific strategy is led by Sandeep Gupta (AI expert), Susanta Sarkar (ultrasensitive detection pioneer), and Susan Racette (clinical trials expert, 34+ years experience). The clinical team at Youth Renewal Sciences' anti-aging clinics, with decades of patient care expertise, will scale and expand the intervention for broad accessibility.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Aviv

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
The Villages, FL, USA

YEAR FOUNDED
2020

NUMBER OF EMPLOYEES
50

FUNDRAISING DETAILS

COMMERCIAL STAGE
Growth Stage (beyond initial customers)

REVENUE RANGE
$20M - $40M

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Strategic Partnership

TYPE OF INVESTORS SOUGHT
Corporate/Strategic, Family Office, Private Equity, Venture Capital

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Series A

Amir Hadanny
amir@avivscientific.com
aviv-clinics.com

AVIV

COMPANY DESCRIPTION

Aviv is a global leader in the research and treatment in humans of the aging process and age related cognitive and functional decline, as well as various brain injuries (e.g. stroke/ TBI). Based on 15+ years of clinical trials, research and clinical operations at the Sagol Center in Israel, the world's largest hyperbaric medicine and research facility, Aviv is rolling out a global network of specialty clinics to deliver the proprietary Aviv Medical Program, with HBOT at its core. Aviv opened its first 2 pilot clinics in Florida and Dubai and holds strong IP. In partnership discussions with leading US healthcare players.

CORE INNOVATION

The Aviv Medical Program differentiates itself through a unique integration of multiple hormetic stressors that work synergistically to enhance healthspan. The core technology combines hyperbaric oxygen therapy (HBOT) using the Hyperoxic-Hypoxic Paradox, physical training, cognitive training, and intermittent fasting. Our HBOT protocol specifically induces cellular regeneration without actual hypoxia, activating stem cell proliferation, mitochondrial function, and angiogenesis. This comprehensive, multimodal approach has demonstrated significant improvements in cognitive performance, aerobic capacity, telomere length, and senescent cell reduction in healthy aging adults through controlled clinical trials.

HEALTHSPAN

The Aviv Medical Program enhances healthspan through a multimodal approach targeting key aging mechanisms. HBOT utilizing the Hyperoxic-Hypoxic Paradox induces stem cell proliferation, angiogenesis, and mitochondrial biogenesis while reducing inflammation and senescent cells. Physical training improves metabolic efficiency and cardiovascular function. Cognitive training strengthens neural networks and neuroplasticity. Intermittent fasting activates autophagy and cellular repair pathways. Clinical trials have demonstrated measurable improvements in executive function, aerobic capacity (VO2Max), telomere length, and reduced senescent cell populations in aging adults. This comprehensive intervention synergistically addresses multiple aging hallmarks simultaneously, creating a holistic approach to healthspan extension.

LEADERSHIP TEAM

The team is led by Dr. Amir Hadanny, a neurosurgeon and hyperbaric medicine specialist with a PhD in bioinformatics, who has published over 65 peer-reviewed papers on HBOT effects on cognitive and physical performance. Co-leader Dr. Shai Efrati, founder of the Sagol Center for Hyperbaric Medicine, has pioneered neurological applications of HBOT, authored 100+ peer-reviewed papers, and leads multidisciplinary research at Tel Aviv University.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Axxium Life

TRACK
Healthspan, FSHD Bonus Track

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Dallas, TX, USA

YEAR FOUNDED
2024

NUMBER OF EMPLOYEES
8

FUNDRAISING DETAILS

COMMERCIAL STAGE
R&D

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Prefer not to say

TYPE OF INVESTORS SOUGHT
Prefer not to say

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
n/a

Mark Joinnides
mark@axxium.life
axxium.life

AXXIUM LIFE

COMPANY DESCRIPTION

Axxium is a purpose-driven biotechnology company committed to democratizing healthcare across the globe. The company is pioneering a new class of medicines known as AIMs (active immunotherapy medicines) with the goal of disrupting the existing treatment paradigm for chronic disease. The company's proprietary AIM technology platform has enabled the innovation of novel synthetic peptide immunotherapy candidates designed to bring the efficiency of active immunotherapies to the treatment of chronic diseases, including Parkinson's and Alzheimer's.

CORE INNOVATION

Axxium is a purpose-driven biotechnology company committed to democratizing healthcare across the globe. The company is pioneering a new class of medicines known as AIMs (active immunotherapy medicines) with the goal of disrupting the existing treatment paradigm for chronic disease. The company's proprietary AIM technology platform has enabled the innovation of novel synthetic peptide immunotherapy candidates designed to bring the efficiency of active immunotherapies to the treatment of chronic diseases, including Parkinson's and Alzheimer's.

HEALTHSPAN

The AIM platform allows for individual or multiple biologic targets in a single formulation, and we believe we can develop preventive medicines that preserve cognitive and motor function in aging adults. We are submitting our clinical candidate AXX-PD, which targets aggregated ^{3}-synuclein (^{3}Syn), which we believe underlies Parkinsonism associated with aging, affecting cognitive, motor, sleep, gastrointestinal, and other function. Given the modular nature of our AIM platform, we believe we can develop candidates for a multitude of disease targets, including a combination of targets for muscle wasting diseases such as facioscapulohumeral muscular dystrophy (FSHD).

LEADERSHIP TEAM

Axxium has established a team of leading executives and scientists in neurology and chronic disease with many successful drug approvals under their collective belt. Rachelle Doody, MD, PhD, is our Chief Medical Officer and Head of Development, and serves as the team's PI for XPRIZE; she was previously head of neurodegeneration at Roche. JC Dodart, PhD, is our Chief Scientific Officer and runs our laboratory. Mark Joinnides, MSE is our Head of Corporate Affairs and XPRIZE team lead and has experience in pharmaceutical market access. Finally, we have Hui Jing Yu, PhD, Executive Director of Clinical Development. Axxium also has a network of esteemed collaborators, as well as a robust supply chain network.

COMPANY OVERVIEW

TEAM / COMPANY NAME
bBHC

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Seoul, South Korea

YEAR FOUNDED
1989

NUMBER OF EMPLOYEES
30

FUNDRAISING DETAILS

COMMERCIAL STAGE
Early Commercial Demonstration

REVENUE RANGE
$10M

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity

TYPE OF INVESTORS SOUGHT
Private Equity

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Angel

MIndy Min Sun Oh
msoh@bbhcws.com
bbhcstri.com

BBHC

COMPANY DESCRIPTION

We develop new type of pluripotent stem cells which is called KHCs. This novel cell type was induced from umbilical cord mesenchymal stem cells (UC MSCs) by treatment with natural compounds without genetic manipulation and demonstrated the ability to differentiate into pancreatic beta cells endoderm, mesoderm and ectoderm. The conversion efficiency from umbilical cord mesenchymal stem cells was over 90%, and the cells were stably induced not only from passage 3 UC MSCs but also from passage 25 UC MSCs. Additionally, no chromosomal abnormalities were observed in either passage. Moreover, these cells exhibited increased expression of anti-aging and tumor-suppressor genes, transcription factors essential for blastocyst formation, and cytotoxic T-cell markers, while significantly inhibiting cancer cell survival and invasion.

The novel cells identified in this study exhibit minimal immunogenicity and extremely low tumorigenicity, making them suitable for allogeneic applications. Their characteristics enable scalable production and commercialization in an off-the-shelf format. Additionally, they have the potential to play a significant role in the prevention and treatment of cancer and aging-related diseases.

CORE INNOVATION

We have discovered a new type of cell has never been known to the world. This cell will introduce a new paradigm to humanity by preventing aging and suppressing cancer.

HEALTHSPAN

It will restore youth by over 20 years.

LEADERSHIP TEAM

According to a report by the Korean Intellectual Property Office based on big data analysis, bBHC's technology ranks 2nd worldwide in the field of regenerative medicine, 4th worldwide in the field of pluripotent stem cells, and 2nd worldwide in the field of stem cell culture technology.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Beijing Joekai Biotechnology

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Beijing, China

YEAR FOUNDED
2001

NUMBER OF EMPLOYEES
28

FUNDRAISING DETAILS

COMMERCIAL STAGE
R&D

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
$30M

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Project Equity, Strategic Partnership, Government Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Corporate/Strategic, Venture Capital

AMOUNT OF CAPITAL SOUGHT
$20M

CURRENT INVESTMENT STAGE
Series B

Weiwei Ma
maweiwei@joekai.com
joekai.com

BEIJING JOEKAI BIOTECHNOLOGY

COMPANY DESCRIPTION

Beijing Joekai is a clinical stage biotech focusing on developing novel therapies in syntactical new targets.

The team has been working together for several years and successfully push 50561 into phase IIa clinical trials, and seeking potential applications of 50561 in healthy aging.

CORE INNOVATION

Starting with the active forgetting protein Rac1, Our team has oversight research and develop a first in class Rac1 inhibitor, 50561, from early scientific discovery, hit finding, PCC determination, IND enabling, phase I and phase IIa clinical trials. Therefore, we understand all aspects of the drug, and how it might develop.

HEALTHSPAN

We belived the hub to improve healthspan is the synaptical funtion of the brain and our intervention is aiming to improve healthspan via regulating key synaptical functions.

LEADERSHIP TEAM

Industrial experience: Oversight translation study and IND enabling work for 50561, which inhibits the active forgetting protein Rac1; Initiated drug development to extend the lifespan of AD patients and developed Rac1 blood test kits; Responsible for the company's financing operations.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Beiwe

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Davis, CA, USA

YEAR FOUNDED
2016

NUMBER OF EMPLOYEES
4

FUNDRAISING DETAILS

COMMERCIAL STAGE
Pre-Commercial Pilot

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
$400K

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Project Equity, Strategic Partnership

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Private Equity, Venture Capital, Pharma

AMOUNT OF CAPITAL SOUGHT
$1M to get to first FDA Meeting

CURRENT INVESTMENT STAGE
Seed

Gino Cortopassi, CEO
Gino@beiwebio.com
beiwebio.com

BEIWE

COMPANY DESCRIPTION

Beiwe pharma is a California LLC. The team is comprised of academic and commercial company individuals, leveraging new academic discoveries (Meclizine is an alternative mTORC1 inhibitor to rapamycin), leveraging NIA ITP findings (Meclizine dose-dependently increases lifespan in mice), to attempt to provide benefit to the US population by forming an investment vehicle (Beiwe) to advance a novel mTORC1 inhibitor to the clinic and gain approval for an age-related indication.This team blends decades of academic research, clinical trial management, and business development expertise, uniquely equipping it to meet the challenges of advancing a novel therapeutic to clinical approval.

CORE INNOVATION

We have identified the first completely mTORC1-specific inhibitor, Meclizine. While inhibition of mTORC1 causes longevity, inhibition of mTORC2 causes side effects. Rapamycin because it inhibits mTORC1 causes longevity but because it also inhibits mTORC2 it causes unacceptable side effect profile in otherwise healthy aging humans. Meclizine is completely mTORC1 specific and dose dependently increases longevity in mice, and yeast.

HEALTHSPAN

Meclizine dosed at 800PPM and 2400PPM in mice extends longevity in males and females, reducing life-ending hazards, cancer and inflammation. Meclizine dosed in vitro dose dependently reduces inflammation of innate immune cells. Age-dependent hyper-inflammation is a cause of age-related degenerative disease, fibrosis, and death.

LEADERSHIP TEAM

Gino Cortopassi, PhD- Beiwe founder, CEO and UC Davis Professor. Aging and longevity researcher for 35yrs. Discovery that mitochondrial mutations accumulate with age in human tissues. Co-discoverer that Meclizine is an mTORC1 inhibitor. Sponsor of ITP's testing of Meclizine for mouse longevity11.Professor of Pharmacology, UC Davis. Zane Starkewolfe, PhD, Beiwe CBO. Zane is a chemist with a background in venture capital and corporate development. He has supported, invested, and been on the boards of companies including of several aging related startups. He has reviewed and supported the CMC and clinical development design for several therapeutic programs and brings business development expertise to the team.

BLUEBIRD LONGEVITY

COMPANY OVERVIEW

TEAM / COMPANY NAME
BlueBird Longevity

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Baar, Zug, Switzerland

YEAR FOUNDED
2023

NUMBER OF EMPLOYEES
35

FUNDRAISING DETAILS

COMMERCIAL STAGE
Growth Stage (beyond initial customers)

REVENUE RANGE
$2M

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Convertible Debt

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Government, Philanthropic, Private Equity, Project Finance, Venture Capital

AMOUNT OF CAPITAL SOUGHT
$25M

CURRENT INVESTMENT STAGE
Debt

Dr. Pierre-Edouard Sottas
research@xlongevity.com
xlongevity.com

COMPANY DESCRIPTION

xLongevity is selling health, not just technology. We empower current actors of the healthcare market to propose all-in-one solutions to their patients. We propose B2B4C longevity packages that include biomarker testing, coaching, personalized supplements, and advanced treatments for a holistic experience.

CORE INNOVATION

More than stem cells, exosomes, and EVs, our technology is based on the production and delivery of conditioned media produced by the own stem cells of the patient (autologous approach) in cell lines, with maximization of the rejuvenative effect (e.g. patient preconditioned for quality and quantity of stem cells, removal of senescent cells both in vivo and in vitro, rejuvenating factors maximized in vivo, etc...) through a combined AI-driven approach.

HEALTHSPAN

Our recent 3-months preliminary study in humans has shown to be safe, with biological age measured by PhenoAge and by epigenetic clock, respectively 6 years and 4 years than the chronological age of the patients. All patients expressed significant mental and physical improvements.

LEADERSHIP TEAM

xLongevity's leadership team brings decades of expertise in longevity science, clinical trial design, and biotechnology innovation. Dr. Pierre-Edouard Sottas, CEO, is a recognized expert in biomarker analysis and clinical trials, with over 90 scientific publications and extensive experience in biotechnology startups. The research team is led by Dr. Sonam Bhathia for clinical trials and quality testing. Wellbeing International adds 14 years of experience in cell-free therapies and regenerative medicine. Max Lewinsohn, Chairman, has led strategic healthcare initiatives for over 40 years. Dr. Esteban Ortega, Medical Director, is an expert in extracellular vesicles and regenerative therapies, while Dr. Stephen Ray, Senior Scientific Consultant, brings over 25 years of experience in cell therapy research.

BOOCS & PLASMALOGEN

COMPANY OVERVIEW

TEAM / COMPANY NAME
BOOCS & Plasmalogen

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Hisayama-machi, Kasuya-gun, Fukuoka Prefecture, Japan

YEAR FOUNDED
1995

NUMBER OF EMPLOYEES
6

FUNDRAISING DETAILS

COMMERCIAL STAGE
n/a

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Project Equity, Strategic Partnership, Government Funding

TYPE OF INVESTORS SOUGHT
n/a

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
n/a

Takehiko Fujino
fujino-t@boocsclinic.com
reoken.com/english

COMPANY DESCRIPTION

We aim to foster a healthy food culture through a scientific approach, embracing the principle “Eat Well to Be Well.” We conduct research to identify and evaluate functional substances in food using cutting-edge technologies. Our clinical trials assess their effects on blood properties and immune function, aiming to prevent lifestyle-related diseases. Moreover, we support the commercialization of foods with immunological benefits.

CORE INNOVATION

Our team has proudly achieved a world-first breakthrough in plasmalogen technology:

1. Novel extraction: Our patented pioneering method efficiently extracts plasmalogens, a vital type of phospholipid, from living organisms.
2. Clinical validation: Scallop-derived plasmalogens have demonstrated safety and efficacy in dementia patients, with clear mechanisms.
3. Immune support: We unveiled plasmalogens’ immunomodulatory roles, including anti-viral and anti-tumor properties, with elucidated mechanisms.
4. Enhanced muscle: Research confirms increased skeletal muscle function and elucidates the underlying mechanisms.

This transformative technology holds immense potential for advancing human health, significantly enhancing healthspan and overall well-being.

HEALTHSPAN

Plasmalogen therapy represents a groundbreaking advancement in the pursuit of healthy aging. Our preclinical studies demonstrate enhanced BDNF signaling and mitigated glial cell activation, translating to improved cognitive function and reduced risk of neurodegeneration. Clinical trials have shown promising results in improving memory, mood, and immune response, particularly in individuals facing cognitive difficulties. This multifaceted mechanism positions plasmalogens as a promising therapeutic strategy for extending healthspan and combating age-related decline, opening a new chapter in preventative health and wellness.

LEADERSHIP TEAM

Our team unites world-renowned experts across key scientific disciplines, including in molecular science, clinical research, and neuropharmacology. With decades of collaborative experience and proven leadership in academia and industry, we have achieved significant advancements in plasmalogen research. Our progress, including pioneering extraction methods and successful clinical trials, has led to the formation of international scientific communities dedicated to this field.

COMPANY OVERVIEW

TEAM / COMPANY NAME
CHANGS

TRACK
Healthspan

ORGANIZATION TYPE
Non-Profit Organization

HQ LOCATION
Shenzhen, Bangkok, Thailand

YEAR FOUNDED
2007

NUMBER OF EMPLOYEES
9,000+

FUNDRAISING DETAILS

COMMERCIAL STAGE
Prefer not to say

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Strategic Partnership, Government Funding, Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
n/a

AMOUNT OF CAPITAL SOUGHT
$10M

CURRENT INVESTMENT STAGE
n/a

Miguel Esteban
miguelesteban@genomics.cn

CHANGS

COMPANY DESCRIPTION

BGI Shenzhen is a world-leading company in the field of genomics. The headquarters are in Shenzhen (China), but it has centers all over China and the world (including Thailand and Europe). BGI has made significant scientific contributions by integrating advanced technologies like genomics, transcriptomics, and other omics. By leveraging extensive datasets from large-scale cohorts, and collaborating with researchers worldwide, BGI has a major focus on identifying biomarkers and molecular pathways linked to age-related diseases. BGI is also a major technology developer from sequencers to medical devices and engineered biomaterials (cells, gene vectors or antibodies).

CORE INNOVATION

A well-established and closely monitored longevity cohort, combined with unmatched capacity and expertise in conducting high-throughput omic measurements.

HEALTHSPAN

We will develop a synergistic combination of clinically approved approaches that have long been hypothesized to have anti-aging effects in humans, but have not yet been formally proven.

LEADERSHIP TEAM

A team of world-class scientists, experienced medical professionals, and a robust industrial foundation.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Cura Therapeutics and collaborators/ Cura Therapeutics Inc.

TRACK
Healthspan, FSHD Bonus Track

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Montreal, Quebec, Canada

YEAR FOUNDED
2020

NUMBER OF EMPLOYEES
3

FUNDRAISING DETAILS

COMMERCIAL STAGE
IND-Enabling Studies

REVENUE RANGE
Pre-Revenue (biotech)

CAPITAL RAISED TO DATE
$2.1M

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Project Equity, Convertible Debt, Strategic Partnership, Government Funding, Philanthropic Funding

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Government, Philanthropic, Private Equity, Project Finance, Venture Capital

AMOUNT OF CAPITAL SOUGHT
$15M

CURRENT INVESTMENT STAGE
Pre-seed

Claudia Penafuerte Diaz
claudiapd@curatherapeutics.com
curatherapeutics.com

CURA THERAPEUTICS

COMPANY DESCRIPTION

Cura Therapeutics develops first-in-class multifunctional immunotherapies to treat complex age-associated diseases and tissue degeneration. Our CT platform harnesses the healing power of the immune system, using AI protein-modeling, experimental techniques, and expertise in pathway analysis to create bio-engineered fusion proteins that engage multiple immune system mechanisms to prevent disease progression and restore the body to a healthy state. Cura's lead immunotherapy CT101 initiates a cascade of reactions that engage multiple immune system mechanisms against senescent cells, malignant cells, damaged tissue, and fibrosis to restore health. Our team combines expertise in immunology, oncology, cell and molecular biology, biomanufacturing, and clinical studies.

CORE INNOVATION

Cura's lead immunotherapy CT101 is a first-in-class multifunctional immunotherapy for treating complex age-associated diseases and tissue degeneration. CT101 harnesses the immune system's healing power by initiating a cascade of immunological reactions that engage multiple immune system mechanisms against senescent cells, damaged tissues, and fibrosis. In preclinical studies conducted in vitro and in vivo, CT101 treatment promoted muscle regeneration and improved organ function. Notably, CT101 has been shown to promote muscle mass gain and enhance the functionality of the liver and kidneys.

HEALTHSPAN

CT101 treatment in vivo boosts innate and adaptive immunity against senescent cells, damaged tissues, and fibrosis, increases skeletal muscle mass, and improves liver and kidney functions. In addition, CT101 effectively inhibits the effect of pro-fibrotic and pro-senescent factors involved in tissue fibrosis, Blood-Brain Barrier (BB) dysfunction, neurogenesis decline, and astrogliosis.

As a first-in-class immunotherapy, CT101 harnesses the immune system's healing power to promote tissue regeneration and improve the function of various organs, which contributes to an extended healthspan and alleviates FSHD symptoms and progression.

LEADERSHIP TEAM

Cura Therapeutics has built a team and scientific advisory board with extensive expertise in age-associated diseases, immunology, oncology, cell and molecular biology, translational research, and drug development. Cura's team has established collaborations with the Rosalind and Morris Goodman Cancer Institute (GCI), Altasciences, and the National Research Council of Canada (NRC), including highly skilled scientists, clinical staff specializing in early-phase studies, and experts in drug biomanufacturing. Additionally, Cura is supported by Berkeley SkyDeck (Biotech cohort Alumni), Capital Bioventures, a non-profit organization that empowers the next generation of biotech pioneers in Canada, and the OBIO Women in Health Initiative program.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Cyclarity Therapeutics

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Novato, CA, USA

YEAR FOUNDED
2019

NUMBER OF EMPLOYEES
10

FUNDRAISING DETAILS

COMMERCIAL STAGE
R&D

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
$24M

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Project Equity, Strategic Partnership, Government Funding, Philanthropic Funding

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Government, Philanthropic, Private Equity, Project Finance, Venture Capital

AMOUNT OF CAPITAL SOUGHT
Series A Tranche 2: $2.6M - $5.6M
Series B: ~$45M

CURRENT INVESTMENT STAGE
Series A

Matthew O'Connor
matthew.oconnor@cyclaritytx.com
cyclaritytx.com

CYCLARITY THERAPEUTICS

COMPANY DESCRIPTION

Cyclarity Therapeutics is a clinical stage pharmaceutical company committed to developing drugs to treat and prevent common age-related conditions by addressing the root cause – accumulation of oxidized cholesterol. Launched from a project at the SENS Research Foundation and founded in 2019, our first product, UDP-003, is a novel therapeutic that binds and extracts oxidized cholesterol from cells and tissues to restore their function. Our therapeutic has applications in a range of age-related conditions, including cardiovascular disease, neurodegenerative diseases, stroke, age-related macular degeneration, and liver disease. We recently began our first in human Phase 1 clinical trial in Australia.

CORE INNOVATION

Cyclarity's approach to treating age-related disease is to develop cyclodextrins, molecules which are in wide use for drug delivery and industrial applications, with proven safety and the ability to bind and carry a range of targets. We have engineered cyclodextrins to have optimized affinity and specificity for oxidized cholesterol. Cyclarity's approach has distinct advantages over competitors: (1) our drug targets the root cause of inflammation rather than mid-stream signaling; (2) our target has no biological function and can be impacted without negative off-target results; (3) clinical development will not require the time and intricacies of a complex biologic therapy.

HEALTHSPAN

UDP-003 combats diseases of aging and improves healthspan by removing oxidized cholesterol from cells and tissues. We target oxysterols that are spontaneously formed and highly toxic, with no known biological function. Most cells and tissues have no mechanisms for their metabolism, allowing accumulation with age. Accumulation is correlated with conditions including cardiovascular disease, neurodegenerative diseases, AMD, and liver disease, as it causes a lack of lipid metabolism, dysfunction, and cell death. By extracting oxidized cholesterol, UDP-003 could prevent, treat, and even reverse a range of age-related diseases, increasing healthspan significantly.

LEADERSHIP TEAM

Cyclarity's principals, Michael Kope and Dr. Matthew O'Connor, are leaders in the development of rejuvenation technologies. Mike Kope, co-founder and co-CEO of Cyclarity, co-established the SENS Research Foundation (now Longevity Research Institute) and was its founding CEO. He has served as CEO and officer of several biotechnology startups. Dr. Matthew O'Connor is the former VP of Research at SENS Research Foundation and has an extensive history of researching aging. Our distinguished clinical advisory group includes Mike Farkouh and P.K. Shah of Cedars-Sinai and Steve Nicholls of Monash University.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Deciduous Therapeutics

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
San Francisco, CA, USA

YEAR FOUNDED
2019

NUMBER OF EMPLOYEES
18

FUNDRAISING DETAILS

COMMERCIAL STAGE
R&D

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Government, Philanthropic, Private Equity, Venture Capital

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Seed

Vishal Sharma
Vishal@deciduoustx.com
deciduoustx.com

DECIDUOUS THERAPEUTICS

COMPANY DESCRIPTION

Deciduous Therapeutics is developing novel therapies to restore immune function and eliminate senescent cells in fibrotic diseases. Our approach aims to reverse fibrosis and improve patient outcomes.

CORE INNOVATION

We are developing a therapeutics that preferentially activates iNKT cells to clear seneceent cells.

HEALTHSPAN

Deciduous Therapeutics's approach enhances healthspan by restoring immune function to eliminate senescent cells, reducing chronic inflammation and tissue damage. By leveraging targeted immunotherapy, our intervention promotes tissue repair and resilience, potentially slowing age-related decline.

LEADERSHIP TEAM

The deciduous therapeutics leadership team brings deep expertise in immunology, fibrosis, and drug development. With backgrounds spanning biotech, pharma, and academic research, our leaders have successfully advanced novel therapies from discovery to clinical translation. Their experience has driven biotech startups through critical growth phases. Committed to scientific rigor and patient impact, our team combines innovation with execution, ensuring the successful development of transformative treatments for fibrotic diseases.

COMPANY OVERVIEW

TEAM / COMPANY NAME
EffePharm Ltd.

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Shanghai, China

YEAR FOUNDED
2017

NUMBER OF EMPLOYEES
130

FUNDRAISING DETAILS

COMMERCIAL STAGE
Growth Stage (beyond initial customers)

REVENUE RANGE
$30M

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
No

TYPE OF CAPITAL SOUGHT
Strategic Partnership

TYPE OF INVESTORS SOUGHT
Corporate/Strategic, Private Equity

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Self funded so far, wasn't looking into outside investment

Hannah LU
Hannah.lu@effepharm.com
effepharm.com

EFFEPHARM LTD.

COMPANY DESCRIPTION

Founded in 2017, EffePharm is a biotechnology company specializing in providing advanced wellness solutions to its global users. EffePharm is founded on the belief that everyone should have equal access to health and nutrition. EffePharm advocates for innovative bioscience applications, increased accessibility of nutrition, and improved quality of life.

CORE INNOVATION

We are the first company in the world to conduct two large scale human clinical trials on NMN and NMNH (reduced NMN). We believe in "clinical-backed" science. Apart from the ingredients, we look into different active ingredient delivery systems to increase their bioavailability in human body. By applying technologies like liposomal, and micro encapsulation, we are able to maximize the absorption of the health ingredients. The results are backed by clinical studies as well.

HEALTHSPAN

Our core products are NAD+ related, with precursors like NMN and NMNH (reduced NMN). NAD+ plays a significant role in human body by providing energy and regulating daily activities. As people age, the NAD level goes down, leading to various health problems. We have completed large-scale human clinical trials using NMN and NMNH to prove its efficacy in improving human NAD levels, additionally, the clinical studies also show potentials in another range of health benefits like stress management and energy improvement.

LEADERSHIP TEAM

The EffePharm team comprises a multidisciplinary group led by Dr. Jianjun Yu, an experienced R&D Director with a background in pharmaceutical innovation and clinical trials, supported by co-leaders Dr. Richard H. Kaszynski and Dr. Rubén Zapata-Pérez. Dr. Kaszynski brings expertise in emergency medicine and global health initiatives, while Dr. Zapata-Pérez specializes in NAD+ metabolism and therapeutic applications. With its complementary expertise, this leadership team effectively integrates scientific, clinical, and regulatory knowledge, fostering innovative research in NAD+ metabolism with significant implications for therapeutic applications.

COMPANY OVERVIEW

TEAM / COMPANY NAME
EpiTransfer

TRACK
Healthspan

ORGANIZATION TYPE
Public Hospital

HQ LOCATION
Oslo, Norway

YEAR FOUNDED
2022

NUMBER OF EMPLOYEES
2

FUNDRAISING DETAILS

COMMERCIAL STAGE
n/a

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Project Equity, Strategic Partnership, Government Funding, Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Government, Philanthropic, Private Equity, Project Finance, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
$3M - $10M

CURRENT INVESTMENT STAGE
Grant

Arne Søraas
arvsoe@ous-hf.no

EPITRANSFER

COMPANY DESCRIPTION

Commercialization is an option for our team. Our hospital supports such initiatives.

CORE INNOVATION

We do plasma exchange with young donor plasma. Our differentiating aspect is that we are safely conducting our procedure in patients. The procedure is designed to support epigenetic reprogramming by varying intensity over time.

HEALTHSPAN

Exposure to signalling factors in young plasma induces a whole-body younger phenotype which we expect will improve outcome in multiple patient groups and healthy individuals. We base this on the rejuvenating effect seen in studies of heterochronic parabiosis in animals and plasma dillution studies in humans.

LEADERSHIP TEAM

We are an academic team of researchers with deep insight into epigenetic mechanisms of aging combined with experience in conducting clinical trials and regulatory expertice relevant to plasma exchange.

COMPANY OVERVIEW

TEAM / COMPANY NAME
ERAP Trial Group

TRACK
Healthspan

ORGANIZATION TYPE
University Team looking to form a start-up off-shoot company

HQ LOCATION
Stockholm, Sweden

YEAR FOUNDED
2021

NUMBER OF EMPLOYEES
2

FUNDRAISING DETAILS

COMMERCIAL STAGE
Pre-Commercial Pilot

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Strategic Partnership, Government Funding, Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Philanthropic, Private Equity, Project Finance, Venture Capital, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
$4M (estimated running costs of phase IIb RCT)

CURRENT INVESTMENT STAGE
University team in a pre-start up phase: we are open for input from any type of interested stakeholder in the field

Pontus Plavén Sigray
eraptrialteam@icloud.com
sigray-lab.github.io/sigray_lab_website/

ERAP TRIAL GROUP

COMPANY DESCRIPTION

University team conducting investigator initiated clinical trials of geroprotective compounds using primarily medical in vivo imaging for assessing endpoints.

CORE INNOVATION

A battery of state-of-the art in vivo medical imaging techniques to assess age-related pathology preceding the onset of disease, allowing for screening of geroprotective compounds in humans (https://link.springer.com/article/10.1007/s11357-025-01514-y).

HEALTHSPAN

We are evaluating rapamycin's geroprotective potential in human clinical trials, building on its status as the most promising longevity-enhancing compound identified in preclinical research. Our comprehensive in vivo imaging protocol, which includes FDA-approved surrogate biomarkers for age-related conditions, aims to detect positive effects across multiple organ systems. Evidence of broad systemic benefits would strongly suggest that rapamycin's geroprotective effects, previously demonstrated in other organisms, extend to humans. These findings would provide the critical foundation needed to advance to phase III clinical trials.

LEADERSHIP TEAM

We are currently conducting the phase IIa trial of rapamycin in early-stage Alzheimer's disease; recruitment has closed, 13 patients have finished the treatment regimen (6 months intermittent dose) and we estimate results to be reported in 2025. We are now planning for the follow-up phase IIb RCT in healthy but at-risk population.

COMPANY OVERVIEW

TEAM / COMPANY NAME
ExoNovaX

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Seoul, South Korea

YEAR FOUNDED
2010

NUMBER OF EMPLOYEES
100

FUNDRAISING DETAILS

COMMERCIAL STAGE
Pre-Commercial Pilot

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Project Equity, Strategic Partnership

TYPE OF INVESTORS SOUGHT
n/a

AMOUNT OF CAPITAL SOUGHT
$3M

CURRENT INVESTMENT STAGE
n/a

Seunghee Lee
leesh@kangstem.com
kangstem.com

EXONOVAX

COMPANY DESCRIPTION

Kangstem Biotech develops regenerative medicine therapies using stem cells and exosomes. The company utilizes umbilical cord blood-derived mesenchymal stem cells (CB-MSCs), adipose-derived mesenchymal stem cells (AD-MSCs), and induced pluripotent stem cells (iPSCs). It is also developing exosome-based therapies derived from these stem cells.

Clinical trials on atopic dermatitis, rheumatoid arthritis, and osteoarthritis using umbilical cord blood-derived stem cells have confirmed their immunomodulatory effects, regenerative efficacy, and safety.

CORE INNOVATION

Kangstem Biotech holds stem cell and exosome technologies derived from umbilical cord blood, adipose tissue, and induced pluripotent stem cells (iPSCs). The company has developed a unique cultivation method that optimizes immunomodulation and regenerative abilities. It also combines therapies with other medical products to maximize regenerative treatment efficiency. With high cell proliferation potential, the company is developing innovative, cost-effective regenerative medicine therapies.

HEALTHSPAN

The immune-modulatory factors secreted by stem cells (such as IDO, PGE2) help control chronic inflammation. Additionally, stem cells and exosomes reduce the expression of aging-related genes in damaged cells while enhancing telomerase activity. This process contributes to the rejuvenation of aged cells throughout the body in a safe manner. By targeting both inflammation and cellular aging, these therapies offer a potential solution for reversing the effects of aging and improving overall tissue health. The combination of immune modulation and regeneration makes stem cell-based treatments a promising approach for age-related conditions.

LEADERSHIP TEAM

Founded in 2010 by Professor Kyung-Sun Kang from the College of Veterinary Medicine at Seoul National University, the leadership team has published over 300 SCIE papers on stem cell and exosome therapies through ongoing collaborative research. The team secured research funding from Germany's Heraeus for osteoarthritis treatment development. With 90 registered patents related to stem cells and exosomes, the team has conducted 11 clinical trials for stem cell commercialization (atopic dermatitis, rheumatoid arthritis, osteoarthritis, Crohn's disease, psoriasis) and 2 clinical studies (cerebellar atrophy, epidermolysis bullosa).

COMPANY OVERVIEW

TEAM / COMPANY NAME
FuturVille

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Nanaimo, British Columbia, Canada

YEAR FOUNDED
2020

NUMBER OF EMPLOYEES
0

FUNDRAISING DETAILS

COMMERCIAL STAGE
Pre-Commercial Pilot

REVENUE RANGE
$1M During 3-Year Startup

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Project Equity, Convertible Debt, Strategic Partnership, Government Funding, Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Corporate/Strategic, Family Office, Government, Philanthropic, Private Equity, Project Finance, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
$1.5M

CURRENT INVESTMENT STAGE
Shareholder Loan to Company

Angela Faye
alive@futurville.com
futurville.com

FUTURVILLE

COMPANY DESCRIPTION

FutureVille is a destination development agency whose mission it is to add 10+ healthy years onto 20 million resident and visitor community members' lifespan by 2035, developing flagship locations and licensing affiliate villages so people can access the world's healthiest built environments, communities, products and services close to home.

CORE INNOVATION

FuturVille is a network-owned community of villages, each with its own specialty, each helping to help make health and longevity accessible to all in every aspect of FuturVilles - optimized environments, nutrition, relationships, technology-for-good, safety and security, and proactive-customized healthcare. As a starting point, our moonshot is to add 10+ healthy years onto 20,000 million community members' lifespan by 2035 by accessing the healthiest environments, products and services in the world.

HEALTHSPAN

Our signature lifestyle service, WeTreats offered guided longevity journeys across 12 lifestyle areas to enhance overall well-being. From 2025-2027, our specialized focus is 'Passion-Fueled Longevity' - leveraing the transformative power of personal MTPs and personal vitality to cultivate health and longevity, wealth, happiness, love and meaningful contribution.

LEADERSHIP TEAM

FuturVille is led by Founder and lead Development Director, Angela Faye. FuturVille's startup team has more than 30 years in destination and community development, real estate development, ownership and management, business and life coaching, exponential organizational training, and team leadership. Current joint venture partners include New Earth Development and 5th World, two regenerative development companies that design and build self-sustaining, zero waste, net positive energy, carbon sequestering eco-homes, communities, centers, and cities around the world. The University of Calgary and Mount Royal University are working with us on applied research projects.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Gobal Health Span Extension Conosrtium - University of Basel

TRACK
Healthspan

ORGANIZATION TYPE
University Team

HQ LOCATION
Basel, Switzerland

YEAR FOUNDED
2024

NUMBER OF EMPLOYEES
15

FUNDRAISING DETAILS

COMMERCIAL STAGE
R&D

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Strategic Partnership, Government Funding, Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Philanthropic, Project Finance, Venture Capital, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
$30M

CURRENT INVESTMENT STAGE
Grant

Heike A. Bischoff-Ferrari
HA.Bischoff-Ferrari@felixplatter.ch
healthspanconsortium.com

GLOBAL HEALTH SPAN EXTENSION CONOSRTIUM - UNIVERSITY OF BASEL

COMPANY DESCRIPTION

The “Global Health Span Extension Consortium” will provide a unique and collaborative Healthy Longevity Platform that combines global research & innovation with the clinical applications of “organ-aging clocks” and other clocks as early medical diagnostics of organ aging, and as control of therapeutic interventions and health promotion.

CORE INNOVATION

The “Global Health Span Extension Consortium” will provide a unique and collaborative Healthy Longevity Platform that combines global research & innovation with the clinical applications of “organ-aging clocks” and other clocks as early medical diagnostics of organ aging, and as control of therapeutic interventions and health promotion.

HEALTHSPAN

We plan to test a multimodal intervention of 4 lifestyle factors plus metformin, where each lifestyle component individually was found to improve muscle, cognitive and immune function, and slow biological aging. see our recent publication: https://www.nature.com/articles/s43587-024-00793-y

LEADERSHIP TEAM

The team is composed of 13 highly-experienced clinical and translational researchers, 2 biotech and 1 app-design company who pioneered the additive effect of lifestyle factors on health span extension and developed organ-aging proteomic clocks and transcriptomics clocks. The team also has a strong background in muscle, cognitive and immune function outcomes, and testing these outcomes in small to large-scale clinical trials in adults age 60+ supported by digital health tool innovation. To ensure optimal target population and outcome validation, we harmonized 6 longitudinal cohorts, including 2 large populational-based life-span cohorts, and 10 clinical trials with phenotyping on muscle, cognitive and immune function (n > 174’000).

COMPANY OVERVIEW

TEAM / COMPANY NAME
Healthspan Quest

TRACK
Healthspan, FSHD Bonus Track

ORGANIZATION TYPE
Non-Profit Organization

HQ LOCATION
San Jose, CA, USA

YEAR FOUNDED
1965

NUMBER OF EMPLOYEES
350

FUNDRAISING DETAILS

COMMERCIAL STAGE
Pre-Commercial Pilot

REVENUE RANGE
$90M

CAPITAL RAISED TO DATE
$100K

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Family Office, Philanthropic, Venture Capital, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
$500K

CURRENT INVESTMENT STAGE
Academic/University Grants

Danny Kim
dkim@vcs.net
vcs.net

HEALTHSPAN QUEST

COMPANY DESCRIPTION

Valley Christian Schools (VCS) in San Jose California is dedicated to education through innovation. VCS has participated in 6 XPRIZE competitions achieving a win, semifinalist, finalist and top 100 and top 30 team statuses.

CORE INNOVATION

Our team of high school students along with seasoned researchers and mentors provides the innovative and creative solutions from young minds combined with the experience and infrastructure needed to bring the solutions to life.

HEALTHSPAN

Our solutions focus on implementing a multi-faceted intervention strategy with a large focus on exercise routines in order to target the main symptoms of FSHD. This will include a combination of: High-Intensity Interval Training (HIIT), Dietary Modifications, and Enhanced External Counterpulsation (EECP).

LEADERSHIP TEAM

Our leadership team including Danny Kim and others are veterans of 6 successful XPRIZE competitions. We've created a proven track record of combing the energy and ideas of high school students with the top mentors and researchers in the industry to create solutions.

COMPANY OVERVIEW

TEAM / COMPANY NAME
HONYA M

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Tainan, Taiwan

YEAR FOUNDED
2011

NUMBER OF EMPLOYEES
10

FUNDRAISING DETAILS

COMMERCIAL STAGE
Early Commercial Demonstration

REVENUE RANGE
$1M

CAPITAL RAISED TO DATE
$3M

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Project Equity, Strategic Partnership, Government Funding, Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Corporate/Strategic, Philanthropic, Private Equity, Project Finance, Venture Capital, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
$10M

CURRENT INVESTMENT STAGE
Series A

Jackson Tsung Kui Liu
jtkliu@honya-m.com
honya--m.com

HONYA M

COMPANY DESCRIPTION

HONYA Medical Co., Ltd., established in 2011 and headquartered in Tainan City, Taiwan, is a pioneering stem cell pharmaceutical company specializing in regenerative medicine. The company focuses on developing advanced stem cell therapies to combat degenerative and age-related diseases, particularly cardiovascular conditions. HONYA's flagship product, MiSaver®, is designed to repair heart tissue damaged by acute myocardial infarction. Committed to innovation, HONYA adheres to strict Good Tissue Practice (GTP) and Good Manufacturing Practice (GMP) standards, ensuring the production of high-quality, ethically sourced stem cell products.

CORE INNOVATION

Our approach to healthy aging goes beyond conventional longevity solutions by leveraging advanced stem cell therapy to restore and maintain youthful biological function. Unlike traditional anti-aging interventions that focus on symptom management, our technology targets the root causes of cellular aging, promoting regeneration and tissue repair at a fundamental level. By harnessing the extensively studied properties of stem cells, we aim to extend youthful healthspan significantly, potentially beyond 300 years. Our focus on practical, clinically viable solutions ensures real-world applicability, setting us apart in the pursuit of truly transformative aging interventions.

HEALTHSPAN

Our therapeutic intervention enhances healthspan by leveraging the regenerative potential of stem cells to repair and rejuvenate aging tissues at a cellular level. While stem cells hold potential for treating FSHD by enhancing muscle regeneration, normal muscle cell replacement, reducing fibrosis, and improving muscle function, we have decided not to participate in FSHD-focused trials because the relatively low prevalence of FSHD in Taiwan, which may pose challenges in patient recruitment.

LEADERSHIP TEAM

Our leadership team is composed of experts with extensive experience in regenerative medicine, stem cell therapies, and clinical research. With backgrounds in both academia and clinical practice, our leaders have successfully spearheaded multiple groundbreaking projects in the field of aging and cellular regeneration. They bring a wealth of expertise in product development, regulatory affairs, and clinical trial management. Their commitment to innovation and patient-centric solutions has driven our company's mission to revolutionize healthspan extension. The team's diverse skill set, combined with a shared passion for advancing regenerative therapies, positions us to lead the charge in transforming healthcare for aging populations.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Hoskinson Health and Wellness Clinic

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Gillette, WY, USA

YEAR FOUNDED
2022

NUMBER OF EMPLOYEES
150

FUNDRAISING DETAILS

COMMERCIAL STAGE
R&D

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
No

TYPE OF CAPITAL SOUGHT
n/a

TYPE OF INVESTORS SOUGHT
n/a

AMOUNT OF CAPITAL SOUGHT
n/a

CURRENT INVESTMENT STAGE
Pre-Seed

Taylor Thompson
taylor.thompson@hoskinsonhealth.com
hoskinsonhealth.com

HOSKINSON HEALTH AND WELLNESS CLINIC

COMPANY DESCRIPTION

Hoskinson Health and Wellness Clinic is a primary healthcare clinic located in Gillette Wyoming. Our research team is focused on treating aging, disease, and regenerative medicine. We have a well rounded team of physicians, exercise physiologists, dieticians, and researchers. Our clinic is focused on improving healthspan and lifespan with advanced testing and preventative lifestyle habits.

CORE INNOVATION

Stem Cell based regenerative medicine technologies.

HEALTHSPAN

Our therapeutic approach combines advanced cell therapy, cutting edge genomics, biotechnological techniques, and personalized lifestyle interventions to target the fundamental mechanisms of aging.

LEADERSHIP TEAM

Sanjay Dhar, PI, MPhil, PhD - Director of Research and Stem Cell Program

Taylor Thompson, MS - Director of Lifestyle and Exercise Physiologist

William Hoskinson, DO - Chief Medical Officer

COMPANY OVERVIEW

TEAM / COMPANY NAME
HumanGood

TRACK
Healthspan

ORGANIZATION TYPE
Non-Profit Organization

HQ LOCATION
Duarte, CA, USA

YEAR FOUNDED
2016

NUMBER OF EMPLOYEES
5,000

FUNDRAISING DETAILS

COMMERCIAL STAGE
Mature

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Prefer not to say

TYPE OF INVESTORS SOUGHT
Prefer not to say

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
n/a

Nick Lindberg
nick.lindberg@humangood.org
humangood.org

HUMANGOOD

COMPANY DESCRIPTION

HumanGood was founded on the belief that everyone should have the opportunity to live life with enthusiasm, confidence, and security, regardless of physical, social, or economic circumstances. Our mission is to ensure that those we serve have every opportunity to become their best selves as they define it. This extends to those who live in our communities, their family and friends, and those who serve them. With approximately 5,000 team members serving more than 14,800 residents in our 23 life plan communities and over 100 affordable housing communities, HumanGood is the sixth-largest nonprofit senior living provider in the country.

CORE INNOVATION

Combining data from lifestyle and behavioral sources with research-proven recommendations and coaching to deliver personalized multi-modal lifestyle interventions to improve your health.

HEALTHSPAN

Our intervention gives you the insight, coaching, and inspiration to take action on multi-modal lifestyle changes to improve your health.

LEADERSHIP TEAM

HumanGood: one of the nation's premier senior housing operator and innovator

Buck Institute for Research and Aging: one of the world's leading research institutes devoted to understanding the biology of aging

svexa: industry pioneers in health and performance optimization by combining human and artificial intelligence

Dr. Heather Sandison: clinical researcher and best-selling author with expertise in improving cognition in the elderly

vEvidation: cutting-edge technology-enabled digital health clinical trial facilitator

COMPANY OVERVIEW

TEAM / COMPANY NAME
Immortalite

TRACK
Healthspan, FSHD Bonus Track

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Honolulu, HI, USA

YEAR FOUNDED
2022

NUMBER OF EMPLOYEES
n/a

FUNDRAISING DETAILS

COMMERCIAL STAGE
Growth Stage (beyond initial customers)

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Prefer not to say

TYPE OF CAPITAL SOUGHT
Corporate Equity

TYPE OF INVESTORS SOUGHT
Angel

AMOUNT OF CAPITAL SOUGHT
Depends on the angel / partner and the scale they can help us reach

CURRENT INVESTMENT STAGE
n/a

Kory Martin Juul
info@immortalite.com
immortalite.com

IMMORTALITE

COMPANY DESCRIPTION

Immortalité is a Hawai'i based longevity company. We currently hold the World Record in Fastest Epigenetic Age Reduction – 8.4 Years in 8 Weeks. We believe that regeneration is the key to longevity and our products and programs allow people to activate the regenerative process within their own bodies. Our research team is made up of regenerative farmers here in Hawai'i who have put their knowledge into regenerating the human body.

CORE INNOVATION

Our products harness the power of nature. Unlike powdered supplements, our products are alive. We focus on regeneration. Our longevity tinctures activate they body's inherent regenerative abilities. We have regenerated completely torn ligaments as well as regenerated a degenerating lower spine in a woman over 60. Our products also boost immune function, protect the DNA and signal the body that it is operating in perfection. 5 drops a day allows for longer and more quality years of life.

HEALTHSPAN

Our tinctures strengthen the kidneys, which prompts the body to release stem cells throughout the body for regeneration. We also reset the body's epigenetics and protect the DNA. DNA methylation tests are showing people without any lifestyle or dietary changes measuring over 10 years younger on our drops. They are slowing their aging process.

For FSHD, we are developing a protocol to treat the underlying organs we believe are responsible for a deficiency causing FSHD as well as reseting epigenetics before regenerating the upper body.

LEADERSHIP TEAM

Kory Martin Juul - Entrepreneur / Filmmaker - Regenerated completely torn ligaments in his elbow without requiring surgery. Kory tested various longevity formulas and protocols on his body to eventually achieve 8.4 epigenetic years younger in just 8 weeks measured with DNA methylation.

Dr. Allison Bachlet PhD, LAc, ND - Clinical Nutrition, Acupuncture & Naturopathic Medicine - Dr. Bachlet was awarded a Rhodes Scholarship and completed her PhD at the University of Oxford, England, in the Faculty of Clinical Medicine, Department of Paediatrics. Her work in pediatric nutrition, gastroenterology and neurological disabilities won awards at several international conferences.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Inner Science

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Gig Harbor, WA, USA

YEAR FOUNDED
2021

NUMBER OF EMPLOYEES
n/a

FUNDRAISING DETAILS

COMMERCIAL STAGE
Prefer not to say

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Prefer not to say

TYPE OF CAPITAL SOUGHT
Prefer not to say

TYPE OF INVESTORS SOUGHT
Prefer not to say

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
n/a

Michelle A Poirier, Ph.D.
michelle@metamorphllc.net
metamorphllc.net

INNER SCIENCE

COMPANY DESCRIPTION

Through our ongoing research, we capture the data of personal change and transformation. By conducting scientific investigations into the effects of meditation, we're furthering a deeper understanding of the mind-body connection. In doing so, we're encouraging people to unlock their full potential – and lead healthier, more fulfilling lives

Through our groundbreaking research at retreats around the world, we're measuring the ways common people do the uncommon. We collect and curate a wide range of personal and biological data, as well as physiological readouts. Using these and other tools, we gather valuable insights into the effects of meditation on human biology.

CORE INNOVATION

Chronic stress has been shown to have a profound negative effect on the body, leading to chronic inflammation and age-related conditions. Meditation and other mind-body practices can improve the stress response. We have studied thousands of individuals in the context of a 7-day intensive meditation retreat using innovative methodologies encompassing 1) multi-omic analyses of various specimens (i.e., blood, stool, urine), 2) advanced physiological monitoring (i.e. EEG, HRV), 3) digital phenotyping by video analysis and 4) validated surveys to track physical and emotional health. This project attempts to incorporate multidimensional data sets into a machine-learning platform to show the tangible effects of intensive meditation as an effective method for promoting healthy longevity.

HEALTHSPAN

Along with meditation, this retreat intervention features lectures aimed at transforming negative beliefs and provides a well-controlled environment whereby study subjects are on the same sleep/wake schedule, are meditating for the same length of time every day, and are given the same food choices throughout the week. These data have demonstrated that tremendous changes in biological and subjective measures can occur in 7 days. We will continue to use this retreat setting for the development of sample sets to probe the biological, physiological, and emotional benefits of meditation, as well as the positive impacts on longevity and well-being.

LEADERSHIP TEAM

This team will be led by Dr. Joe Dispenza, a New York Times best-selling author, researcher, and lecturer. His work integrates essential knowledge that teaches people how to heal their bodies of health conditions, make significant life changes, and evolve their consciousness. Dr. Hemal Patel, team co-lead, is a Tenured Professor and Vice-Chair for Research at UC San Diego. He has made seminal contributions to defining the impact of membrane structure on cell, organ, and organismal physiology. He is currently working to discover the molecular and biochemical signatures generated during meditation that impact human potential for health and disease management.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Initiate Age Reversal

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Auckland, New Zealand

YEAR FOUNDED
2020

NUMBER OF EMPLOYEES
10

FUNDRAISING DETAILS

COMMERCIAL STAGE
Growth Stage (beyond initial customers)

REVENUE RANGE
$10M

CAPITAL RAISED TO DATE
$2M

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Prefer not to say

TYPE OF CAPITAL SOUGHT
Prefer not to say

TYPE OF INVESTORS SOUGHT
Prefer not to say

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Seed

Greg Macpherson
srw.co

INITIATE AGE REVERSAL

COMPANY DESCRIPTION

SRW Laboratories is a longevity nutraceutical company that has a clinically proven protocol that reverses biological and physiological aging.

CORE INNOVATION

We have developed a proprietary supplement protocol that we have clinically proven to reverse biological age by 6 years, significantly slow stem cell stress as measured by the mitotic clock and are now working with an AI drug discovery company to develop a next generation product.

HEALTHSPAN

We target the Hallmarks of Aging using a clinically validated nutraceutical protocol and are building a AI driven APP that learns about its user and seeks to nudge them towards a longevity lifestyle.

LEADERSHIP TEAM

Greg Macpherson, Pharmacist, author, serial entrepreneur, over a decade in biotech either as CEO/President or Founder.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Klotho Longevity

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Mill Valley, CA, USA

YEAR FOUNDED
2024

NUMBER OF EMPLOYEES
2

FUNDRAISING DETAILS

COMMERCIAL STAGE
R&D

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
No

TYPE OF CAPITAL SOUGHT
Government Funding

TYPE OF INVESTORS SOUGHT
Government

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Pre-seed

Gail Humble, MD
drgail@drgailhumble.com

KLOTHO LONGEVITY

COMPANY DESCRIPTION

Klotho Longevity has a novel delivery oral form to increase endogenous Klotho levels and delay age related diseases.

CORE INNOVATION

This will involve a novel oral delivery sytsem.

HEALTHSPAN

The age suppresing Klotho protein delays age related diseases we will be gving and exogenous source which will cause an endogenous increase in Klotho levels.

LEADERSHIP TEAM

Gail Humble and Joe Cleaver are experts on the Klotho gene/protein and they have developed a novel delivery system for oral absorption.

COMPANY OVERVIEW

TEAM / COMPANY NAME
LIFE IS LONG

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Kasumnigaseki, Tokyo, Japan

YEAR FOUNDED
2019

NUMBER OF EMPLOYEES
15

FUNDRAISING DETAILS

COMMERCIAL STAGE
Growth Stage (beyond initial customers)

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
No

TYPE OF CAPITAL SOUGHT
Corporate Equity, Project Equity, Strategic Partnership

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Government, Project Finance, Venture Capital

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Corporate

Masanobu Kanou
kanou@nomon.jp
nomon.jp

LIFE IS LONG

COMPANY DESCRIPTION

A healthcare company that takes a positive view of ageing and is committed to helping people lead fulfilling lives. We aim to achieve productive ageing, enabling people to live their own lives from birth to their last day. We will provide health information based on reliable data.

CORE INNOVATION

We are a company founded by scientists from a pharmaceutical company. We apply our experience and knowledge of pharmaceutical research and development to the food sector. We have particular strengths in generating evidence, evaluating it, confirming safety and ensuring quality.

HEALTHSPAN

This programme focuses on ingredients that are already on the market as dietary supplements. The combination has been shown to be effective for muscle strength, cognitive function and immune function, but as it is not a disease, it is a combination that has been shown to be safe from a preventative perspective.

LEADERSHIP TEAM

The team is led by NOMON and the Osaka University Faculty of Medicine, who have been conducting joint research since 2018. In the past, this team conducted the first specific clinical research on NMN in Japan. They will work with a joint venture company that will evaluate muscle strength, cognitive function and immune function.

COMPANY OVERVIEW

TEAM / COMPANY NAME
LiGHT Team (Lithium as a Geroprotective Human Treatment)

TRACK
Healthspan

ORGANIZATION TYPE
University Medical Center

HQ LOCATION
New York, NY, USA
Jongno-gu, Seoul, South Korea

YEAR FOUNDED
n/a

NUMBER OF EMPLOYEES
n/a

FUNDRAISING DETAILS

COMMERCIAL STAGE
n/a

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
150K

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Academic / University Grants, Strategic Partnerships

TYPE OF INVESTORS SOUGHT
Academic / University Grants, Philanthropic

AMOUNT OF CAPITAL SOUGHT
$1.25M

CURRENT INVESTMENT STAGE
n/a

LIGHT TEAM

COMPANY DESCRIPTION

The LiGHT Team is a highly interdisciplinary team of faculty at Columbia University Medical Center (CUMC) and Seoul National University Hospital (SNUH) who represent leaders in the field of Geroscience and Clinical Psychiatry. The LiGHT Team aims to evaluate whether low-dose lithium treatment can restore cognitive, immune, and muscle function in older adults. The clinical trials will be conducted at the Clinical Trials Center at SNUH, an academic medical center with advanced facilities, including a research ward, specialized laboratories, and outpatient clinics capable of pharmacokinetics, bioanalysis, and safety oversight systems necessary to support Phase I to IV clinical trials.

CORE INNOVATION

The LiGHT Team proposes low-dose lithium as a geroprotector in humans. While lithium is best known for treating mood disorders, preclinical studies have demonstrated that it targets fundamental biology of aging, extending lifespan and healthspan in animal models. The team's innovation lies in testing subtherapeutic lithium in healthy older adults at doses significantly lower than typical therapeutic concentrations used in psychiatry. This approach builds on epidemiological data showing correlation between lithium levels in drinking water and longevity across independent populations, suggesting lithium's potential as a safe, scalable, and accessible tool to promote human longevity.

HEALTHSPAN

Lithium positively influences the three domains targeted by XPRIZE Healthspan: cognitive, immune, and muscle function. Clinical and preclinical studies show lithium is neuroprotective, reducing Alzheimer's disease risk and enhancing neurocognitive functioning and increasing gray matter volume in cognitive control regions, and improving metabolic integrity of cerebral tissue. Lithium treatment may improve immune function by reducing long COVID syndromes and inflammatory cytokine levels. Low therapeutic doses promote myoblast fusion and myogenic differentiation, showing potential for various myopathic conditions. The LiGHT study aims to evaluate whether these benefits also extend to restoration of age-related functional decline in older adults.

LEADERSHIP TEAM

The team is led by three Principal Investigators with complementary expertise: Dr. Yousin Suh (contact PI) at CUMC is the Charles and Marie Robertson Professor with extensive experience in aging biology using human genetics and functional genomics approaches; Dr. Ralph Wharton (mPI) at CUMC is Professor of Clinical Psychiatry with distinguished expertise in lithium therapy whose research on lithium carbonate was noted in the Special Sesquicentennial Issue of the American Journal of Psychiatry; and Dr. Yong Min Ahn (mPI) at SNUH is Professor and Chair of Neuropsychiatry with decades of experience in psychiatry, behavioral sciences, and clinical trials, including leadership of large-scale cohort studies.

COMPANY OVERVIEW

TEAM / COMPANY NAME
LinkGevity

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Cambridge, England, UK

YEAR FOUNDED
2023

NUMBER OF EMPLOYEES
8

FUNDRAISING DETAILS

COMMERCIAL STAGE
Prefer not to say

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Project Equity, Convertible Debt, Strategic Partnership, Government Funding, Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Government, Philanthropic, Private Equity, Venture Capital, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Seed

Dr. Carina Kern
carina@linkgevity.com
linkgevity.com

LINKGEVITY

COMPANY DESCRIPTION

LinkGevity is a pioneering biotech company developing Anti-Necrotic™, the world's first therapeutic targeting necrosis—a key driver of aging, tissue degradation, and frailty. Headquartered at Babraham Research Campus, Cambridge, their team specializes in longevity science, drug-discovery, and clinical trials. Supported by prestigious EU and UK Government grants, NASA's Space-H Program, and The Francis Crick Institute, LinkGevity aims to establish Anti-Necrotic™ as a breakthrough longevity therapy. Necrosis is one of the few well-characterized aging mechanisms, enabling the use of accelerated aging models. This positions Anti-Necrotic™ as a leading contender for the first therapy to gain regulatory approval for treating aging itself.

CORE INNOVATION

Necrosis has long been considered untreatable—until now. Unlike programmed cell death, necrosis is a chaotic, pathological process that drives inflammation, senescence, fibrosis and tissue degeneration. The Anti-Necrotic™ is a first-in-class therapy to directly inhibit necrosis, preventing degradation of cells and tissues. The Anti-Necrotic™ is a proprietary combination of two repurposed drugs. Validated by four world-class independent CROs, the technology has demonstrated almost complete necrosis inhibition and function preservation in a number of disease and aging models. With expedited regulatory pathways and broad applications across age related decline, the Anti-Necrotic™ represents a paradigm shift in longevity medicine.

HEALTHSPAN

Aging is characterized by frailty, loss of resilience, and multi-morbidity, with necrosis as a key driver. By inhibiting necrosis, the Anti-Necrotic™ has the potential to counter age-related degeneration, including tissue-integrity loss, inflammation, fibrosis, and senescent cell accumulation. LinkGevity's lead clinical focus—kidney disease (9th leading cause of death, WHO 2024)—serves as an accelerated aging model, where necrosis drives dysfunction. The planned Phase 2a kidney disease trial marks the first step in positioning necrosis inhibition as a foundational therapy for extending healthspan across biology, from necrosis-driven cognitive decline to sarcopenia and immune dysfunction, paving the way for broad anti-aging applications.

LEADERSHIP TEAM

LinkGevity is led by Dr. Carina Kern(CEO&CSO), a recognized innovator in aging and necrosis research, whose work has been backed by NASA's Space-Health program, alongside EU and UK Government funding. The full-time team includes Dr. Bill Davis (ex-GlaxoSmithKline director with 25+ years in clinical trials and drug development experience). Co-leads include leading medics and scientists such as Prof. Joseph Bonventre(Harvard, leading expert in necrosis and organ aging); Prof. Justin Stebbing(Imperial College London, expert in cell death, drug repurposing and expedited regulatory approval); Prof Richard Faragher (leading longevity scientist) and Dr Annalisa Jenkins (served on the Scientific Board of the FDA).

COMPANY OVERVIEW

TEAM / COMPANY NAME
Marcus STAMINA Team

TRACK
Healthspan

ORGANIZATION TYPE
Non-Profit Organization

HQ LOCATION
Boston, MA, USA

YEAR FOUNDED
1903

NUMBER OF EMPLOYEES
100+

FUNDRAISING DETAILS

COMMERCIAL STAGE
n/a

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Prefer not to say

TYPE OF CAPITAL SOUGHT
Government Funding, Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Philanthropic

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
n/a

Lewis Lipsitz
Lipsitz@hsl.harvard.edu
hebrewseniorlife.org

MARCUS STAMINA TEAM

COMPANY DESCRIPTION

The Marcus Institute is a non-profit research Institute that is a division of Hebrew Senior Life and an affiliate of Harvard Medical School. We are one of the largest gerontological research facilities in a clinical setting in the US. Our mission is to conduct high caliber, pioneering research to help diagnose, understand, and treat age-related conditions across a diverse array of content areas, including frailty, dementia, cardiology, Alzheimer's disease, osteoporosis, depression, falls, balance and more.

CORE INNOVATION

Senolytic strategies aimed at mitigating the harmful effects of cellular senescence, which contribute to declines in muscle, cognitive, and immune function, hold significant potential to enhance the healthspan of older adults. Our recent intervention with two senolytics, Dasatinib and Quercetin (DQ, a chemotherapeutic and a flavonoid, respectively), yielded compelling data suggesting that a pharmacological senolytic may improve these key functions in older adults with MCI (manuscript revision under review). Additionally, exercise is a well-established intervention to improve cognition and muscle function, possibly through senescent cell clearance. However, the high cost Dasatinib and the numerous interactions it may have with medication commonly prescribed to older adults severely limits the potential impact of DQ. Therefore, other combinations of more practical senolytic interventions need further exploration. The integration of Quercetin alone and exercise creates a potentially powerful intervention for enhancing muscle strength, cognitive health, and immune resilience by enhancing their clearance and reducing their toxic by-products. Together, these two approaches act as a foundation for healthy aging, disease prevention, and overall vitality, reinforcing the importance of lifestyle modifications in achieving holistic health. Thus, for the Semi-Finals, our plan is to evaluate a synergistic intervention that combines two senolytics—exercise and flavonoid compounds—to enhance muscle, cognitive, and immune function in older adults with mild cognitive impairment. The main goal of this study will be to determine feasibility and preliminary effect of a combined exercise and flavonoid approach on these domains.

HEALTHSPAN

Senescent cells and their toxic by-products are hypothesized drivers of age-related conditions, including impairments in muscle, cognitive, and immune function. Strategies that target the reduction or elimination of senescent cells (e.g., senolytics) and decrease their toxic by-products hold promise for preserving muscle, cognitive, and immune functions, thereby promoting health and longevity in aging. Our approach for the Semi-Finals focuses on evaluating the synergistic effects of combining two senolytic strategies (i.e., Quercetin supplementation and exercise) to help identify a scalable and accessible strategy to increase healthspan.

LEADERSHIP TEAM

Our multidisciplinary team, composed of experts in aging and cellular senescence, collectively brings over 100 years of experience in designing and conducting high-quality trials in older adults. Leading our team is Dr. Lewis Lipsitz, a highly distinguished geriatrician and clinical researcher, who has dedicated his career to advancing aging research. Complimenting his expertise are specialists from diverse fields, including the musculoskeletal system (Dr. Douglas Kiel), clinical trials and biostatistics (Dr. Tom Travison), flavonoids (Dr. Courtney Millar), and exercise and neuroscience (Dr. Amani Norling). Together, our team brings a wealth of knowledge and experience to advance our research goals.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Matter Bio

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
New York City, NY, USA

YEAR FOUNDED
2022

NUMBER OF EMPLOYEES
6

FUNDRAISING DETAILS

COMMERCIAL STAGE
Early Commercial Demonstration

REVENUE RANGE
$1M

CAPITAL RAISED TO DATE
$7M

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Convertible Debt, Strategic Partnership, Government Funding, Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Government, Philanthropic, Private Equity, Venture Capital, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
$30M

CURRENT INVESTMENT STAGE
Seed

Chris Bradley
chris@matterbio.com
matterbio.com

MATTER BIO

COMPANY DESCRIPTION

At Matter, we aim to harness these naturally occurring DNA stability variants and deliver them to human cells to dramatically enhance cellular longevity.

CORE INNOVATION

Matter Bioworks is a longevity company committed to preserving genomic integrity. Drawing inspiration from the information theory of aging, we posit that age-related diseases—and possibly aging itself—result from the accumulated loss of DNA integrity due to damage.

HEALTHSPAN

As we age, our genomes accrue damage from both external and internal sources at a roughly linear rate. While cells possess powerful DNA repair mechanisms, these systems are not infallible. Errors can be missed, leading to mutations, structural variations, epigenetic drift, and other forms of information loss. This accumulation triggers a cascade of problems that culminate in age-related diseases.

At Matter, we aim to harness these naturally occurring DNA stability variants and deliver them to human cells to dramatically enhance cellular longevity. We are addressing four critical stages in the decay of biological information:

1. Read: Employ ultra-high-resolution error-corrected sequencing (ecNGS) to precisely understand genomic changes.
2. Repair: Utilize pro-longevity gene variants to bolster DNA repair mechanisms and maintain genomic integrity.
3. Replace: Substitute genes that have become excessively corrupted and pathological, including oncogenes and genes involved in inherited progeroid disorders.
4. Remove: Safely eliminate cells that have accumulated irreversible damage, such as tumor cells and senescent cells.

LEADERSHIP TEAM

Our co-founders are leaders in the fields of genetics, aging, and biotechnology:

Chris Bradley, MS: With 16 years of startup experience and a successful exit.

Sam Sharifi, PhD: An expert in aging science.

George Church, PhD: Harvard University
https://wyss.harvard.edu/team/core-faculty/george-church/

Jan Vijg, PhD: Albert Einstein College of Medicine
https://www.einsteinmed.edu/faculty/11318/jan-vijg/

Alex Maslov, MD, PhD: Albert Einstein College of Medicine
https://www.einsteinmed.edu/faculty/11319/alexander-maslov/

Claudia Gravekamp, PhD: Albert Einstein College of Medicine
https://www.einsteinmed.edu/faculty/11288/claudia-gravekamp/

COMPANY OVERVIEW

TEAM / COMPANY NAME
Memory Air

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Dana Point, CA, USA

YEAR FOUNDED
2017

NUMBER OF EMPLOYEES
7

FUNDRAISING DETAILS

COMMERCIAL STAGE
Early Commercial Demonstration

REVENUE RANGE
Pre Revenue

CAPITAL RAISED TO DATE
$10M

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Project Equity, Government Funding, Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Corporate/Strategic, Family Office, Government, Philanthropic, Venture Capital, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Seed

Michael Leon
mleon@uci.edu
memoryair.com

MEMORY AIR

COMPANY DESCRIPTION

The loss of olfaction increases the risk for memory loss, depression, heart disease, Alzheimer's disease, and Parkinson's disease. Conversely, we and others have found that olfactory enrichment (multiple scents experienced on a regular basis) is needed to maintain the health of the brain's memory and emotional centers. Indeed, it is currently the only effective treatment for dementia. Unfortunately, few people are willing to sample 80 scents/day, which is the intensity that is needed for the dramatic improvement in neural function. Therefore, we developed Memory Air, a device that accomplishes that task while you are sleeping, allowing the universal compliance that we think will produce a revolution in brain health.

CORE INNOVATION

Olfactory dysfunction accompanies human aging, memory loss, chronic inflammation, and frailty. Indeed, by middle age, olfactory loss accurately predicts all-cause mortality. Fortunately, olfactory enrichment improves memory loss, inflammation and frailty, but the effort to obtain these gains are more than m most people will do. Therefore, we have developed Memory Air, which blows 40 odors twice a night at you without any effort. This kind of environmental enrichment greatly improves memory, decreases the chronic inflammation that is involved in many aging issues, and improves frailty symptoms. We therefore think that olfactory enrichment will be key to any effective healthspan program and that Memory Air will play a critical role in it.

HEALTHSPAN

The loss of olfaction is associated with at least 139 medical disorders, which are also associated with chronic inflammation, including cancer, heart disease, autism, anorexia, schizophrenia, epilepsy, kidney, lung, and liver disease. Indeed, by middle age, your all-cause mortality can be accurately predicted based on your olfactory ability. Surprisingly, olfactory receptors are located in about a dozen organs of the body and they have demonstrable functions in these organs. Indeed, they are even found in cancers, where scents are being used to treat tumors effectively. On the other hand, activation of these receptors may maintain the health of these organs to promote healthspan.

LEADERSHIP TEAM

Michael Leon, PhD and Cynthia Woo, PhD have discovered the importance of olfactory enrichment in maintaining the health of the memory centers of the brain. They are working with Alan Bernstein, MBA, our CEO, to develop and market Memory Air.

COMPANY OVERVIEW

TEAM / COMPANY NAME
MetroBiotech

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Worcester, MA, USA

YEAR FOUNDED
2013

NUMBER OF EMPLOYEES
15

FUNDRAISING DETAILS

COMMERCIAL STAGE
R&D

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Project Equity, Strategic Partnership, Government Funding, Philanthropic Funding

TYPE OF INVESTORS SOUGHT
Corporate/Strategic, Family Office, Government, Philanthropic, Private Equity, Project Finance, Venture Capital

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Series A

David Livingston
info@metrobiotech.com
metrobiotech.com

METROBIOTECH

COMPANY DESCRIPTION

NAD is critically important to the function of all living cells. Metro International Biotech is designing new therapeutics that can impact cell metabolism by modulating NAD levels in tissues. NAD levels have been shown to decline as humans age and preclinical models have demonstrated the broad therapeutic potential of increasing NAD to preserve organ function and normal metabolism. Some of the company's molecules are NAD precursors, and some inhibit or activate enzymes required for NAD metabolism. The company is in mid-stage clinical trials for the treatment of diseases or disorders of heart, muscle, kidney, and CNS.

CORE INNOVATION

Metro International Biotech has a superior, experienced medicinal chemistry team who have created the world's largest library of proprietary NAD precursors and modulators. The company's scientific founders and advisors are leading experts in NAD biology, epigenetics, and pharmacology. The company has several clinical collaborations with experienced clinical trial researchers in metabolism, neuroscience, and metabolic diseases of aging. The company and its collaborators have published several reports on its clinical and preclinical findings.

HEALTHSPAN

Aging is a major risk factor for many common diseases, such as diabetes, chronic kidney disease, cardiovascular disease, and Alzheimer's disease. The geroscience suggests that targeting the pathways of aging have the potential to prevent or treat multiple aging-related conditions. Raising NAD levels in model organisms by administration of NAD precursors improves glucose and lipid metabolism; attenuates weight-gain, diabetes, diabetic kidney disease; reduces endothelial dysfunction, protects heart from injury; attenuates cerebrovascular and neurodegenerative disorders; and increases health-span. We are investigating NAD elevation in humans as a therapeutic intervention to prevent and treat age-related conditions.

LEADERSHIP TEAM

Our team at Metro International Biotech have decades of experience in pharmaceuticals, biotechnology, medicinal chemistry, cell biology, molecular biology, and clinical science. We have been extraordinarily capital-efficient in our R&D efforts that have resulted in seven IND-enabled human clinical trials, numerous collaborations on preclinical pharmacology of NAD producing compounds, and a pharmaceutical grade manufacturing capability that has produced our investigational drugs on multi-kilogram scale. The team also can access the wisdom and guidance of world-class advisors in NAD biology, genetics, genomics, and drug discovery and development.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Minovia

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Tirat Hacarmel, Israel

YEAR FOUNDED
2012

NUMBER OF EMPLOYEES
23

FUNDRAISING DETAILS

COMMERCIAL STAGE
Pre-Commercial Pilot

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
$30M

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Strategic Partnership, Government Funding, Philanthropic Funding

TYPE OF INVESTORS SOUGHT
Family Office, Government, Philanthropic, Private Equity, Venture Capital

AMOUNT OF CAPITAL SOUGHT
$30M

CURRENT INVESTMENT STAGE
Series A

Natalie Yivgi Ohana
info@minoviatx.com
minoviatx.com

MINOVIA

COMPANY DESCRIPTION

The first clinical stage company to develop mitochondrial transplantation and novel biomarkers for rare-genetic and age-related mitochondrial diseases.

CORE INNOVATION

There are no diagnostic tests or approved drugs for mitochondrial diseases. Minovia's approach is that aging is actually a mitochondrial disease, and primary mitochondrial diseases are the best models to study aging. Our novel biomarkers measure mitochondrial quality in blood, and our technology restores mitochondrial function in the hematopoietic system. Our allogeneic mitochondria bank allows scalability and affordability of the treatment.

HEALTHSPAN

Tested in 20 pediatric and adult patients, our technology was proven to be safe and to stop the progression of the disease, as well as improve the function of several organ systems: immune and hematopoietic; renal; muscular; cognitive; GI; frailty. In children affected with mitochondrial diseases the treatment seems to improve survival. In animal models of MDS mitochondrial augmentation resulted in delayed AML progression and increased survival rate. The novel biomarkers were shown to correlate with disease severity and improvement.

LEADERSHIP TEAM

Natalie Yivgi Ohana, PhD – Scientific Co-Founder and CEO. Natalie is a life science entrepreneur; led the company since incorporation in 2012. Natalie has twenty years' experience in mitochondrial research and received her PhD in Biochemistry at The Hebrew University in 2007, after which she performed her postdoctoral fellowship at the Weizmann Institute of Science until 2010. Natalie founded Minovia with a passion to help children and adults with mitochondrial diseases worldwide.

Noa Sher, PhD – Chief Scientific Officer. Noa is a molecular and cellular biologist by training and an experienced research leader in cell therapy. Noa received her PhD in Biochemistry at The Hebrew University in 2007, and performed her postdoctoral studies at the Whitehead Institute, MIT and at the Technion Institute of Technology. She joined Minovia after several years as head of a research team heading preclinical development and characterization of all clinical-stage products at Pluristem, an Israeli-based cell therapy company.

Nadav Eshkol – VP Operations. Nadav is an expert with more than 10 years of experience in developing and implementing complex cell therapy processes, optimization, scale-up, tech transfer from development to manufacturing, both in start-ups, and in large companies.Before joining Minovia, Nadav led the departments of development and manufacturing at Pluristem, an Israeli-based cell therapy company.

Oren Ziv, PhD – Clinical Research Field Lead. Oren is an expert in molecular biology and microbiology. Oren completed his PhD studies in 2010 in the field of developmental genetics at the Hebrew University of Jerusalem. He then pursued postdoctoral studies in the field of diabetes and beta cell toxicity. He was a lab manager at the Azrieli faculty of medicine, Bar-Ilan University, focusing on microbiome in health and disease. Oren was a senior scientist in the research collaboration with Astellas pharma.

Maayan Portnoy, M.Sc – Director of Quality & Head of Analytical Development. Maayan has twelve years of experience in the biotech industry, leading QC teams, QC GMP and method development. Maayan has extensive knowledge in microbiology, biochemistry and molecular biology methods. She received her MSc in Biotechnology engineering from Ort-Braude college in 2016. Before joining Minovia, Maayan worked for 9 years at Protalix biotherapeutics, an Israeli based biotech company, as a QC lab manager.

COMPANY OVERVIEW

TEAM / COMPANY NAME
NeuExcell

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Suzhou, Jiangsu, China

YEAR FOUNDED
2021

NUMBER OF EMPLOYEES
13

FUNDRAISING DETAILS

COMMERCIAL STAGE
R&D

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Project Equity, Convertible Debt, Corporate Debt, Strategic Partnership, Government Funding, Philanthropic Funding

TYPE OF INVESTORS SOUGHT
Corporate/Strategic, Family Office, Government, Philanthropic, Private Equity, Project Finance, Venture Capital

AMOUNT OF CAPITAL SOUGHT
$15M

CURRENT INVESTMENT STAGE
Series-A

Yuchen Chen
ycchen@neuexcell.com
neuexcell.com

NEUEXCELL

COMPANY DESCRIPTION

NeuExcell Therapeutics is a biotech company focused on developing innovative therapies for neurological diseases. Utilizing its groundbreaking in situ neural regeneration technology, the company aims to address unmet medical needs in conditions such as stroke, Alzheimer's, glioblastoma, and other neurological disorders. Led by world-renowned scientists, NeuExcell is advancing its research and clinical applications through strategic partnerships with leading academic institutions and pharmaceutical companies. With a commitment to scientific excellence and innovative solutions, NeuExcell strives to revolutionize the treatment landscape for central nervous system injuries and diseases, offering new hope for patients worldwide.

CORE INNOVATION

NeuExcell's core innovation is its in situ ATN ASTROCYTES TO NEURONS conversion technology, which directly transforms glial cells, such as astrocytes, into functional neurons in areas of the brain affected by neurodegenerative diseases or neural injuries. This breakthrough technology leverages the natural similarity between neurons and glial cells, allowing for the regeneration of neurons in damaged tissue. By converting abundant glial cells at lesion sites into new neurons, NeuExcell's technology repairs neural damage, restores brain function, and improves cognitive and motor outcomes. Preclinical successes in stroke and Huntington's disease models underscore its potential to treat a range of neurological disorders.

HEALTHSPAN

NeuExcell's therapeutic intervention enhances healthspan by promoting the regeneration of functional neurons in the brain, addressing the root cause of many neurodegenerative diseases and neural injuries. By converting glial cells into neurons at injury sites, the therapy repairs damaged neural tissue, restores cognitive and motor functions, and mitigates disease progression. This not only improves quality of life but also extends the functional lifespan of affected individuals, delaying or preventing further deterioration in brain function. Preclinical studies demonstrate significant improvements in motor abilities, cognitive health, and overall life expectancy, ultimately enhancing both healthspan and longevity.

LEADERSHIP TEAM

NeuExcell's leadership team is composed of world-class scientists and industry experts with extensive experience in both academia and the biopharmaceutical sector. Led by Professor Gong Chen, a pioneer in neuroregenerative medicine, the team includes renowned researchers in neuroscience and gene therapy. The management team also boasts deep expertise in drug development, clinical research, and global business collaborations, having worked with leading pharmaceutical companies. Our combined experience in advancing cutting-edge technologies and navigating the complexities of clinical translation enables NeuExcell to drive innovative solutions for neurological diseases and accelerate the path to transformative treatments.

NISHIMURA LAB

COMPANY OVERVIEW

TEAM / COMPANY NAME
Nishimura Lab

TRACK
Healthspan

ORGANIZATION TYPE
University-Startup Collaboration Team

HQ LOCATION
Tokyo, Japan

YEAR FOUNDED
2016

NUMBER OF EMPLOYEES
5

FUNDRAISING DETAILS

COMMERCIAL STAGE
Prefer not to say

REVENUE RANGE
Prefer not to say

CAPITAL RAISED TO DATE
Prefer not to say

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Academic/University Grants

TYPE OF INVESTORS SOUGHT
Corporate/Strategic, Academic/ University Grants

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Joint Academic and Venture Team

https://eaderm.com/contact/
eaderm.com

COMPANY DESCRIPTION

The Japanese bio-startup EADERM, established in 2017, is developing compounds based on Professor Nishimura's cutting-edge research. Professor Nishimura's lab has published numerous papers in top-tier journals. This world-leading scientist has been researching a novel mechanism of action (MoA), "Prevention of Stem Cell Exhaustion," for 20 years. This MoA has potential clinical applications across various diseases.

CORE INNOVATION

Nishimura Lab has identified tissue stem cell populations in the skin and has demonstrated that they play a central role in systemic health. The team is developing methods to minimize the progression of biological aging and achieve healthy longevity. We have developed compounds targeting for type XVII Collagen which is critical for the maintenance of skin stem cells to improve healthspan.

HEALTHSPAN

Nishimura Lab has identified tissue stem cell populations in the skin and has demonstrated that they play a central role in skin aging. We are now testing the possibility that skin stem cells may be involved in systemic frailty and are attempting to elucidate the mechanisms involved. Through elucidating and applying the mechanisms, we aim to develop methods to minimize the progression of biological aging and achieve healthy longevity through the early prevention of frailty syndromes.We have developed compounds targeting for type XVII Collagen in skin stem cells to improve healthspan.

LEADERSHIP TEAM

The development of this team is based on the stem cell research and aging research of Professor Emi Nishimura, a member of the US National Academy of Sciences, over many years.

COMPANY OVERVIEW

TEAM / COMPANY NAME
NOVOS Labs

TRACK
Healthspan

ORGANIZATION TYPE
US Public Benefit Corporation (PBC)

HQ LOCATION
New York, NY, USA

YEAR FOUNDED
2018

NUMBER OF EMPLOYEES
11-50

FUNDRAISING DETAILS

COMMERCIAL STAGE
Growth Stage (beyond initial customers)

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Prefer not to say

TYPE OF CAPITAL SOUGHT
Prefer not to say

TYPE OF INVESTORS SOUGHT
Corporate/Strategic

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
n/a

Diogo Barardo
diogo@novoslabs.com
novoslabs.com

NOVOS LABS

COMPANY DESCRIPTION

NOVOS leverages science and data to provide the best nutraceuticals, tests & knowledge to extend human healthspan and lifespan. NOVOS is a scientific leader in longevity with a mission to add a billion years of healthy life to humanity by making the latest scientific advances in longevity accessible and achievable by all.

CORE INNOVATION

NOVOS Labs' core innovation is a multi-modal therapeutic approach that synergistically targets multiple aging hallmarks through a strategically combined intervention of exercise, precision nutrition, targeted supplementation, and structured stress management. Unlike traditional longevity solutions that focus on a single mechanism, NOVOS leverages scientifically validated interactions between interventions to create amplified healthspan benefits. NOVOS Core alone has demonstrated an 18% lifespan extension in aged mice, while human studies show a measurable reduction in biological aging pace. Scalable, non-invasive, and cost-effective, the intervention is designed for broad accessibility via the NOVOS Life App and existing healthcare infrastructure.

HEALTHSPAN

NOVOS Labs' intervention actively enhances key healthspan metrics by improving physical performance, cognitive function, and metabolic health. Unlike traditional approaches that focus on lifespan extension alone, this program optimizes quality of life through muscle strength, cardiovascular endurance, body composition, and neurological resilience. Clinical data demonstrate slowed biological aging (DunedinPACE), increased resistance to frailty, and improved cognitive markers, alongside reductions in oxidative stress and inflammation. Designed for real-world adoption, the intervention is accessible, affordable, and adaptable, integrating seamlessly into everyday life through digital support and structured implementation in clinical settings.

LEADERSHIP TEAM

Chris Mirabile graduated from NYU Stern School of Business and later won their business plan competition with his startup company, Hotlist, a location-based social network that scaled to 220 million people's social plans. Chris has launched multiple successful technology ventures, has advised biotech startups and NYU Langone Hospital. Diogo Barardo, PhD is a distinguished longevity researcher, machine learning and omics expert, and former Postdoctoral Research Fellow at Professor Brian Kennedy's renowned Center for Healthy Longevity at the National University of Singapore. Diogo authored the first paper of machine learning on predicting anti-aging compounds, and also created DrugAge, the world's largest database of more than 1,000 longevity-enhancing compounds across 37 distinct species. Diogo's studies range from C. elegans to mice to humans and have been cited in over 1,700 research papers.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Pacific Neuroscience Institute Foundation

TRACK
Healthspan

ORGANIZATION TYPE
Non-Profit Organization

HQ LOCATION
Santa Monica, CA, USA

YEAR FOUNDED
2016

NUMBER OF EMPLOYEES
20

FUNDRAISING DETAILS

COMMERCIAL STAGE
Early Commercial Demonstration

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
No

TYPE OF CAPITAL SOUGHT
Philanthropic Funding

TYPE OF INVESTORS SOUGHT
Philanthropic

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Philanthropy

Ryan Glatt
rglatt@pacificneuro.org
pacificneuro.org

PACIFIC NEUROSCIENCE INSTITUTE FOUNDATION

COMPANY DESCRIPTION

The **Pacific Neuroscience Institute Foundation (PNIF)** is a nonprofit organization dedicated to advancing brain health through research, education, and innovative clinical programs. PNIF supports interdisciplinary initiatives in neurology, psychiatry, neurosurgery, and lifestyle medicine, with a strong focus on cognitive wellness, neurodegenerative disease prevention, and integrative care. Through philanthropic support, PNIF funds groundbreaking research, patient-centered programs like FitBrain, and educational outreach to empower individuals and caregivers. Collaborating with leading experts, PNIF strives to enhance brain health outcomes, bridge the gap between science and clinical practice, and make cutting-edge neurological care accessible to diverse communities.

CORE INNOVATION

The Pacific Neuroscience Institute Foundation (PNIF) stands out through its integrative, evidence-based approach to brain health, combining clinical exergaming, dual-task training, precision lifestyle interventions, and cognitive training. Unlike traditional programs, PNIF merges neurology, psychiatry, and lifestyle medicine to develop personalized, multimodal interventions for brain aging and neurodegenerative disease prevention. Our FitBrain exergame program leverages real-world coaching and validated therapeutic strategies to enhance cognitive and physical resilience. By integrating cutting-edge neuroscience with engaging, interactive methods, PNIF delivers innovative and accessible brain health solutions for individuals across the cognitive spectrum.

HEALTHSPAN

The Pacific Neuroscience Institute Foundation (PNIF) enhances healthspan through a multimodal lifestyle intervention that integrates aerobic, resistance, and neuromotor training, cognitive stimulation, stress management, sleep optimization, and targeted nutrition. This approach supports brain and body resilience, promoting cognitive function, mobility, and metabolic health to reduce the risk of age-related decline. By combining scientifically validated strategies with personalized coaching, PNIF helps individuals maintain independence, improve quality of life, and optimize overall well-being. Through engaging, evidence-based interventions, PNIF fosters long-term vitality and neuroprotection, empowering individuals to age actively and maintain optimal brain and physical health.

LEADERSHIP TEAM

The Pacific Neuroscience Institute Foundation (PNIF) leadership team includes renowned experts in neurology, psychiatry, geriatrics, and lifestyle medicine, dedicated to advancing brain health through innovative clinical programs and research. Led by Dr. David Merrill, a board-certified geriatric psychiatrist, and Ryan Glatt, a senior brain health coach and leader in cognitive-motor training, the team integrates expertise in cognitive neuroscience, rehabilitation, and integrative health. With a strong track record in program development, clinical innovation, and community outreach, PNIF's leadership drives impactful, evidence-based solutions to support aging, neuroprotection, and disease prevention, empowering individuals to optimize lifelong brain health.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Pentara Brain Stride

TRACK
Healthspan, FSHD Bonus Track

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Salt Lake City, UT, USA

YEAR FOUNDED
2001

NUMBER OF EMPLOYEES
70

FUNDRAISING DETAILS

COMMERCIAL STAGE
Pre-Commercial Pilot

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Strategic Partnership, Government Funding, Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Government, Philanthropic, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Corporate

Suzanne Hendrix
shendrix@pentara.com
pentara.com

PENTARA BRAIN STRIDE

COMPANY DESCRIPTION

Pentara provides statistical, data management, and regulatory services to public and private entities investigating treatments for neurodegerative diseases, rare diseases, and age-related diseases.

CORE INNOVATION

Our core innovation is the specific combination of multi-factorial treatments that address aging through lifestyle, nutrition, therapeutic, and device interventions. Our experience has uniquely allowed us to identify the factors that are most likely to have the highest impact.

HEALTHSPAN

Our intervention improves healthspan by recognizing that aging and degeneration are heterogeneous and many people will not see significant improvement without treating muliple factors affecting aging and health, whether it be through improving lifestyle and nutrition, stimulating the body's immune system, improving diurnal cycle, or altering blood chemistries.

LEADERSHIP TEAM

The Pentara Brain Stride team is primarily employees of Pentara, a commercial company leading the world in clinical trials for neurodegenerative diseases for the past 16 years, focusing on statistics and data management. The team also includes a neurologist, a clinical neuropsychologist, and an expert in health and nutrition. After decades facilitating Alzheimer's and aging research, the team is sponsoring a study integrating the best anti-aging treatments, identified from an in-silico assessment into one protocol.

COMPANY OVERVIEW

TEAM / COMPANY NAME
PrintBio, Inc.

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Long Island City, NY, USA

YEAR FOUNDED
2023

NUMBER OF EMPLOYEES
8

FUNDRAISING DETAILS

COMMERCIAL STAGE
Early Commercial Demonstration

REVENUE RANGE
Revenue to begin in mid 2025

CAPITAL RAISED TO DATE
$10M

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Strategic Partnership, Government Funding

TYPE OF INVESTORS SOUGHT
Corporate/Strategic, Family Office, Government

AMOUNT OF CAPITAL SOUGHT
$10M

CURRENT INVESTMENT STAGE
Series A

Kevin Slawin, M.D.
kslawin@printbio.com
printbio.com

PRINTBIO, INC.

COMPANY DESCRIPTION

PrintBio is a clinical- and commercial-stage biotechnology company and leader in regenerative medicine using novel 3D-bioprinting technologies and bioprinted materials to deliver safe, functional and personalized living tissues, products and organs, engineered on-demand for patients.

CORE INNOVATION

Leveraging first-in-human clinical experience, PrintBio is developing an array of products, beginning with 3DMatrix™, an FDA 510(k)-cleared 3D-printed monofilament bioresorbable surgical mesh, and next generation product 3DMatrix Dynaflex™ (FDA 510(k) clearance pending) that incorporates PrintBio's proprietary Uniflex™ unidirectional flexible mesh technology, both utilizing proprietary technologies clinically tested in patients. PrintBio is using this expertise to formulate a skin rejuvenation product, called Yuuth, that has the potential to reverse the functional declines seen as we age throughout the organs of the body.

LEADERSHIP TEAM

Our Team Leader is Kevin Slawin, M.D., the Founder and CEO at Eos SENOLYTIX, Inc., a gerotherapeutics company whose lead programs are focused on proprietary senolytic peptides, that may restore the youthful balance of aged or "senescent" and young cells throughout the organs of the body. He is also the Founder and CEO of Phoenix SENOLYTIX, Inc., a longevity company developing novel gene therapies targeting senescent cells, among other fundamental mechanisms of aging. He was the co-founder of Bellicum Pharmaceuticals, Inc., the first of the original three CAR-T cell companies, along with Kite and Juno, leading Bellicum to a successful $161 million IPO in December 2014. He is also Founder, Chairman and CEO of PrintBio, Inc., the only clinical- and commercial-stage regenerative medicine company solving medical challenges with custom-engineered 3D-bioprinted living implants. He currently lives in Miami, FL where he is Founder and CEO of Miami Medicos, a membership organization of physicians, founders, executives, and investors catalyzing the healthcare entrepreneurial ecosystem in Miami and worldwide.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Propion Inc.

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
San Francisco, CA, USA

YEAR FOUNDED
2022

NUMBER OF EMPLOYEES
2

FUNDRAISING DETAILS

COMMERCIAL STAGE
Early Commercial Demonstration

REVENUE RANGE
$50K

CAPITAL RAISED TO DATE
$150K

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Project Equity, Convertible Debt, Strategic Partnership, Government Funding

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Government, Venture Capital

AMOUNT OF CAPITAL SOUGHT
$3M

CURRENT INVESTMENT STAGE
Pre-seed

Nicholas Tubach
nicholas@propion.com
propion.com

PROPION INC.

COMPANY DESCRIPTION

Award-winning gut microbiome researcher Dr. Daniel Winer has identified byproducts of gut metabolism that could reshape the health industry. His company, Propion Inc., will start with a nutritional approach to increasing levels of these beneficial gut metabolites before pivoting the core science into beauty, petcare, and pharmaceuticals.

CORE INNOVATION

Gut metabolites are now recognized as key mediators of many bodily systems. They, and the bacteria which produce them, both influence and are influenced by processes implicated in aging and poor health. New evidence suggests that levels of tryptophan metabolites, particularly indole-3-propionic acid (Propion 1™), could be a common predictive factor of age, diet, and immune-related function, and could even play a role in female reproductive longevity. However, supplementing with tryptophan alone is not helpful. What if a relatively simple blend of protein, vitamins, superfoods, and amino acids could help ensure humans get the tryptophan metabolites they need to regulate cognitive health, gut health, immune health, and the interplay between these systems as we age? While no single metabolic axis suffices to explain the whole picture of aging, evidence surrounding the tryptophan metabolites indole-3-propionic acid (Propion 1™) and indolepropionamide (Propion 2™) indicates that a nutritional approach to increasing their levels in the body could address a substantial portion of what determines healthspan.

HEALTHSPAN

Propion BLEND™ was developed over two decades by an expert in tryptophan to direct tryptophan metabolism from the diet towards the gut microbiota, in order to produce Propion 1™ and Propion 2™. The pea protein base of the blend acts as a carrier, forming vesicles to encapsulate amino acids, including added arginine and tryptophan, to facilitate their sustained release. Arginine increases nitric oxide, while the nitric oxide, coupled to the blend's vitamin C and bioflavonoid mixture (derived from sea buckthorn and acerola), scavenge superoxide anion radicals that are cosubstrates for tryptophan catabolism enzymes like indole 2,3 dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO). Reducing IDO activity along the intestinal mucosa decreases metabolic breakdown of tryptophan, increasing availability of tryptophan for the gut microbiota. B vitamins in the blend (in part from buckwheat extract) further prevent tryptophan degradation by IDO. In addition, the rich anti-oxidant protection from blend ingredients also increases tryptophan and its indole product bioavailability directly within the intestinal tract as it prevents their oxidative breakdown. The net result is a blend with components that act in synergy to boost levels of tryptophan and the Propion Molecules™ in the intestinal tract. Our website propion.com hosts links to many of the published studies on these molecules.

LEADERSHIP TEAM

The management team and board of directors combines significant entrepreneurial and scientific expertise. The CEO has cofounded 3 biotech companies which have raised pre-seed funding, while the Scientific Director is one of North America's top gut microbiome researchers. Specifically, Dr. Winer studies how the immune system living in the gut interfaces with the rest of the body to contribute to or prevent diseases of aging. He is best known for research on type II diabetes.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Qu Biologics

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Vancouver, British Columbia, Canada

YEAR FOUNDED
2017

NUMBER OF EMPLOYEES
25

FUNDRAISING DETAILS

COMMERCIAL STAGE
R&D

REVENUE RANGE
Pre-Revenue

CAPITAL RAISED TO DATE
$35M equity funding and $15M non-dilutive funding

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Convertible Debt, Strategic Partnership, Government Funding, Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Government, Philanthropic, Private Equity, Venture Capital, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
$25M

CURRENT INVESTMENT STAGE
Series A

Hal Gunn, MD, CEO
hal@qubiologics.com
qubiologics.com

QU BIOLOGICS

COMPANY DESCRIPTION

Qu Biologics is a Phase 2 clinical stage biotechnology company developing a transformative immunomodulation platform designed to restore innate immunity and all its important roles to extend healthy longevity, optimize health, and prevent and treat a wide range of important diseases. Clinical proof of principle has been demonstrated in four completed Phase 2 studies with an excellent safety profile in more than 360 patients treated to date. A randomized placebo-controlled trial is enrolling in people aged 65 or older to assess the efficacy of Qu's immunomodulation platform in restoring innate immunity in the elderly to extend healthy longevity.

CORE INNOVATION

Qu Biologics' unique immunomodulation platform, Site Specific Immunomodulators (SSIs), are uniquely designed to restore innate immune function and all its important roles in a targeted organ by safely and effectively 'training' innate immunity. SSI-induced restoration of innate immunity clears many important underlying causes of disease, including resolution of chronic inflammation and clearance of senescence, and reprograms innate immune cells to be resilient and effective in response to immunological challenge, including restoring innate immune plasticity, modulation, and balance to optimize health and clear disease. Proof-of-concept has been demonstrated for the prevention and treatment of a broad range of diseases.

HEALTHSPAN

Innate immune function declines with age, leaving us vulnerable to the development of cancer, chronic inflammatory diseases, degenerative metabolic conditions, and neurodegenerative diseases. Innate immunity plays a central role in tissue healing, tissue regeneration, clearance of chronic inflammation, and the clearance of senescent cells, infection, and cancer. Restoring and maintaining optimal innate immune function with Qu's unique immunomodulation platform is anticipated to enhance all aspects of healthy aging, including the maintenance of the musculoskeletal system and cognition by promoting the effective clearance of dysfunctional senescent cells, clearing chronic inflammation, maintaining barrier function, as well as enhancing the body's regenerative capacity.

LEADERSHIP TEAM

Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by Founder/CEO Dr. Hal Gunn, a physician and expert on the body's immune response to chronic disease; Chief Medical Officer - Oncology Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control in Canada and internationally; and Chief Medical Officer – Infectious Disease Dr. Ted Steiner, a clinician-scientist specializing in immune responses to infections and Head of the UBC Division of Infectious Diseases. For more information, please visit www.qubiologics.com.

COMPANY OVERVIEW

TEAM / COMPANY NAME
R42 Group

TRACK
Healthspan, FSHD Bonus Track

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Palo Alto, CA, USA

YEAR FOUNDED
2020

NUMBER OF EMPLOYEES
5

FUNDRAISING DETAILS

COMMERCIAL STAGE
R&D

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
$45M

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Project Equity, Convertible Debt, Strategic Partnership, Government Funding, Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Government, Philanthropic, Project Finance, Venture Capital, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
$5M

CURRENT INVESTMENT STAGE
Early Stage VC

Ronjon Nag
ronjon@r42group.com
r42group.com

R42 GROUP

COMPANY DESCRIPTION

R42 Group is a venture fund itself that invests in AI and Longevity companies and also creates longevity companies via its R42 Institute. Investments in the R42 Longevity Fund and its underlying companies are possible.

CORE INNOVATION

R42 has submitted an Xprize proposal encompassing a combination of technologies both from its investments and its created longevity companies. We believe this combination can accomplish the goals of the Xprize which most single offering company will not be able to accomplish.

HEALTHSPAN

We have a number of technologies ranging from an aging vaccine, and plasma transfusion to regular aging supplements. Many are AI driven.

LEADERSHIP TEAM

The team is led by Dr. Ronjon Nag, a pioneer in AI, and teaches longevity science and AI at Stanford University where he is an adjunct Professor. CEO and chief scientists of its investee companies are part of the team. Also there are other Stanford professors as advisors such as Prof. Michael Snyder.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Regenerative Bio

TRACK
Healthspan, FSHD Bonus Track

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Hangzhou, Zhejiang China

YEAR FOUNDED
2021

NUMBER OF EMPLOYEES
100

FUNDRAISING DETAILS

COMMERCIAL STAGE
Growth Stage (beyond initial customers)

REVENUE RANGE
$60M

CAPITAL RAISED TO DATE
$15M

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Project Equity, Convertible Debt, Strategic Partnership, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Corporate/Strategic, Family Office, Venture Capital, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
Pre-A

Gavin Zhou
gavin.zhou@regen-bio.com
LinkedIn Profile

REGENERATIVE BIO

COMPANY DESCRIPTION

Regenerative Bio is a longevity company driven by artificial intelligence. Founded in 2021 with the vision of “Health Equity - Empowering Everyone to Age Gracefully and Healthily”, the company has developed “Organ-level aging clock” technology and applied it into their platform RevOrgan through precise measurements and effective intervertions solutions. Regenerative Bio’s team consisted of world-class scientists and top-level business operation talents. Its Scientific Advisory Board includes renowned professors Dr. George Church, Dr. Vadim Gladyshev and Dr. Tian Xu. The company has raised over $10 million in Angel Round and pre-A Round, backed up by investors including IMO Ventures, 5Y Capital, K2VC, Uphonest Capital, Taihill Venture and Yael Capital.

CORE INNOVATION

The pursuit of precision anti-aging solutions has been significantly advanced by the development of organ-specific aging biomarkers. Regenerative Bio has developed the Methylation-based Organ-Level agEing (MOLE) clock, and applied it in the field of anti-aging. With the efforts in technology improvements, clinical research, and industrial applications, we combined our MOLE clock together with our artificial intelligence-driven substance screening platform, RevOrgan™ towards high-quality anti-aging solutions. The MOLE clock’s predictive accuracy is highlighted through its performance in Next-Generation Sequencing (NGS) datasets. with superior predictive capabilities compared to other technologies, and validated robustness and reliability in BioLearn and other public available datasets. The integration of the MOLE clock and RevOrgan™ represents a synergistic approach to combating aging, offering a precision medicine perspective that could transform the understanding and management of the complex biological processes underlying aging.

HEALTHSPAN

Regenerative Bio leverages advanced AI technologies to develop novel senolytics and anti-aging therapeutics using FDA-approved products. This approach significantly enhances the efficiency of R&D for longevity solutions and addresses ethical challenges associated with conducting clinical trials. Our proposed approaches include clinical trials targeting related diseases to evaluate the anti-aging efficacy of repurposed senolytics identified through large language model analysis and large-scale, multi-centered clinical trials worldwide to validate the organ-based anti-aging effects of our LAIFE® products, which are powered by advanced AI-driven drug discovery (AIDD) technology. Additionally, we will focus on validating the efficiency and accuracy of the MOLE clock as a reliable measurement of biological age at the organ level. And this will be specifically tailored for muscle improvements using the repurposed senolytics, which also validated by large-scale, multi-centered clinical trials to bring precise, personalized treatment methods for FSHD.

LEADERSHIP TEAM

Regenerative Bio Inc was born in the campus of Harvard University, with a scientific board consisted by Dr. George Church, Dr. Vadim Gladyshev, Dr. Tian Xu and other world’s most renowned experts leading the aging research. Regenerative Bio co-founder & CTO Dr. Guangyu and his team incorporate artificial intelligence to multiple aspects of aging science, aiming to develop the world’s top-tier aging assessment and intervention products to improve human lifespan and healthspan.

COMPANY OVERVIEW

TEAM / COMPANY NAME
RenewalBio

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Rehovot, Israel

YEAR FOUNDED
2022

NUMBER OF EMPLOYEES
15

FUNDRAISING DETAILS

COMMERCIAL STAGE
R&D

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
n/a

TYPE OF INVESTORS SOUGHT
n/a

AMOUNT OF CAPITAL SOUGHT
$7.3M

CURRENT INVESTMENT STAGE
n/a

vladislav krupalnik
vladik@renewal.bio

RENEWALBIO

COMPANY DESCRIPTION

RenewalBio's stembroid platform is a transformative therapeutic solution in regenerative medicine, addressing the critical shortage of high-quality, transplantable cells. By creating patient-specific cells from induced pluripotent stem cells (iPSCs), it addresses the demand for authentic, functional cells for transplantation. Current therapies face challenges such as immune rejection, limited differentiation fidelity, and engraftment failure, which this platform is designed to overcome.

CORE INNOVATION

The stembroid platform addresses the challenges of current IPSC differentiation protocols by faithfully mimicking critical stages of embryonic development. Stembroids, 3D organoids generated from iPSCs, recreate the spatial organization and the intrinsic signaling. Unlike traditional "directed differentiation" methods, which rely on external manipulations such as artificial timing controls and speculative morphogen concentrations, stembroid establishes neutral conditions that allow self-organization and accurately capture critical developmental events. Stembroid produces authentic, "young" cells, which significantly enhance their regenerative capacity. Stembroids set a new standard for generating superior, highly functional differentiated cells for therapeutic applications.

HEALTHSPAN

The stembroids technology enables the generation of young- identical-blood cells for transplantation. Blood cell transplantation is the only well-studied and approved method to increase lifespan. We emphasize the generation of patient-specific blood banks ready for transfusion.

The stembroid protocol can produce multiple cell types, significantly reducing costs and increasing efficiency. The initial focus includes hematopoietic stem and progenitor cells, neural progenitors, and hepatocytes, designed to treat conditions such as bone marrow failure, epilepsy, and acute liver failure. These cells also promise to reverse age-related degeneration and restore organ function, addressing significant unmet clinical needs and generating the ultimate platform for tissue regeneration.

LEADERSHIP TEAM

Prof. Jacob Hanna, a world leader in stem cell biology at the Weizmann Institute, has pioneered research in iPSC reprogramming and regenerative medicine. Dr. Omri Amirav-Drory, NFX Bio's General Partner, has vast experience in AI-driven medical innovations. Dr. Ohad Gafni, CSO of RenewalBio, has made groundbreaking contributions to pluripotent stem cells and regenerative medicine. Dr. Vladislav Krupalnik, RenewalBio's CEO, is a biotech leader with expertise in genetics, bioinformatics, and stem cell research. Together, their expertise in stem cells, AI, and biotech is driving transformative advancements in regenerative medicine and human health.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Rejuvenate Bio

TRACK
Healthspan, FSHD Bonus Track

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
San Diego, CA, USA

YEAR FOUNDED
2018

NUMBER OF EMPLOYEES
10

FUNDRAISING DETAILS

COMMERCIAL STAGE
R&D

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
$40M

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Project Equity, Strategic Partnership, Government Funding, Philanthropic Funding

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Government, Philanthropic, Private Equity, Venture Capital

AMOUNT OF CAPITAL SOUGHT
$30M - $40M

CURRENT INVESTMENT STAGE
Series A

Daniel Oliver
xprize@rejuvenatebio.com
rejuvenatebio.com

REJUVENATE BIO

COMPANY DESCRIPTION

Rejuvenate Bio is increasing healthspan and extending lifespan through the creation of novel therapies. They are the first group to show life extension with epigenetic reprogramming. Their initial focus on cardiovascular health involves a groundbreaking “one-shot” treatment for heart disease and obesity. The therapy aims to restore healthy levels of a vital soluble protein that diminishes with age, showcasing compelling data on heart damage reversal and metabolic reset, potentially replacing GLP-1s in the future.

CORE INNOVATION

Rejuvenate Bio’s technology leverages in vivo partial reprogramming (IVPR) to restore youthful gene expression and cellular function across muscle, neurons, and immune cells using a compact, highly controllable inducible system. Unlike conventional gene therapies, our aptazyme-based regulation ensures tight spatiotemporal control, preventing unwanted expression and enhancing safety. Our engineered AAV vectors efficiently target multiple tissues while remaining scalable and cost-effective for broad clinical use. This approach uniquely enables systemic rejuvenation, addressing neuromuscular degeneration and age-related decline with high translatability, reduced immunogenicity, and regulatory compliance for seamless clinical translation and commercialization.

HEALTHSPAN

Our therapeutic intervention utilizes in vivo partial reprogramming (IVPR) to restore youthful gene expression and enhance cellular resilience in muscle, neurons, and immune cells, counteracting age-related degeneration. In FSHD, it reduces fibrosis, enhances muscle regeneration, and restores neuromuscular function, improving strength and endurance. In neurons, it promotes axonal repair and protects against neurodegeneration, addressing ALS-related decline. By resetting epigenetic markers and improving cellular stress resistance, this therapy has the potential to extend healthspan, reverse disease pathology, and improve overall functional longevity in both diseased and aging populations.

LEADERSHIP TEAM

Rejuvenate Bio’s leadership team is led by Noah Davidsohn, Ph.D., CSO and cofounder, a pioneer in in vivo partial reprogramming (IVPR) with extensive experience translating gene therapies from discovery to the clinic. Daniel Oliver, MBA, CEO and cofounder, has secured over $70M in biotech funding and successfully built multiple science-driven companies. The team is supported by George Church, Ph.D., a genomics and gene therapy pioneer, and Kathy High, M.D., a leading expert in AAV gene therapy who played a key role in the development and approval of the first FDA-approved AAV gene therapy for rare diseases.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Retro-Epigerna

TRACK
Healthspan

ORGANIZATION TYPE
University Team

HQ LOCATION
Macau, China

YEAR FOUNDED
25

NUMBER OF EMPLOYEES
1,600

FUNDRAISING DETAILS

COMMERCIAL STAGE
Growth Stage (beyond initial customers)

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Project Equity, Strategic Partnership, Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Corporate/Strategic, Philanthropic, Venture Capital, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
$300K

CURRENT INVESTMENT STAGE
Academic/University Grants

Zhi-Hong Jiang
zhjiang@must.edu.mo
must.edu.mo

RETRO-EPIGERNA

COMPANY DESCRIPTION

A company for the the research and deveopment of anti-aging products using the technolgy of reversing tRNA epigenetic alteration induced by aging.

CORE INNOVATION

We found the relationship between decrese of a specific modification on tRNA and aging. We also discovered a natural product in Chinese herbal medicine could significant increase this modification on tRNA. In vitro and in vivo experiments demonsrated its extremely potent efficacy in anti-aging with very low dosage (10 ug/kg for mouse). This product could significantly reverse the aging of mouse.

HEALTHSPAN

This product could significantly reverse the aging of mouse by supplement of a specific modification on tRNA. The life quality and health status of aging mouse have been largely improved.

LEADERSHIP TEAM

Our team is composed of Chair professor, associate professor, assistant professor, physician, clinical pharmacist, economist of public health.

RIGHT TRIAL

COMPANY OVERVIEW

TEAM / COMPANY NAME
RIGHT Trial

TRACK
Healthspan

ORGANIZATION TYPE
University Team

HQ LOCATION
Pittsburgh, PA, USA

YEAR FOUNDED
1787

NUMBER OF EMPLOYEES
28,000

FUNDRAISING DETAILS

COMMERCIAL STAGE
R&D

REVENUE RANGE
Pre-Company Formation

CAPITAL RAISED TO DATE
$1.5M

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Government Funding, Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Corporate/Strategic, Government, Philanthropic, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
$10M - $15M

CURRENT INVESTMENT STAGE
Grant

Anne Newman, MD, MPH
anewman@pitt.edu
pitt.edu

COMPANY DESCRIPTION

The RIGHT Trial Group, based at the University of Pittsburgh, is dedicated to developing innovative therapies targeting inflammation, particularly IL-6, to enhance healthspan and lifespan in aging populations. Leveraging the geroscience hypothesis, we aim to delay, improve, or reverse age-related conditions. Our lead candidate, clazakizumab, a monoclonal antibody targeting IL-6, has shown promising results in preclinical and clinical studies. As part of Pitt Health Sciences and the Aging Institute—a joint venture between the University of Pittsburgh and UPMC Senior Services—we operate within one of the world's largest and most innovative aging research environments. The University of Pittsburgh is a leader in scientific discovery, clinical innovation, and interdisciplinary training, with a legacy of advancing global healthcare. Our multidisciplinary team of researchers is dedicated to understanding the mechanisms of aging and developing therapies that extend healthspan by preventing and treating age-related diseases.

CORE INNOVATION

Our technology uniquely targets IL-6 to combat chronic inflammation, a key driver of aging and age-related diseases. Clazakizumab, a monoclonal antibody with a proven safety profile, provides a targeted approach to reducing inflammation and improving multiple physiological functions simultaneously. Unlike other approaches, IL-6 inhibition addresses cardiovascular, cognitive, and immune function declines in an integrated manner. Supported by robust preclinical and clinical data, our therapeutic strategy positions us at the forefront of aging therapeutics, offering a comprehensive and scientifically validated solution to improve healthspan and quality of life for older adults.

HEALTHSPAN

Our therapeutic intervention directly targets IL-6 to reduce chronic inflammation, a major contributor to aging and age-related decline. By inhibiting IL-6 with clazakizumab, we aim to improve physical strength, cognitive function, vascular health, and immune resilience. This multi-faceted approach simultaneously addresses several key factors that drive age-related deterioration. Preclinical and clinical studies demonstrate that lowering IL-6 levels enhances healthspan by extending the years individuals remain healthy and active. Our work represents a promising and scalable strategy to delay the onset of age-related diseases and improve overall quality of life in aging populations.

LEADERSHIP TEAM

The RIGHT Trial Group is led by internationally recognized experts in aging research. Dr. Anne Newman, a distinguished leader in population health and aging, holds key roles at the University of Pittsburgh and UPMC, leading groundbreaking clinical trials such as the Health ABC Study, LIFE, and ASPREE. She has authored over 900 manuscripts and served as Editor-in-Chief of the Journal of Gerontology. Dr. Toren Finkel, Director of the Aging Institute at the University of Pittsburgh/UPMC, is a world-renowned expert in aging biology, with over 200 publications. His research focuses on reactive oxygen species, metabolism, and mitochondrial function. Both leaders bring unparalleled expertise, securing substantial research funding and shaping the future of aging science.

TAZ INC

COMPANY OVERVIEW

TEAM / COMPANY NAME
TAZ Inc.

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Bunkyo-ku, Tokyo, Japan

YEAR FOUNDED
2020

NUMBER OF EMPLOYEES
6

FUNDRAISING DETAILS

COMMERCIAL STAGE
Early Commercial Demonstration

REVENUE RANGE
$2M

CAPITAL RAISED TO DATE
$16K

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Strategic Partnership, Government Funding, Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Corporate/Strategic, Government, Philanthropic, Private Equity, Project Finance, Venture Capital, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
$7M

CURRENT INVESTMENT STAGE
Angel

Shoko Takahashi
info@taz-co.jp
taz-co.jp/

COMPANY DESCRIPTION

TAZ Inc. is a biotechnology startup originating from the University of Tokyo with the mission of bringing “anti-aging technologies for everyone.” The company conducts drug discovery research and product development related to anti-aging technology. Their work includes screening research for anti-aging components, development of biomarkers unique to age-related diseases, and drug discovery research targeting these diseases. TAZ Inc. is also advancing the research and development of anti-aging products in collaboration with medical institutions.

CORE INNOVATION

The removal of senescent cells—cells that can no longer proliferate due to aging—has been reported to prevent or delay physical dysfunctions, thereby extending a healthy lifespan. Most senolytics discovered so far are anticancer drugs, which often have side effects that make regular use problematic for healthy individuals. We demonstrated with aged mice that safe food ingredients effectively eliminate senescent cells. Our findings underscore the potential of these components in removing senescent cells, offering a viable strategy for utilizing senolytic foods to prevent aging and age-related diseases in healthy individuals.

HEALTHSPAN

We aim to extend healthy lifespan by 10 years through an approach that combines senolytics—focused on the removal of senescent cells—with nutritional methods involving high-protein diets. It has been reported that removing senescent cells can delay or prevent the dysfunction of immune, cognitive, and muscular functions associated with aging, thereby extending healthy lifespan. Our research group has newly discovered a food component that is effective in removing senescent cells. Our proposal for “senolytics through food” has the advantage of being extremely safe, making it accessible to a wide range of people worldwide and potentially having a significant impact.

LEADERSHIP TEAM

Shoko Takahashi, PhD, founded aging-biotech startup company TAZ Inc. and genomic startup company Genequest Inc., establishing her as a notable Japanese female serial entrepreneur. She received a Technology Award from the Japanese Society of Nutrition and Food Science. Additionally, she serves on the University of Tokyo’s management council and the government’s science and technology policy council. Her work has gained global acclaim; she was featured in Forbes’ “30 Under 30 Asia,” the World Economic Forum’s “Young Global Leaders,” and Newsweek Japan’s “100 Most Respected Japanese by the World. As part of TAZ Inc team, the team includes experts in senescent cells, immunity, cognitive functions, muscle functions, and clinical trials.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Team Everest

TRACK
Healthspan

ORGANIZATION TYPE
Not-yet-incorporated Team

HQ LOCATION
Tempe, AZ, USA

YEAR FOUNDED
2017

NUMBER OF EMPLOYEES
10

FUNDRAISING DETAILS

COMMERCIAL STAGE
Growth Stage (beyond initial customers)

REVENUE RANGE
$1.4M

CAPITAL RAISED TO DATE
$3M

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Project Equity, Convertible Debt, Strategic Partnership, Philanthropic Funding, NIH SBIR

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Government, Philanthropic, Project Finance, Venture Capital

AMOUNT OF CAPITAL SOUGHT
$5M

CURRENT INVESTMENT STAGE
Seed

Dr. Urban Kiernan
ukiernan@imbiopharma.com
imbiopharma.com

TEAM EVEREST

COMPANY DESCRIPTION

Team Everest was founded out of the passion and purpose to advance human healthspan. Healthspan, the period of life spent in good health, is a key focus in aging research with a clear goal of developing therapeutic approaches for its extension. Headquartered out of Tempe, AZ, we are a collaborative joint venture that brings together organizations with unique technologies that work toward the collective effort of healthspan.

CORE INNOVATION

Our patented IP solutions looks to address complexities of aging biology, including cellular senescence, sarcopenia, mitochondrial dysfunction, and telomere shortening. Bringing together world-class leaders from the realms of science, academia, and business, Team Everest has developed a multidisciplinary approach to address this challenging biology by integrating three interventions: autologous human Very Small Embryonic-Like Stem Cells (hVSELs) transplant, bioactive peptide supplementation, and functional resistance exercise.

HEALTHSPAN

Our therapeutic intervention integrates hVSELs infusion, bioactive peptide supplementation, and functional exercise into a hybrid treatment for healthspan extension. A 60-day, double-blinded trial with 24 participants (ages 40–60) will compare a treatment group receiving all three modalities to a control group (exercise only). Assessments using widely accepted metrics correlated with healthspan include: VO2 fitness, grip strength, DEXA, clinical chemistry, DNA age, and quality of life metrics. Participants receive activated hVSELs and a bioactive peptide regimen. Controls receive placebo peptides and inactive hVSELs. Exercise emphasizes strength, endurance, and recovery. This supports the individual at the molecular, cellular, and physiological levels.

LEADERSHIP TEAM

This project is being led by Urban A. Kiernan, PhD (Principal Investigator), and supported by Drs. J. Christian Jensen (Clinical Director) and Micah Olson (Medical Director). This core team has a strong background in drug innovation, as well as the development and execution of both pre-clinical and clinical research programs. Cellular and exercise therapies will be overseen by Dr. Neil Morris and Mr. Thomas Fabbri, respectively. All team members have a longstanding history in one-off collaborative projects and strong complementary expertise.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Team Inflammasome

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Lehi, Utah, USA

YEAR FOUNDED
2018

NUMBER OF EMPLOYEES
27

FUNDRAISING DETAILS

COMMERCIAL STAGE
Pre-Commercial Pilot

REVENUE RANGE
$8M

CAPITAL RAISED TO DATE
$60M

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Philanthropic, Private Equity, Venture Capital

AMOUNT OF CAPITAL SOUGHT
$75M

CURRENT INVESTMENT STAGE
Series C

David Bearss
dbearss@haliatx.com
haliatx.com

TEAM INFLAMMASOME

COMPANY DESCRIPTION

Halia Therapeutics is a biotechnology company pioneering the development of novel therapies targeting chronic inflammation-driven diseases. With a focus on NLRP3 inflammasome inhibition, Halia is advancing a pipeline of small-molecule therapeutics to address conditions such as Alzheimer's, metabolic, and autoimmune diseases. Its lead compound, HT-6184, is an allosteric Nek7/NLRP3 inhibitor currently in Phase 2 clinical trials. Halia's innovative approach integrates precision medicine and biomarker-driven strategies to accelerate drug development and improve patient outcomes. Headquartered in Lehi, Utah, Halia is committed to transforming the treatment landscape for inflammatory and neurodegenerative diseases.

CORE INNOVATION

Halia Therapeutics' core technology stems from the discovery that RAB10 genetic variants confer protection against Alzheimer's disease in APOE4 homozygous individuals, a high-risk population. RAB10 phosphorylation by LRRK2 is a key event in immune signaling, and its dysregulation contributes to NLRP3 inflammasome activation, driving neuroinflammation. Halia's approach targets this pathway by developing HT-6184, an allosteric Nek7/NLRP3 inhibitor, to block inflammasome assembly and reduce chronic inflammation. By modulating innate immune responses, Halia aims to disrupt the inflammatory cascade underlying Alzheimer's, metabolic diseases, and neurodegeneration, providing a precision medicine approach to inflammation-driven disorders.

HEALTHSPAN

Halia Therapeutics' therapeutic intervention improves healthspan by targeting chronic inflammation, a key driver of age-related diseases. By inhibiting the NLRP3 inflammasome, Halia's lead compound HT-6184 reduces systemic inflammation, metabolic dysfunction, and neurodegeneration—hallmarks of aging. Chronic inflammation accelerates diseases such as Alzheimer's, cardiovascular disease, and metabolic disorders, limiting both lifespan and quality of life. By modulating innate immune responses, Halia's approach preserves cellular function, enhances tissue repair, and improves metabolic resilience, ultimately delaying disease onset and extending healthspan. This precision medicine strategy aims to promote longevity by preventing inflammation-induced aging and functional decline across multiple organ systems.

LEADERSHIP TEAM

Halia Therapeutics is led by David Bearss, Ph.D., a renowned drug developer and biotech entrepreneur with a track record of advancing almost 20 novel therapeutics from discovery to clinical trials. With expertise in oncology, inflammation, and immunology, Dr. Bearss has co-founded and led multiple successful biotech companies. Halia's leadership team includes seasoned scientists, clinicians, and industry executives with deep experience in translational research, precision medicine, and global drug development. Their collective expertise spans small-molecule therapeutics, biomarker-driven strategies, and regulatory pathways, positioning Halia at the forefront of NLRP3 inflammasome-targeted therapies for neurodegenerative and inflammatory diseases.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Team NovaVita

TRACK
Healthspan

ORGANIZATION TYPE
University Team

HQ LOCATION
Beijing, China

YEAR FOUNDED
2024

NUMBER OF EMPLOYEES
n/a

FUNDRAISING DETAILS

COMMERCIAL STAGE
n/a

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Government Funding, Academic/ University Grants

TYPE OF INVESTORS SOUGHT
n/a

AMOUNT OF CAPITAL SOUGHT
Prefer not to say

CURRENT INVESTMENT STAGE
n/a

Jingdong J. Han
jackie.han@pku.edu.cn

TEAM NOVAVITA

COMPANY DESCRIPTION

Team NovaVita is dedicated to developing solutions to reverse the aging process and enhance the quality of life for humanity.

CORE INNOVATION

The discovery of novel, effective anti-aging compounds that do not harm normal mammalian cells is particularly desirable. Our primary goal is to broaden the scope of anti-aging compounds and identify functional substructures that can reverse the aging process.

HEALTHSPAN

We are committed to leveraging artificial intelligence for anti-aging drug design, aiming to discover effective, stable, and non-toxic drugs that can reverse aging.

LEADERSHIP TEAM

Team NovaVita, led by Prof. Jing-dong J. Han, is a well-organized team with multidisciplinary backgrounds and extensive experience in the field of aging research.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Team Twilight

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
Beverley, MA, USA

YEAR FOUNDED
2022

NUMBER OF EMPLOYEES
5

FUNDRAISING DETAILS

COMMERCIAL STAGE
R&D

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
$3M

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity, Project Equity, Strategic Partnership, Government Funding, Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Government, Philanthropic, Private Equity, Venture Capital, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
$12M

CURRENT INVESTMENT STAGE
Pre-Seed

Ajay Verma
ajay@twlbio.com

TEAM TWILIGHT

COMPANY DESCRIPTION

Twilight Bioscience is a precision immunotherapy company taking a novel approach to chronic diseases often associated with aging. Our platforms allow us to measure and refine immune performance to treat and prevent chronic diseases. Our science is supported by greater than 20 years of research in academia and the NIH, and our platforms have been validated for monitoring and treating SARS-COV2. Our team brings together world-class expertise in aging biology, biomarker and drug development, neurodegeneration, company formation, clinical trial design, biostatistics, and product commercialization.

CORE INNOVATION

Twilight Bioscience has developed a Fc-fusion vaccine targeting HERV-K, a human endogenous retrovirus that has recently been spotlighted as a main contributor to cellular senescence and accelerated aging. HERV-K becomes activated in normal aging and premature aging syndromes and antibodies against it prevent the spread of cellular senescence. Our vaccine triggers high-titer neutralizing antibodies against HERV-K envelope protein and shows protection from HERV-K neurotoxicity and inflammation. Furthermore, we have developed a proprietary neuron-derived exosome biomarker platform that can identify HERV-K activation in patients with neurodegeneration, aging populations, and individuals with advanced aging syndromes, and monitor treatment efficacy.

HEALTHSPAN

HERV-K env protein, a key driver of neuromuscular and cognitive decline in neurodegeneration and aging, becomes pathologically de-repressed, triggering protein aggregation, neuroinflammation, and cellular senescence. In ALS, strong endogenous antibody responses against HERV-K Env correlate with a three-fold survival advantage. Such antibodies also inhibit senescence transmission in progeria models. Twilight's proprietary biomarker and Fc-vaccine therapeutic platforms measure HERV-K env expression in neuronal exosomes and shape immunity against it. By strengthening the aging immune system to combat this pro-aging cascade, Twilight offers a novel precision medicine approach to extend human healthspan and potentially improve resilience against age-related diseases.

LEADERSHIP TEAM

Dr. Ajay Verma, MD, PhD, CEO (Twilight Bioscience), bringing over 30 years of experience spanning academic research, military medicine, and pharmaceutical development. At Biogen, Novartis and Merck he led development of multiple breakthrough therapeutics and pioneered the use of blood-based and imaging biomarkers for patient selection and treatment response. Dr. Verma also brings critical insight into clinical trial design and patient care.

Dr. Marta Garcia-Montojo, PhD, Director (Twilight Bioscience), provides foundational expertise in HERV-K biology through her groundbreaking discoveries linking HERV-K to aging mechanisms, including pivotal work demonstrating protective adaptive immunity against HERV-K in ALS patients correlates with extended survival.

COMPANY OVERVIEW

TEAM / COMPANY NAME
The EBIMA Trial

TRACK
Healthspan

ORGANIZATION TYPE
University Team

HQ LOCATION
Miami, FL, USA

YEAR FOUNDED
1952

NUMBER OF EMPLOYEES
n/a

FUNDRAISING DETAILS

COMMERCIAL STAGE
n/a

REVENUE RANGE
n/a

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
No

TYPE OF CAPITAL SOUGHT
n/a

TYPE OF INVESTORS SOUGHT
n/a

AMOUNT OF CAPITAL SOUGHT
n/a

CURRENT INVESTMENT STAGE
n/a

Dileep Yavagal
dyavagal@med.miami.edu

THE EBIMA TRIAL

COMPANY DESCRIPTION

The University of Miami Miller School of Medicine is a medical school with home to some of the top programs in the United States and one of the largest research enterprises in the field of medicine.

CORE INNOVATION

Our solution is a biological product which has proven safety of use in humans, can be easily accessible at several health institutes and clinics across the globe, and is easy to administer.

HEALTHSPAN

Our therapeutic invention which aims to administer exosome therapy in the aging population will believed to improve healthspan by support several biological pathways, allowing more repair, reduction of inflammation, and having a more systemic effect on the overall body to help improve healthspan.

LEADERSHIP TEAM

Our team leader, Dr. Dileep Yavagal is a pioneer in the world with his leading work on stem cell based therapies and access to treatments for aging disorders like stroke. Our team also includes some of the world's leading experts on cell based therapies for several aging related cardiovascular disorders and Alzheimer's disease. We also have a team of some of excellent scientists whose expertise in brain research and inflammation, as well as translational therapies bring to the table an excellent combination of clinicians and scientists to take our therapy to the next level.

COMPANY OVERVIEW

TEAM / COMPANY NAME
Unlimited Bio

TRACK
Healthspan

ORGANIZATION TYPE
For-Profit Private Company

HQ LOCATION
St. John's Bay, Roatan, Islas de Bahia, Honduras

YEAR FOUNDED
2024

NUMBER OF EMPLOYEES
4

FUNDRAISING DETAILS

COMMERCIAL STAGE
Early Commercial Demonstration

REVENUE RANGE
$100K

CAPITAL RAISED TO DATE
$410K

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
Yes

TYPE OF CAPITAL SOUGHT
Corporate Equity

TYPE OF INVESTORS SOUGHT
Angel, Corporate/Strategic, Family Office, Private Equity, Venture Capital

AMOUNT OF CAPITAL SOUGHT
$2M

CURRENT INVESTMENT STAGE
Pre-seed

Ivan Morgunov
ivan@unlimit.bio
unlimit.bio/

UNLIMITED BIO

COMPANY DESCRIPTION

Unlimited Bio is a Prospera-based startup advancing a combination approach to combat aging. We aim to dramatically reduce drug-to-market costs, license a wide portfolio of therapies, and create the most potent combination treatment for healthspan extension.

The team combines leading scientists, clinicians, biostatisticians, and managers with decades of expertise in biotechnology, gene therapies, regenerative medicine, clinical trials, and biostatistics.

CORE INNOVATION

We focus on combination therapies because aging is too complex to be targeted with a single therapeutic. We license therapies from BioTechs, collect clinical data by running trials in special economic zones, some of the trials can be with a participation fee. The best performing treatments get patented and selected for trials within classic regulators. This way we bing a drug to market 10 times faster and up to 1000 times cheaper then the classic BioTechs do. It allows us to assemble a broad and diverse portfolio to test combination treatments.

HEALTHSPAN

Our flagship treatment combining Klotho, Follistatin, BDNF and VEGF AAV gene therapies with small molecules and lifestyle interventions has a tremendous potential to simultaneously offset several key age-related processes such as cognitive decline, loss of capillarization, sarcopenia, decline in immune function and reduction in endurance.

LEADERSHIP TEAM

Ivan Morgunov has led advancements in aging research, founding and leading Longaevus Technologies, Elastin Biosciences and Unlimited Bio.

Dr. Anna Vakhrusheva has 10+ years of experience in advancing vaccines and gene therapies. She led Russia's first recombinant SARS-CoV-2 vaccine (Betuvax JSC) from R&D to clinical trials in two years.

Vladimir Leshko is a biomedical engineer with 5 years of experience in leading operations in startups.

Our XPRIZE team is fortified by distinguished BioTech leaders Arthur Isaev, MD and Liz Parrish, MBA.

COMPANY OVERVIEW

TEAM / COMPANY NAME
YouthGeizer

TRACK
Healthspan

ORGANIZATION TYPE
University Team

HQ LOCATION
Los Angeles, CA, USA

YEAR FOUNDED
1881

NUMBER OF EMPLOYEES
n/a

FUNDRAISING DETAILS

COMMERCIAL STAGE
Early Commercial Demonstration

REVENUE RANGE
$1M

CAPITAL RAISED TO DATE
n/a

ACTIVELY RAISING CAPITAL FOR ANY PURPOSE?
No

TYPE OF CAPITAL SOUGHT
Strategic Partnership, Government Funding, Philanthropic Funding, Academic/University Grants

TYPE OF INVESTORS SOUGHT
Corporate/Strategic, Government, Philanthropic, Project Finance, Venture Capital, Academic/University Grants

AMOUNT OF CAPITAL SOUGHT
$2M

CURRENT INVESTMENT STAGE
Pre-seed

Dr. Helen Lavretsky
latelifewellness@mednet.ucla.edu
semel.ucla.edu/latelife

YOUTHGEIZER

COMPANY DESCRIPTION

We are University team partnering with companies that can develop a platform for interventions delivery.

CORE INNOVATION

Anti-aging intervention app.

HEALTHSPAN

Reverses brain, immune and cellular aging.

LEADERSHIP TEAM

We are a group of well-established academic researchers in gero-science of aging.

XPRIZE HEALTHSPAN | HEVOLUTION | SOLVE FSHD

QUALIFIED TEAMS BOOK 2025

TOP 100 HEALTHSPAN & TOP 8 FSHD TEAMS

REIMAGINE AGING

MAY 2025